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CHARACTERISATION OF THE PHOSPHATASE 
CONTROL SYSTEM THAT PREVENTS PREMATURE 
MITOTIC ENTRY IN MAMMALIAN CELLS 
 
 
Accurate chromosome segregation during mitosis prevents aneuploidy and cancer. The 
Wee1-Cdc25-Cdk1 feedback loop ensures cells enter mitosis in a timely and orderly 
manner. This signalling system has been proposed to work as a bistable switch that is 
maintained by the counterbalancing action of kinases and phosphatases. However, the 
phosphatases critical for this transition in mammalian cells are yet to be identified. 
Cdc14 is the major phosphatase antagonising CDK in yeast. But its eukaryotic 
homologue does not appear to play an essential role in mitotic control. Studies in 
Drosophila and Xenopus have shown that PP2A/B55 inhibition is crucial for MPF 
activation, and that this is brought about by Greatwall kinase and its substrates, the 
closely related 17kDa proteins Ensa and Arpp19. However, it remains unclear, if 
PP2A/B55 inhibition by phosphorylated Ensa/Arpp19 is a critical event in regulating 
mitotic entry in somatic cells.  
 
In this thesis I have performed a cell biological, genetic and biochemical 
characterisation of Ensa/Arpp19. I have generated and optimised tools to study the 
function of these two proteins and characterised their localisation, their depletion 
phenotypes, the nature of their interaction with the PP2A/B55 phosphatase and their 
protein interactome in metaphase and anaphase in mammalian cells. In parallel I have 
been optimising a novel protein transfection based method to study the effects of 
constitutively phosphorylated Ensa/Arpp19 in cells.  
 
The experiments described in this thesis show a surprising divergence of the functions 
of Ensa/Arpp19 and their upstream kinase Greatwall, suggesting a more complex 
signaling cascade involving these proteins. Our biochemical characterization of the 
Ensa/B55 interaction also suggests a novel mechanism of action for these proteins. 
Overall this work sheds light on how the balanced activity of the Cdk1 activation switch 
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CHAPTER1 INTRODUCTION 
 
1.1 Cell Cycle Control 
1.1.1 Historical Overview  
 
Cells are the universal building blocks of any living organism. Robert Hooke in late 
1600 coined the word “cell”, meaning “unit”, while observing a sliced cork under a 
basic light microscope. Although he was observing the cell walls of dead plant cells, the 
term has been used ever since to describe the fundamental unit in all living organisms 
(Alberts et al. 2014). 
 
The ancestral cells were formed 3–4 million years ago by spontaneous chemical 
reactions and have been passing down their characteristics to the daughter cells through 
cell division. The observations and work of Matthias Schleiden (1838), Theodor 
Schwann (1839) and Rudolf Virchow (1858) have led to the “cell theory”, which 
indicates that “living cells were made from division of the pre-existing ones”; this 
theory was later experimentally proven by Pasteur (1860) (Alberts et al. 2014; Turner 
1890). 
 
However, features of the parents and daughters were not exactly the same always. 
Darwin explained these differences were owing to random adaptations and natural 
selection in organisms for survival in different environments(Alberts et al. 2010). Over 
the years, numerous studies have been done to gain an in-depth understanding of cell 
reproduction. 
 
Cell reproduction needs to be a robust process that occurs over generations and is 
common to all living organisms and a fundamental characteristic of life. However, due 
to the fundamentally different organisations of prokaryotic and eukaryotic cells, the 
reproductive processes differ dramatically between the two super-regna; in this thesis, 
we will only consider eukaryotic cells. The advent of sexual reproduction introduced a 
dramatic change in the way organisms pass on their genetic material from one 
	   2	  
generation to the next, and this is reflected by the specific meiotic cell division as 
compared to the standard mitotic cell cycle, which is the major subject of this thesis. 
The mitotic cell cycle consists of a stepwise and well-regulated series of events. Each 
cell first duplicates its genetic material, distributes it evenly to its daughter cells, and 
then splits into two cells. This order of events maintains the genetic integrity in an 
organism. In unicellular organisms like amoeba, a new organism is generated, and in 
multicellular organisms like humans, cell division contributes to development and tissue 
repair. 
 
The timely duplication and segregation of chromosomes in eukaryotic cell cycle is key 
to successful cell division. This regulation is achieved by a number of signalling 
molecules that activate or deactivate effector proteins, thus leading to a cascade of 
events that eventually forms two daughter cells. These regulatory mechanisms also 
enable the survival of cells via energy production and maintenance of the structural 
components of the cell (Morgan 2007; Alberts et al. 2014). 
 
De-regulation of these mechanistic pathways and mutations in the regulatory proteins 
may lead to uncontrolled cell proliferations and cancer. According to the World Health 
Organisation, cancer has been responsible for 8.2 million deaths in the world in 2014 
(Cancer Research UK 2014). Hence, it is an area of intensive research. Although the 
cell division machinery differs in different organisms and different cell types, there are 
broad similarities that allow valuable insight for cancer research even in diverse 
organisms like yeast, Drosophila, frogs and mice. In recent years, the molecular 
machinery that drives the cell cycle has been defined in detail. This chapter introduces 
the key aspects of cell cycle regulation in mammalian cells relevant to the work in this 
thesis. 
 
1.1.2 Phases of the Cell Cycle  
 
  
The cell cycle has been historically categorised into different phases based on the 
microscopic observation of dividing cells under the light microscope (Flemming 1882; 
Paweletz 2001) and on radiolabelling cells to measure the timing of DNA synthesis  
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Figure 1.1 Phases of the cell cycle  
A) The cell cycle has two major phases: interphase and M phase. G1: gap phase 1, G0: 
specialised resting state in G1, S: DNA synthesis phase, G2: gap phase 2 and M: mitotic 
phase. The G1-S-G2 collectively is called interphase. B) Mitotic stages in HeLa cells 
expressing GFP-tubulin and mCherry-H2B. Animal mitosis is divided into five main phases 
of nuclear division: prophase, prometaphase, metaphase, anaphase and telophase. 
Cytokinesis follows nuclear division to produce two identical daughter cells. 	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(Howard & Pelc 1953). These were further characterised based on the biochemical 
events occurring at the specific times. Initially, proliferating cells were either in 
‘mitosis’, where their chromosomes were divided, or in ‘interphase’, the intervening 
phase between the divisions. The cell cycle, as we know today, comprises four distinct 
phases: the S phase and the Gap phases (G1 and G2) that constitute the interphase and 
the mitotic phases, respectively (Fig. 1.1A).  
 
S Phase 
The DNA duplicates during S phase by semi-conservative replication of its two 
complementary strands (Meselson & Stahl 1958), a process tightly regulated by the 
replication molecular machinery. Replication begins at the specific points on the DNA 
called “replications origins” that are scattered in large numbers on the chromosomes. 
The replications machinery employs a helicase that opens up the double helix at these 
positions, a primase generates a short stretch of RNA at the start of replication and the 
DNA polymerase continues replication by extending complementary nucleotides to the 
template strand from the 5’ end of the RNA primer. This is done continuously on the 
leading strand and discontinuously on the lagging strand. The two strands are looped, so 
that a uniform single replication fork proceeds from the origin replicating both leading 
and lagging strands. DNA replication also requires histone synthesis, which form 
nucleosomes and package the DNA within the cell behind the replication fork. The 
duplicated chromosomes are called sister chromatids and they are held together by a 
ring-shaped protein complex called cohesin consisting of the structural maintenance 
complex proteins SMC1/3, alpha-Kleisin (SCC1) and Scc3. 
 
The Gap Phases 
The two Gap phases, G1 and G2 give the cell time to grow and prepare for their 
transition into S phase and M phase respectively. These phases are also essential to 
regulate progression of the cell to the next stage integrating intracellular and 
extracellular mechanisms.  
During Gap phase 1 (G1), the cells coordinate molecular signals and prepare for the 
duplication of the DNA material. The G1 phase is also the time when the cell decides 
whether to enter the next cell cycle. In the event of nutrient deficiency or any such 
hindrances, the cell might choose to enter the G0 or the non-dividing stage. This is 
usually observed in highly proliferative populations such as stem cells. In budding yeast 
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(Rupes 2002) and possibly also higher eukaryotes (Zetterberg et al. 1984), this is also 
the time when most of the new cell mass is gained. Interestingly, fission yeast performs 
this predominantly in G2 phase. The precise coordination of cell growth and division 
remains poorly understood so far. G2 is the tail end of interphase, when the cell 
prepares to enter mitosis. During G2, the proteins essential for mitosis, such as A and B-
type Cyclins, are synthesised. This is also the time when DNA damage that occurred 
during the S phase is repaired. Transition between the gap phases and the S and M 
phases is strictly monitored by cell cycle checkpoints to ensure genome integrity and to 
prevent aberrant cell division (Barnum & O’Connell 2014)(Fig. 1.1). G1/S and G2/M 
are the two main checkpoints leading from the gap phase to the next cell cycle phase. 
The G2/M checkpoint is discussed in detail in the later sections. 
 
Mitosis 
Once the DNA is duplicated, cell division can occur symmetrically or asymmetrically. 
Asymmetric divisions are usually observed during developmental stages or during 
production of differentiated cell types from stem cells. Symmetric divisions occur in 
somatic cells and leads to doubling the cell number with every division. Mitosis is the 
complex process of cell division comprising of four sub-phases: prophase, metaphase, 
anaphase and telophase (Fig. 1.1B).  
1. During prophase, the replicated chromosomes condense and the mitotic 
apparatus starts to form. The centrosome duplicates and migrates to the poles forming 
the spindle poles. The nuclear envelope breaks down. 
2. The condensed chromosomes then pair up as sister chromatids and align in the 
midzone called the metaphase plate. The microtubules attach to the sister chromatids 
through the kinetochore, and tension is generated. 
3. In anaphase, the microtubules begin to shorten. This results in pulling apart the 
sister chromatids to the opposite poles. 
4. Lastly, during telophase the chromosomes de-condense and the nuclear envelope 
reforms. With the help of the actin and microtubule cytoskeleton the cell forms the 
cytokinesis furrow and splits into two daughter cells with equal number of 
chromosomes (Morgan 2007; Alberts et al. 2010). 
In addition to the distribution of the genetic material (DNA), other cellular organelles 
such as centrosomes, mitochondria and Golgi should also be distributed among the 
daughter cells. This is achieved by association of the fragmented organelles with the 
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components of the cytoskeleton and is not a passive process (Shima et al. 1998; 
Boldogh et al. 2001; Alberts et al. 2010; Morgan 2007). The biochemical components 
driving this process are described in detail in the following sections. 
 
1.1.3 Cell Cycle Models and the Discovery of MPF  
  
The cell cycle has to be tightly regulated so that DNA replication occurs ‘once and once 
only’ per cell cycle. The centrosomes, the microtubule organising centre and residence 
of the centrioles also undergo an analogous semi-conservative replication cycle and are 
evenly distributed between daughter cells. Thus, the cell cycle consists of nuclear 
division cycle, a centrosome cycle and cellular division (cytokinesis), ideally controlled 
by the same timing mechanism (Alberts et al. 2014; Morgan 2007). Two lines of work 
determined the molecular mechanisms that orchestrate the cell division cycle. The 
major initial breakthrough came from genetic studies in budding and fission yeast in the 
1970s and from biochemical characterisation of cell cycle control enzymes in Xenopus 
oocytes and sea urchin eggs. 
 
Two models were proposed for the control of the cell cycle. Yeast studies proposed the 
domino model: where one cell cycle event occurred after another and showed inter-
dependence on each other. This was observed in experiments where a cell lacking a 
gene necessary for the initiation or the completion of a particular phase, prohibited the 
cell from progressing in the cell cycle. This eventually led to the concept of cell cycle 
checkpoints that ensures the sequential order of the cell cycle phases to safeguard its 
fidelity (Nurse et al. 1976; Weinert & Hartwell 1989; Nishimoto 1992). The ‘cell 
division control’ (cdc) mutant strains, in particular cdc2, were identified in yeast 
screens. These mutants were characterised by their size, once identified by their arrest in 
a particular stage of the cell cycle. In Schizosaccharomyces pombe, the cdc2 mutants 
fail to divide at restrictive temperatures and are elongated as compared to the wild type 
(Nurse & Thuriaux 1980). These findings were consistent with the budding yeast 
phenotypes (Saccharomyces cerevisiae) where the cdc28 mutants failed to divide 
(Hartwell et al. 1974). These proteins were implicated to have important roles in the cell 
cycle, especially for the ‘Start’ (yeast equivalent of restriction point) and for mitotic 
control.  
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On the other hand, Xenopus oocytes and cytoplasmic extracts studies predicted the 
Clock model: a cytoplasmic clock triggered entry into mitosis and was independent of 
each phase. An unknown activity was found to promote meiotic entry in Xenopus 
oocytes. Xenopus oocytes have rapid mitotic to interphase cycles, which makes it easier 
to sturdy cell cycle transitions. The cytoplasm form M-phase oocytes but not interphase 
oocytes could induce M-phase entry in immature oocytes. This unknown activity was 
the named ‘maturation-promoting factor’ (MPF) (Masui and Markert 1971; Smith and 
Ecker 1971). This led to the ‘clock model’ where a biochemical component was 
responsible to drive the cell cycle, which was present in the cytoplasm. Similar 
biochemical component from mitotic HeLa cells when injected in Xenopus oocytes led 
to germinal vesicle breakdown (GVBD). Thus, the MPF activity was found to be 
conserved among higher eukaryotes (Sunkara et al. 1979). However, later as the 
molecular mechanisms underlying these cell cycle transitions were revealed, both 
models were reconciled (K. Hara et al. 1980; Hartwell 1978). 
 
1.1.4 Discovery of Cyclins and the Unifying Theory of the Cell Cycle 
 
In the meanwhile, T. Hunt and colleagues did continuous methionine labelling studies 
in sea urchin to observe protein synthesis in the initial few cell cycles. This led to the 
discovery of the 56-kDa protein that oscillates between mitosis and interphase. Due to 
the cyclic appearance of this protein, it was named Cyclin. On the basis of sequence 
comparison, they were divided into 2 classes: Cyclin A and B (Evans et al. 1983; Pines 
& Hunt 1987b). Cyclin A was cloned from the clam embryos and it was similar to sea 
urchins. Additionally, the mRNA also triggered M phase in Xenopus oocytes (Swenson 
et al. 1986). Similar results were observed with Cyclin B as well (Pines & Hunt 1987a). 
The fact that Cyclins are associated with MPF was shown by cell-free extracts 
experiments in Xenopus. MPF was purified from oocytes and was found to be 
composed of two subunits of approximately 34 kDa and 45 kDa. The kinase activity of 
MPF was also able to phosphorylate the endogenous 45-kDa protein as well as H1 
(Lohka et al. 1988). Further studies with purified MPF and antibodies related the two 
subunits of MPF to be cdc2 and Cyclin B (both B1 and B2) (Gautier et al. 1988; Gautier 
et al. 1990). The Cdc2 protein from clams was found to form a complex with both 
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Cyclin A and Cyclin B. Both these protein complexes showed cell-cycle dependent 
kinase activity (Draetta 1993). Thus, the concept of Cyclin-dependent kinases (Cdk) 
was introduced in cell cycle regulation. 
 
Moreover, protein synthesis studies in cell-free extracts by Kirschner and colleagues 
showed that Cyclin synthesis was important and sufficient for mitotic entry. Cell-free 
extracts were treated with ribonuclease to degrade endogenous Cyclin mRNA. These 
extracts could enter the cell cycle when exogenous Cyclin mRNA was added (Murray & 
Kirschner 1989a). Additionally, Minshull et al. (1989) showed that the mRNA of 
Cyclin B in particular induced mitotic entry in Xenopus extracts (Minshull et al. 1989). 
Thus, Cyclin synthesis is crucial for mitotic entry similar to MPF. Cdc13 was found to 
be crucial for G2/M entry and proper cytokinesis in fission yeast. The gene interacted 
closely with both yeast and human cdc2 and was similar to the sea urchin Cyclin. In 
addition to these experiments, a unified view of the cell cycle emerged when it was 
demonstrated that the critical players of the embryonic (Xenopus) and somatic (yeast) 
cell cycle are proteins encoded by homologous genes. In 1982, Beach et al. 
complemented cdc mutants in S. pombe with the cd28 gene from budding yeast. This 
rescued the elongated phenotype in S. pombe thus showing that Cdc2 and Cdc28 are 
functional homologues of the ‘cell division control’ proteins and encoded a protein with 
kinase activity (Reed et al. 1985; Simanis & Nurse 1986). Cross-species gene 
complementation assays were done with purified MPF activity, the human homologue 
of Cdc 2, in yeast. The human Cdc2 (later named CDC2) could complement the 
temperature-sensitive cdc2 mutants and a cdc2-deficient strain. A comparison of the 
amino-acid sequence of CDC2 with Cdc2 and Cdc28 revealed 63% and 58% homology, 
respectively (M. G. Lee & Nurse 1987). Similarly, the product of the gene cdc13 is 
homologous to Cyclin. Humans were also found to have several Cdk and Cyclins that 
were homologous to the yeast, sea urchin and Xenopus equivalents.  
 
Thus, the cell cycle as we know it today is regulated by a wide variety of Cdk-Cyclin 
complexes as shown in Fig. 1.3. The Cyclins bind to their Cdk partners via the ‘Cyclin-
box’. This is a 150 amino acid sequence and is highly conserved(Kobayashi et al. 1992).  
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1.2 MPF Regulation: Cdk-Cyclin Complex Regulation in Mitosis 
 
The basic regulatory elements of the cell cycle are the Cdk-Cyclin complexes. Although 
around 20 ‘Cdk’ proteins and 29 ‘Cyclin’ genes were found in humans due to sequence 
similarity, only a few have been known to have a function linked to the cell cycle. 
These are Cdks 1, 2, 4, 6 and 7 and Cyclins A, B, D, E and H (Malumbres & Barbacid 
2005). Among these Cyclins, Cdks characteristically bind with a particular Cyclin 
partner to drive different stages of the cell cycle. Cdk1 binds Cyclin A or Cyclin B, 
Cdk2 with Cyclin E or Cyclin A, and both Cdk4 and Cdk6 with Cyclin D (Draetta et al. 
1989; Pines & Hunter 1989; Tsai et al. 1991; Koff et al. 1992; Matsushime et al. 1992; 
Rosenblatt et al. 1992; Meyerson & Harlow 1994). 
 
Of these Cdk -Cyclin complexes, Cdk1-Cyclin B is known to be the master regulator of 
mitosis. When MPF was purified, Cdk was observed to co-purify with Cyclin (Lohka et 
al. 1988). Although Cyclin binding is an important part of Cdk activation, it is not 
sufficient to activate Cdk completely. The Cdk-activating kinase phosphorylates Cdk in 
the Cdk -Cyclin complex and activates it fully(Jeffrey et al. 1995). However, due to the 
presence of CAK throughout the cell cycle, it is not considered as one of the regulatory 
mechanism in Cdk -Cyclin activation. Inhibitory phosphorylations by Wee1/Myt1 and 
their dephosphorylation by Cdc25 maintain the on/off state of the Cdk -Cyclin complex 
at G2/M transition (Nurse & Thuriaux 1980; Gautier et al. 1991; Parker et al. 1992; 
McGowan & Russell 1993; Mueller et al. 1995). Additionally, the action of Cdk 
inhibitors like p21, p27 and p57 or the INK4 family, keep Cdks inhibited. They function 
mainly in the G1/S transition of the cell cycle (Sherr & Roberts 1999). Cyclin 
proteolysis at the end of mitosis is the irreversible step in MPF regulation, which occurs 
at the end of mitosis. Once the cell exits mitosis, they need to re-synthesise the Cyclins 
to initiate the next cell cycle (Evans et al. 1983; Murray & Kirschner 1989b). Thus, Cdk 
activation is regulated by a combination of mechanisms such as Cyclin synthesis and 
binding, phosphorylation of specific residues and the action of Cdk inhibitors (CdkIs). 
Among these, the mechanisms controlling the mitotic Cdk -Cyclin complexes are 
described in detail in the following sections. 
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1.2.1 Cyclin Synthesis and Cdk Binding 
 
Cyclins were named based on their fluctuating concentrations throughout the cell cycle. 
These proteins were observed to accumulate through interphase and disappear abruptly 
in mitosis. Cyclin levels are mostly regulated by both transcriptional and degradative 
mechanisms. This, in turn, drives the cell cycle by inducing the appropriate Cdk 
activity. Cdk remains constant throughout the cell cycle, while the oscillations in Cyclin 
activity and the resulting Cdk activity is crucial in licensing cell cycle progression. The 
activated Cyclin A/B-Cdk1 complex phosphorylates mitotic substrates and initiates 
mitotic entry. However, not all cyclins alter their activities throughout the cell cycle, 
and some of them have also been found to function in other phases of the cell cycle at 
later time points. Cyclins are classified according to their Cdk binding domain, the 
conserved Cyclin box structure (Hochegger et al. 2008; Fung & Poon 2005). The 
presence of a particular Cyclin defines a period where the accompanying Cdk is 
competent for activation (Fig. 1.2A). 
 
In mammalian cells, Cyclin A and Cyclin B are the mitotic Cyclins as they are 
synthesised and degraded around mitosis. Cyclin A binds and activates both Cdk1 and 
Cdk2, whereas Cyclin B only binds Cdk1. Two types of Cyclin A (A1 and A2) (Girard 
et al. 1991; Zindy et al. 1992; Sweeney et al. 1996; Ravnik & Wolgemuth 1999) and 
three types of Cyclin B (B1, B2, B3) (Pines & Hunter 1989; Chapman & Wolgemuth 
1992; Gallant & Nigg 1992; Lozano et al. 2002; Nguyen et al. 2002) are present in 
mammalian cells. Of these A2, B1 and B2 are known to function in proliferating 
somatic cells. These Cyclins have similar promoters containing CCAAT-boxes. These 
promoters are regulated by transcriptional factors like CBP (Cyclin A) (Krämer et al. 
1997) and trimeric NF-Y transcriptional activator (Cyclin A and B) (Katula et al. 1997; 
Bolognese et al. 1999). Additionally, the synergistic p300 co-activator that binds to the 
promoters activates transcription of Cyclin B1 and B2 (Wasner, Tschöp, et al. 2003; 
Salsi et al. 2003). The mRNA of Cyclin A starts accumulating earlier than Cyclin B at 
the start of DNA replication (Henglein et al. 1994; Erlandsson et al. 2000), whereas the 
Cyclin B levels rise in mid-S phase (Norbury & Nurse 1992; Pines & Hunter 1989). 
Cyclin A protein levels peak at the beginning of mitosis whereas the Cyclin B levels 
peak slightly later at the metaphase-anaphase transition. During S phase the NF-Y is 
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further activated by Cyclin E/A-Cdk2, leading to a rise in the Cyclin B transcription 
(Katula et al. 1997). In HeLa cells, the NF-Y factor remains bound to the promoter and  
Figure 1.2 Control of the mammalian cell cycle by Cyclin-Cdks 
 
A) Cyclin-Cdk complexes regulating the cell cycle. Schematic representation of mammalian 
Cyclin-Cdk complexes, involved in progression throughout different phases of the cell cycle. 
These are the master regulators of the cell cycle. Adapted from Malumbres et al. 
(Malumbres & Barbacid 2005). B) Cyclin expression during the cell cycle. D-type cyclins 
are relatively stable throughout the cell cycle but have an important role in early G1. E-type 
cyclins are expressed at G1/S to drive S-phase entry. A-type cyclins allow progression into 
mitosis from S phase and B-type cyclins are responsible for mitosis. Adapted from Morgan 
(Morgan 2007). 	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Cyclin B transcription continues even in mitosis. This occurs as the Cyclin B gene 
maintains an open chromatin configuration even in the mitotic stage (Sciortino et al. 
2001). Conversely, the transcription of Cyclin B1 and B2 is repressed in response to 
DNA damage and this repression requires the NF-Y and CCAAT boxes (Manni et al. 
2001). 
 
Cyclin A transcription is repressed during G1 by a repressor element called cell cycle 
responsive element (CCRE) or cell cycle dependent element (CDE), which contains an 
E2F binding site. The Cyclin B1 promoter also houses both positive and negative acting 
E2F-promoter elements. In the S phase, Cyclin D/E-Cdk hyperphosphorylates pRb and 
releases E2F, leading to the transcription of Cyclin A2. This works through the 
CCRE/CDE elements. Moreover, Cyclin A-Cdk2 also inhibits the transcriptional 
activity of E2F by phosphorylating it (Zwicker et al. 1995; Huet et al. 1996; Soucek et 
al. 1997; Schulze et al. 1995; Zhu et al. 2004; Knudsen et al. 1999). Additional elements 
contributing to repression of mitotic Cyclins (Cyclin A2, Cyclin B1 and Cyclin B2) in 
G1 are cell cycle gene homology regions (CHRs), which are also present in many G2/M 
genes along with CCAAT boxes, NF-Y and B-MYB binding. B-MYB is regulated by 
E2F and its expression is enhanced by Cyclin a-Cdk2. This in turn regulates 
transcription of Cyclin A and Cyclin B positively. Additionally, FOXM1 is another 
transactivator of Cyclin B1 expression (Wasner, Haugwitz, et al. 2003; Wasner, Tschöp, 
et al. 2003; Zwicker et al. 1995; N. Liu et al. 1998; Philips et al. 1999; Joaquin & 
Watson 2003; Laoukili et al. 2005) (Fig. 1.2B).  
 
Once synthesised Cyclins bind to Cdks and act as allosteric activators. The crystal 
structure of human Cdk2 shows that the protein-binding site is sandwiched between the 
small amino and large carboxyl-terminal lobes. Binding of the substrate in this cleft 
enables it to be closer to the γ-phosphate of the ATP. However, this substrate binding 
site is blocked by an alpha-helix called the ‘T’ loop, which acts as an auto-inhibitor of 
the kinase (De Bondt et al. 1993). This ‘T’ loop undergoes conformational changes on 
binding Cyclin A, due to the presence of conserved charged residues interacting with 
Cdk. Thus, the active site is no more blocked. However, Cdk1 structure with Cyclin B 
shows fewer interactions between the activation segment and Cyclin B, has a disordered 
region and substrate-recognition requires considerable re-arrangement (Nicholas R 
Brown et al. 2015; Petri et al. 2007). Cyclins themselves have no enzymatic activity but 
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have substrate binding sites and target Cdks to specific subcellular locations (Evans et 
al. 1983; Dorée & Hunt 2002). 
 
1.2.2 Post-translational Modification of Cdk-Cyclins: CAK Phosphorylation 
 
Once Cyclin binds to Cdk, it needs to be activated by post-translational modifications. 
The Cyclin-binding region on Cdk1 has the PSTAIRE motif, which contains Thr160 in 
humans. This residue needs to be phosphorylated by the Cdk-activating kinase (CAK) 
in order to fully activate the Cdk-Cyclin complex. Human Cdk2/Cyclin A is 
phosphorylated at Thr161 by CAK. In budding yeast, cdc2 alone is not a substrate of 
CAK, unlike Cdk2 in vertebrates. Structural data of unphosphorylated Cdk2/Cyclin A 
complex show the T-loop interfering with the putative substrate-binding site as well as 
the subsequent Cdk2-Cyclin A contacts. Phosphorylation of Thr160 leads to a 
conformational change in the T-loop. Thus, phosphorylation of Thr160 is required to 
activate the Cdk-Cyclin complex, which allows access to the active site and stabilises 
ATP binding (Draetta 1993; Endicott & Noble 2013; Russo et al. 1996; Fisher & 
Morgan 1994; Mäkelä et al. 1994) 
 
CAK is very similar to MO15, a kinase protein structurally related to cdc2 in Xenopus 
laevis. Two types of CAK have been identified. Budding yeast contains monomeric 
CAK1p that localises in the cytoplasm, while the trimeric p40MO15 (Cdk7)/Cyclin 
H/MAT complex in vertebrates localizes in the nucleus. MO15 is the catalytic subunit 
of CAK and Cyclin H is its prime partner. 
The trimeric complex is also a subunit of TFHII (general transcription factor) and 
phosphorylates various components in the transcription machinery in addition to Cdks 
(Fisher & Morgan 1994; Mäkelä et al. 1994; Kaldis et al. 1998; Kaldis 1999). Although 
CAK phosphorylation fully activates the Cdk-Cyclin complex, it is not considered as a 
regulatory step, because CAK is not regulated in a cell-cycle dependent manner and is 
ubiquitously present throughout the cell cycle (Lolli & L. N. Johnson 2005). 
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1.2.3 Post-translational Modification of Cdk-Cyclins: Cdk Inhibitors 
 
Another regulatory mechanism is the binding of small peptides called Cdk inhibitors 
(CKIs). Two types of these peptides have been identified based on sequence homology 
and targets of inhibition: Cdk4 (INK4) family and the Cdk-interacting protein or Kinase 
inhibitory protein (Cip/Kip) family (Sherr & Roberts 1999). 
 
Cdk4/INK4 binds Cdk4/6 as monomers. The family comprises of p15(INK4b), 
p16(INK4a), p18(INK4c) and p19(INK4d). p16 is a prominent Cdk4 inhibitor that 
accumulates in cells lacking pRb. Its transcription is repressed by pRb, which in turn is 
phosphorylated and inhibited by active the Cyclin D-Cdk4/6 complex, which results in 
a negative feedback loop. Structural data indicate that these CKIs bind Cdk directly and 
cause distortion of both the Cyclin and ATP binding sites. The activity of Cyclin D-
Cdk4/6 is important in re-entry into the cell cycle from the G0 phase. Thus, both p16 
and pRb are important in cell proliferation from quiescence (Ruas & G. Peters 1998; 
Sherr 2001; Jeffrey et al. 2000).  
 
The Cip/Kip family has a preference for bound Cdk-Cyclin complexes. This family 
comprises of p21(Cip1), p27(Kip1) and p57(Kip2). These CKIs can have activating or 
inhibitory effects. The N-terminal of the inhibitory domain is conserved, and this 
domain is essential and sufficient for Cdk2 inhibition (J. Chen 1996; Nakanishi et al. 
1995; Luo et al. 1995). These CKIs negatively regulate Cyclin A-Cdk2, Cyclin E-Cdk2 
and Cyclin B-Cdk1 and positively regulate Cyclin D-Cdk4/6. p21 leads to high 
expression of Cyclin D, which eventually leads to an increase in Cdk activity. The 
active Cdk-Cyclin complex phosphorylates the pocket proteins to release the EF2 
transcription factors. Thus, cell cycle genes are expressed in G1 to induce S phase 
progression (Sherr & Roberts 1999; LaBaer et al. 1997). 
 
1.2.4 Post-translational Modification of Cdk-Cyclins: Wee1/Myt1 Inhibitory 
Phosphorylations 
 
CAK phosphorylation fully activates the mitotic Cdk -Cyclin complexes. These 
complexes need to be kept inert until it is required in the cell cycle. This is achieved by 
	   15	  
phosphorylating two key residues on Cdk1 and Cdk2, Thr14/Tyr15. This layer of 
negative regulation contributes to the switch-like property of cells during mitotic entry 
(Welburn et al. 2007; Gu et al. 1992).  
 
Wee1 was originally identified in a fission yeast screen for cell cycle regulators. The 
functional loss of this gene in Schizosaccharomyces Pombe (fission yeast) leads to the 
formation of smaller daughter cells after premature mitosis followed by death. These 
phenotypes suggest a role of this kinase in co-ordinating cell size with cell cycle to 
prevent smaller cells from entering mitosis. This was the first evidence suggesting a 
G2/M role of Wee1. In yeast Wee1 phosphorylates both T14 and Y15 residues of Cdc2, 
while human Wee1 only phosphorylates Tyrosine 15 residue on Cdk1 (Nurse & 
Thuriaux 1980; Parker & Piwnica-Worms 1992; Parker et al. 1992; McGowan & 
Russell 1993). This suggests the need for another kinase to phosphorylate the Thr14 
residues in vertebrates. A dual-specificity kinase, Myt1, phosphorylates both Thr14 and 
Tyr15 residues in Xenopus leavis cdc2 and is conserved in humans (Mueller et al. 1995; 
Fattaey & Booher 1997).  
 
Both these kinases show different localisation in interphase. While Wee1 is nuclear or 
associated with centrosomes, Myt1 is associated with endoplasmic reticulum and Golgi 
complex (Mueller et al. 1995; F. Liu 1997; Kornbluth et al. 1994; Baldin & Ducommun 
1995). The differential impact of these kinases on the G2/M transition is yet to be 
determined. Although studies with Wee1 depletion have been documented, very little is 
known about Myt1. Wee1 depletion in yeast and Drosophila induce premature mitotic 
entry. Depletion of Wee1 in mice causes embryonic lethality (Tominaga et al. 2006) and 
in human cell lines leads to striking mitotic phenotypes (Neumann et al. 2010). 
Interestingly, in HeLa cells, treatment with Wee1 specific inhibitor (Pd0166285) at the 
S/G2 border causes abrupt and premature mitotic entry even in the absence of G2. This 
strongly suggests a critical role of this kinase in the G2/M transition (Potapova et al. 
2011). Functions of Myt1 have only been characterised in DNA damage, where it 
contributes to checkpoint recovery independent of Wee1(Chow & Poon 2013). The 
importance of Myt1 in the G2/M transition is yet to be determined. 
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1.2.5 Cdk-Cyclin Activation: Cdc25 Phosphatases 
 
Inhibitory phosphorylations by Wee1/Myt1 have to be removed to activate Cdk1 at the 
onset of mitosis(Gautier et al. 1991). Dual-specificity phosphatase called Cdc25 
performs this function. They were initially identified in fission yeast. The protein 
encoded by cdc25+ gene was found to be antagonistic to Wee1+ and the overexpression 
of this protein induced mitosis in cells with reduced cell size (Russell & Nurse 1986; 
Galaktionov & Beach 1991). Xenopus leavis studies revealed these phosphatases can 
dephosphorylate both serine-threonine and tyrosine residues (Dunphy & Kumagai 
1991). The cdc25 gene was found to be hyperphosphorylated near the onset of mitosis 
at the N-terminal region. Moreover, purified cdc25 could rescue and induce mitosis in 
Xenopus leavis interphase extracts arrested due to inhibition of DNA synthesis 
(Kumagai & Dunphy 1991; Kumagai & Dunphy 1992). Thus, the activation of cdc2 by 
cdc25 dephosphorylation appeared to be mandatory for mitosis. The cdc25 gene was 
highly conserved in all eukaryotic organisms (Sadhu et al. 1990; Draetta & Eckstein 
1997; Khadaroo et al. 2004). In humans there are three different of cdc25 located on 
chromosomes 3, 20 and 5, encoding the paralogues Cdc25 A, B and C, respectively 
(Alonso et al. 2004). 
 
 All three paralogues in humans regulate cell cycle checkpoints by activating 
Wee1/Myt1 inactivated Cdk -Cyclin complexes. Cdc25A is thought to activate Cdk2 
and promote S-phase entry as depletion of Cdc25A in G1 phase blocks entry into S 
phase. Cdc25A is also expressed predominantly in G1 phase and is mostly nuclear. It 
accumulates in late S phase but is present in all phases in the cell cycle. It is 
transcriptionally controlled by c-Myc and E2F transcription factors. (Hoffmann et al. 
1994; Blomberg & Hoffmann 1999; Jinno et al. 1994). 
 
On the other hand, CDC25B and C primarily regulate G2/M transition. They are 
targeted to the centrosomes in G2 and activate Cdk1-CyclinB1 there. CDC25B 
increases in the cytoplasm, and the prophase microtubule nucleation is thought to be a 
consequence of this increase (M. S. Chen et al. 2001). Surprisingly, knockout mouse 
models of Cdc25 B and C are viable both individually and together, but Cdc25A 
deletion has a lethal effect. Double deletion of Cdc25 B and C was found to only cause 
sterility, which already occurs in Cdc25B knockout mice (M. S. Chen et al. 2001; 
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Ferguson et al. 2005; Lincoln et al. 2002); this suggested that Cdc25A steps in to 
perform mitotic functions in the absence of the other paralogues. It was later found that 
Cdc25A activates Cdk1-CyclinB and plays a role in chromatin condensation. Similarly, 
Cdc25 B and C were also shown to be involved in promoting S phase, in addition to 
controlling Cdk1-CyclinB activation at the G2/M transition (Hoffmann et al. 1994; 
Gabrielli et al. 1996; Lindqvist et al. 2005; Boutros et al. 2006). 
 
Localisation of the Cdc25 paralogues changes during the course of the cell cycle. In G2 
phase, Cdc25 A, B and C shuttle between the nucleus and the cytoplasm. The 
subcellular localisation is regulated by a nuclear localisation sequences and nuclear 
export signal located in the N-terminal regulatory domain of Cdc25 phosphatases 
(Kumagai & Dunphy 1999; Uchida et al. 2004). Additionally, interactions with 14-3-3 
proteins also partly regulate the localisation of Cdc25 by binding to the phosphatase 
upon phosphorylation by CHK1 and/or C-TAK1 kinases (Dalal et al. 1999; Conklin et 
al. 1995; C. Y. Peng et al. 1998; M.-S. Chen et al. 2003). Dissociation of the 14-3-3 
protein activates Cdc25 at the G2/M transition. The nuclear export signals and 14-3-3 
binding enable the shuttling of the Cdc25 between the cytoplasm and the nucleus. 
 
The regulation of these mitotic elements: Wee1/Myt1 and Cdc25 are discussed in detail 
in the next sections 
 
1.2.6 The G2/M Checkpoint  
 
DNA damage leads to varied response mechanisms in the cells of which some are 
involved in stalling the replication fork, some in repairing the damaged DNA and some 
in preventing entry into mitosis. Of these, G2/M checkpoint that regulates and inhibits 
mitotic entry in response to DNA damage is described here. 
 
Mitotic entry is prevented by two pathways in response to DNA damage at the G2/M 
checkpoint: the ATM/ATR signalling pathway and the p53 pathway. CHK1 and CHK2 
kinases are activated in the ATM/ATR pathway, which in turn phosphorylate specific 
serine residues on Cdc25 and inactivate it. CHK1, CHK2 and Plk3 phosphorylations 
leads to 14-3-3 binding on Cdc25, which is then sequestered into the cytoplasm and 
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becomes inaccessible to Cdk1-Cyclin B (Bulavin et al. 2001; Xiao et al. 2003; Q. H. 
Liu et al. 2000). CHK1 and CHK2 also inhibit Cdk1 by activating the p53 pathway. 
p21Cip1, Gadd45 and 14-3-3σ are the transcriptional targets of p53, which inhibit Cdk1 
directly or indirectly (Charrier-Savournin et al. 2004; Hermeking et al. 1997; 
Vairapandi et al. 2002; Stewart & Pietenpol 2001). p21 isolates inactive the Cdk1-
Cyclin B complex in the nucleus and prevents its activation and recruitment to the 
centrosome, where it first gets activated (Charrier-Savournin et al. 2004). Gadd45 binds 
Cdk1 directly and prevents Cyclin association in a p53-dependent manner (Vairapandi 
et al. 2002; Zhan et al. 1999; X. W. Wang et al. 1999). Furthermore, 14-3-3 σ binds 
Cdk1-Cyclin B complexes, which leads to the retention of the kinase in the cytoplasm, 
and this binding is induced by p53. (Chan et al. 2000; Hermeking et al. 1997). Plk1 
kinase, which promotes mitosis by activating Cdk1-Cyclin B is also downregulated to 
ensure G2 arrest (Shaltiel et al. 2015; Takaki et al. 2008; van Vugt & Medema 2005). 
 
1.2.7 Mitotic Entry 
 
Once the G2/M checkpoint is satisfied, the activation of Cdk1- Cyclin B starts and is 
amplified to initiate mitosis. Multiple feedback loops in addition to spatial regulation of 
the mitotic entry elements control the G2/M transition (Fig. 1.3). All these events 
eventually lead to the rapid and irreversible activation of the Cdk1-Cyclin B complex, 
and cells enter mitosis when the Cdk1 activity threshold is attained. In this section, the 
spatial reorganisation of the mitotic entry network elements and the positive and 
negative feedback loops of Cdk1-Cyclin B activation are discussed. 
 
Cdk1-Cyclin B complexes are mostly cytoplasmic, although Cyclin B1 shuttles between 
nucleus and cytoplasm with short nuclear retention time (J. Yang & Kornbluth 1999). 
The first active complexes of Cdk1-Cyclin B are seen at the centrosomes. This is 
thought to trigger the nuclear import of Cyclin B1 and Cdc25, where more active Cdk1-
Cyclin B complexes are found later(Jackman et al. 2003; Toyoshima-Morimoto et al. 
2002; Yuan et al. 2002). The nuclear translocation of the Cdk1-Cyclin B complex is 
mediated by phosphorylation of various serine residues in the cytoplasmic retention 
sequence (CRS) or the nuclear export signals (NES) of Cyclin, which in turn is 
regulated by Plk1 and Cdk1 kinases (Toyoshima-Morimoto et al. 2001; Hagting et al. 
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1999). The other components of the entry switch, such as Cdc25B and C and Myt1, are 
also cytoplasmic, while Wee1 and Greatwall kinases (described in the later sections) are 
nuclear (Alvarez-Fernández & Malumbres 2014). Following the translocation of Cyclin 
B1, Greatwall kinase, which is involved in the phosphatase control of the entry switch, 
is activated in the nucleus. Active Greatwall then translocates to the cytoplasm to start 
the phosphatase control pathway necessary for mitotic entry (Alvarez-Fernández et al. 
2013).  
 
The continuous rise of Cdk2/Cyclin A activity contributes to the inhibition of Wee1 and 
a decrease in the threshold for Cdk1 activity and entry into mitosis. Cyclin A2 RNAi 
increases Wee1 activity and lowers Plk1 and Cdc25C in HeLa cells (Fung et al. 2007). 
Moreover, siRNA depletion experiments with Cyclin A2 suggest that it could constitute 
the initial trigger of Cdk1 activation (Fung et al. 2007; Gong et al. 2007; Gong & Ferrell 
2010); however it is unclear if these effects of Cyclin A2 depletion are due to problems 
in the previous S phase. Clearly, both Wee1/Myt1 and Cdc25 are regulated by 
phosphorylation by Cdk1, which constitute the negative and positive feedback loops of 
Cdk1-Cyclin A and B activation (Perry & Kornbluth 2007). These initial feedback 
loops are complex and involve a number of regulatory elements. 
 
The regulation of Cdc25 phosphatase occurs via phosphorylation of various inhibitory 
and activating residues. Some of the kinases involved in this regulation, Chk1/2 and 
cTAK1 are described before. CDC25 is hyperphosphorylated at the onset of mitosis. 
These activating phosphorylations of CDC25 are mediated through Plk1, Cdk1 and 
Cdk2. The 14-3-3 inhibitory binding is released in G2 mediated by Cdk2 and Plk1 
activities (Margolis et al. 2003; Elia et al. 2003; Kumagai & Dunphy 1992). Cdk1 
further activates Cdc25 via PP1 dephosphorylation of the inhibitory Ser287 (Margolis et 
al. 2006) and the conformational change via Pin1. Pin 1 is a cis/trans peptidyl-prolyl 
isomerase that catalytically modifies the conformation of Cdc25 in response to 
phosphorylation (Stukenberg & Kirschner 2001; Crenshaw et al. 1998). Thus active 
Cdk1-Cyclin B initiates a positive feedback loop to drive up the concentration of active 
Cdk1-Cyclin B (Kumagai & Dunphy 1992; Izumi & Maller 1993; Hoffmann et al. 
1993). Cdc25A concentration also increases in cells since S-phase as it is protected 
from targeted proteolysis by Cdk1 (Busino et al. 2003). 
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Figure 1.3 Cyclin B-Cdk1 activation at mitotic entry 
 
Schematic representation of Cyclin b-Cdk1 activation at mitotic entry. Cyclin B binds with 
Cdk1 and is fully activated by CAK by phosphorylation at Thr161 (Kaldis 1999). This 
complex is inactivated by T14 and Y15 inhibitory phosphorylations by Wee1/Myt1 kinase 
(Nurse & Thuriaux 1980; Mueller et al. 1995). At G2/M transition, Cdc25 dephosphorylates 
the T14 and Y15 residues to activate Cyclin B-Cdk1 complex, which then phosphorylates 
the mitotic substrates (GAUTIER et al. 1991). Cdk1 also activates its activator, Cdc25, and 
inhibits its inhibitor, Wee1/Myt1. The faded colours show inactivated proteins and the 
brighter ones show active proteins/protein complexes. 	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Similar regulatory mechanism are involved in inhibiting Wee1/Myt1 kinase from 
phosphorylating mitotic Cdk -Cyclin complexes (Perry & Kornbluth 2007). Myt1 is 
hyperphosphorylated via Plk1 that eventually inhibits its kinase activity (Booher et al. 
1997). Wee1 is degraded at the G2/M transition by SCF (Skp, Cullin and F-box) E3-
ubiquitin ligase complex (Ayad et al. 2003; Michael & Newport 1998). Phosphorylation 
of Wee by Cdk1 itself and other kinases such as Plk1 and Casein kinase 1 target it for 
proteolysis by SCF complex, by generating a phospho-degron. This is achieved by 
phosphorylating the Ser53 and Ser123 residues which are then recognized by β-TrCP 
that binds Skp and leads to SCF mediated proteolysis (Watanabe et al. 2004; Watanabe 
et al. 2005; Bartholomew et al. 2001). Moreover, Cdk phosphorylates a conserved 
threonine in the N-terminal region of Wee1, called Wee-box that is essential for normal 
kinase activity. This phosphorylation enables binding of Pin1, which disrupts the active 
conformation of the kinase (Okamoto & Sagata 2007). Additionally, 14-3-3 binding in 
the presence of protein kinase inhibitor UCN-01 stimulates the Wee1 interphase kinase 
activity (Rothblum-Oviatt et al. 2001; J. Lee et al. 2001).  
 
As observed above Plk1 phosphorylation is involved in activating Cdc25, inhibiting 
Myt1 (Nakajima et al. 2003) and inhibiting Wee1 kinase (Watanabe et al. 2005). This 
auxiliary kinase is activated by Aurora-A kinase by phosphorylating Thr210 via the co-
factor Bora binding (Seki et al. 2008; Macůrek et al. 2008). Cdk1-Cyclin B 
phosphorylation (Hutterer et al. 2006) enhances this interaction, thus activating Plk1 to 
contribute in its positive feedback loops at G2/M transition. Additionally, Aurora-A 
kinase can also directly act on Cdc25B by phosphorylating it at Serine 353 at the 
centrosomes. This indicates that Aurora A kinase is involved in the initial activation of 
Cdk1-Cyclin B along with Plk1 (Cazales et al. 2005; Dutertre et al. 2004). Moreover, 
Plk1 and Aurora A kinases need to be activated to facilitate centrosome maturation and 
bipolar spindle formation in parallel to Cdk1-Cyclin B activation, to ensure well-timed 
mitotic entry (Lindqvist et al. 2009). However, it is noteworthy that Cdk1-Cyclin B 
activation can proceed without significant delays even in the absence of both Plk1 and 
Aurora-A (Hégarat et al. 2011). 
 
Thus, Cdk1 phosphorylations generate a positive feedback loop via cdc25 activation 
and Wee1/Myt1 inhibition. Cdk1 activates its activator and inhibits its inhibitor, directly 
or indirectly via auxiliary kinases such as Plk1 and Aurora A. Together these positive 
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feedback loops rapidly drive up the concentration of active Cdk1-Cyclin B1 at G2/M 
transition. Once the sufficient threshold is reached, the nuclear lamina is disassembled 
by Cdk1 phosphorylation of the lamins (Smoyer & Jaspersen 2014). The nuclear 
envelope is then broken and cells are committed to enter mitosis. The fine balance of 
these activating and inhibitory pathways tightly controls mitotic entry (O'Farrell 2001; 
Boutros et al. 2006; Hochegger et al. 2008; Lindqvist et al. 2009). 
 
1.2.8 Regulation of Kinetochore-Microtubule Attachments 
 
Initial activation of mitotic Cdk1-Cyclin B complex occurs at the centrosomes as 
discussed earlier. The regulatory networks controlling Cdk1-Cyclin B activation at the 
centrosomes need to be tightly controlled to facilitate subsequent mitotic entry (Hagan 
2008). The centrosomes are also microtubule-nucleating centres at the beginning of 
mitosis that are important for the formation of the spindle apparatus and thus 
maintaining genome stability (Abal et al. 2002; Chevrier et al. 2002). Centrosome 
duplication occurs at the same time as DNA synthesis in the G1/S transition (Blagden & 
Glover 2003). Centrosome maturation occurs during late G2/M, where Plk1 and Aurora 
A mitotic kinases recruit γ-ring complexes and microtubule nucleation components to 
initiate spindle formation (Blagden & Glover 2003). Centrosomes then migrate to the 
poles to form microtubule-emanating centres. Microtubules from these opposite poles 
of the cells connect condensed chromosomes to the spindle pole via a proteinaceous 
structure on the centromere of each sister chromatid called the kinetochore. Each sister 
chromatid is held together by cohesins, and is attached to the opposite poles ensuring 
bi-orientation of the chromosomes which in turn leads to faithful chromosome 
segregation(Miyazaki & Orr-Weaver 1994; Nicklas 1997). During the formation of 
bipolar spindles, erroneous sister kinetochore attachments are corrected by mechanism 
mediated by Aurora B kinase to prevent chromosome mis-segregation and 
aneuploidy(Tanaka et al. 2002; D. Liu et al. 2009). 
 
Aurora B is at the heart of the Chromosome Passenger Complex that promotes 
chromosome alignment by preventing kinetochore-microtubule mis-attachments and is 
localised to the centromeres. Aurora B along with the non-enzymatic subunits INCENP 
(Inner Centromere Protein), Borealin and Survivin form the Chromosome Passenger 
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Complex (CPC) (ref). It is a key component in detecting aberrant kinetochore-
microtubule attachments, as spindle attachments from the same pole exhibit lack of 
tension (Cheeseman & Desai 2008; Ruchaud et al. 2007; Vader et al. 2006). Lack of 
tension activates the kinase activity of Aurora B, which phosphorylates various 
kinetochore bound substrates such as yeast Dam 1 ring complex and the mammalian 
Ska complex, and the kinesis MCAK and Ndc80 complex (ref). This negatively 
regulates the microtubule binding as it destabilises the kinetochore-microtubule 
interaction (Cheeseman et al. 2006; Cheeseman et al. 2002; Deluca et al. 2006; 
Andrews et al. 2004; Lan et al. 2004). PP1γ is recruited in early mitosis to kinetochore 
by kinetochore-null1 (KNL1) and inactivates Aurora B as it comes into contact with it 
(Pinsky et al. 2006; Trinkle-Mulcahy et al. 2003). PP1γ at the outer kinetochore keeps 
Aurora B activity minimal. Thus, the kinase activity is maximal at the centromere and 
minimal at the outer kinetochore. Erroneous attachment cannot push the kinetochore 
away from the centromere, which leads to Aurora B phosphorylating Ndc80 and 
destabilizing the attachments. The correct attachment pushes the kinetochore away from 
the centromere and active Aurora B, thus stabilizing the end-to-end attachments (Cimini 
2007; Kelly & Funabiki 2009; Maresca & Salmon 2009). PP1γ is thus the Aurora-B 
counteracting phosphatase involved in promoting end-to-end attachments (ref). 
Furthermore the phosphatase PP2A-B56 also contributes in regulating influencing PP1γ 
recruitment (Etemad & Kops 2016; Rosenberg et al. 2011). 
 
1.2.9 Spindle Assembly Checkpoint (SAC) 
 
To ensure the chromosomes are equally segregated to the daughter cells, eukaryotic 
cells have evolved the Spindle Assembly Checkpoint (SAC). The SAC proteins monitor 
kinetochore-microtubule attachments and proper alignment of chromosomes on the 
metaphase plate. SAC controls the onset of anaphase in response to tension generated 
by correct bipolar attachment (McIntosh et al. 2002; Musacchio & Salmon 2007). 
Mutation screens in S. cerevisiae uncovered the proteins involved in spindle assembly 
checkpoint. In humans, SAC comprises of serine-threonine kinases: Mps1 (monopolar 
spindle protein), Bub1 (budding uninhibited by benomyl), a putative pseudokinase 
Bub1-related (BubR1; human orthologues of yeast Mad3) and other components like 
mitosis arrest deficient 1 (Mad1), Mad2 and Bub3. These proteins are highly conserved 
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among eukaryotes and are essential for preventing mitotic progression in the presence 
of unattached kinetochores to ensure normal cell division (Li & Murray 1991; Hoyt et 
al. 2016; Weiss & Winey 1996). Loss of SAC function in higher eukaryotes leads to 
inaccurate chromosome segregation and aneuploidy (Wassmann & Benezra 2001; Kops 
et al. 2005). 
 
The Sac proteins Mps1, Mad1, Mad 2, Bub 1, BubR1 and Bub 3 bind kinetochores prior 
to chromosome attachment. Additionally, the kinase Aurora B and APC/C cofactor 
Cdc20 are also recruited to the kinetochore along with motor proteins CENP-E (kinesin) 
and dynein (Musacchio & Salmon 2007; Cheeseman & Desai 2008). APC/C is an 
ubiquitin ligase (see Section 2.10) that mediates the ubiquitination of securin, a 
stoichiometric inhibitor of the protease Separase. Separase is required to cleave the 
cohesins that hold sister chromatids together, and enable equal distribution of 
chromosomes to the daughter cells (J.-M. Peters 2006). SAC negatively targets Cdc20 
ability to activate APC/C-mediated poly-ubiquitination and subsequent proteosomal 
degradation of Cyclin and securin (Kim et al. 1998; Hwang et al. 1998). Cyclin 
degradation by APC/C is described in the following section. SAC catalyses the 
formation of this mitotic checkpoint complex (MCC) that binds APC/C and prevents it 
from ubiquitinating its substrates. The MCC is a heterotetramer comprising of three 
SAC proteins, MAD2, BUBR1/Mad3 and BUB3, as well as CDC20 itself, and is the 
effector of SAC. The current model of SAC focuses on conformational changes in Mad-
2 from the open conformation (O-Mad2) to the closed conformation (C-Mad2). C-Mad2 
binds unattached kinetochores and promotes the binding of O-Mad2 to Cdc20. Once 
bound to Cdc-20, Mad-2 is converted to a closed conformation in an Mps1-dependent 
manner. The C-Mad2-Cdc20 complex is sequestered away from APC/C by binding the 
BubR1-BuB3 complex (Sudakin et al. 2001; H. Yu 2002; Hagting et al. 2002; R.-H. 
Chen et al. 1999). On the other hand, once all the kinetochores are attached to bipolar 
spindles the SAC is satisfied, MCC releases the sequestered Cdc20 and APC/C is 
activated by mitotic Cdks. This leads to securin degradation that results in sister 
chromatid separation. The mechanism proposed for checkpoint inactivation includes 
dynein-mediated pole-ward transport of checkpoint proteins (Howell et al. 2001; 
Gassmann et al. 2010), capping of the Mad1-Mad2 complex using the Mad-2 inhibitor 
p31Comet (De Antoni et al. 2005; M. Yang et al. 2007; Fava et al. 2011; Xia et al. 
2004; Mapelli et al. 2006) and finally antagonising the activity of PP2 phosphatase by 
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dephosphorylating substrates of checkpoint kinases like Aurora-B and Mps-1 (Shepperd 
et al. 2012; Qian et al. 2011; London et al. 2012). The inactivation of SAC leads to the 
onset of anaphase and activation of APC/C. Securin is degraded to release Separase, 
which cleaves cohesins, and an equal number of chromosomes migrates towards the 
opposite poles (Hauf et al. 2001). Kinesin and dynein motors as well as microtubule 
dynamics facilitate the poleward movement of chromatin (Brust-Mascher et al. 2004). 
 
Even minor alterations in the microtubule dynamics causes errors in chromosome 
attachment and lack of tension, which in turn activates SAC (Zhou et al. 2002). Thus, 
onset of anaphase is delayed which allows for chromosome re-alignment and spindle 
tension corrections. 
 
1.2.10 APC/C Activation and Cyclin Degradation 
 
In contrast to Cdk1 activation, which is mainly regulated by dephosphorylation of 
Thr14/Tyr15, inactivation of Cdk1 during mitotic exit is achieved by Cyclin 
degradation. As mentioned earlier, many key cell cycle regulators like Wee1 and CKIs 
are targeted for 26S proteosomal degradation by ubiquitination. Basic cell cycle control 
involves two ubiquitination complexes: the SCF complex (Skp-cullin-F-box) and the 
APC/C complex (Anaphase promoting complex/ Cyclosome). The SCF plays pivotal 
roles in G1/S and G2/M transition. The role of SCF in Wee1 regulation at the G2/M 
transition has been described earlier (Section 2.7). Conversely, APC/C is the major 
driver of the metaphase-anaphase transition and the establishment of G1 phase 
following mitotic exit. 
 
Protein degradation by 26S proteasome following poly-ubiquitination is a system to 
target misfolded and damaged proteins, also proven to have essential role in signal 
transductions mechanisms (Hershko & Ciechanover 1998; Alberts et al. 2014). The 
ubiquitination process is mediates by three enzymes: an activating enzyme (E1), a 
conjugating enzyme (E2) and an ubiquitin ligase (E3). These enzymes act in a stepwise 
manner to covalently attach multiple ubiquitin chains to the target protein, which is 
subsequently recognised and degraded by the proteosomal complex (Harper et al. 2002; 
J.-M. Peters 2002). 
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APC/C is a RING finger family E3 ubiquitin ligase and comprises of 14 subunits in 
humans (Schreiber et al. 2011). It targets specific substrates for degradation at the 
metaphase-anaphase transition (Pines 2011). APC/C is activated via two co-factors: 
Cdc20 and Cdh1. APC/A recognises substrates containing degradation motifs like D-
box and KEN-box. APC/C-Cdc20 prefers D-box containing substrates while APC/C-
Cdh1 can target both D-box and KEN box containing substrates (Pfleger & Kirschner 
2000). 
 
Cdc20 is expressed during S phase, G2 and mitosis. However, its binding to APC/C is 
dependent on phosphorylation of several subunits of the complex by mitotic kinases 
such as Plk1 and Cdk1. Thus, cdc20-mediated activation of APC/C only occurs in 
mitosis from prophase to anaphase (Shteinberg et al. 1999; Kramer et al. 2000; 
Acquaviva & Pines 2006; J.-M. Peters 2006). Additionally, in G2, APC binds to 
inhibitor Emi1 (early mitotic), thus preventing its interaction with Cdc20. Plk1 
phosphorylation of Emi1 in prophase directs it for SCF-mediated degradation and 
activates APC/C (Hansen et al. 2004). The APC subunit, APC15 is responsible for 
Cdc20 turnover and MCC release when the SAC is satisfied. If this subunit is absent, 
MCC and ubiquitylated Cdc20 remains attached to APC even when the SAC is satisfied 
(Mansfeld et al. 2011).  
 
Active APC/C-Cdc20 mediates degradation of Cyclin A and Nek2 in prometaphase 
(Sedgwick et al. 2013; Geley et al. 2001; Elzen & Pines 2001)and Cyclin B and Securin 
(See Section 2.9) at metaphase-anaphase transition. Cyclin degradation is mediated by 
two motifs within the N-terminal region: the D-box (sufficient for degradation in 
Xenopus) and the KEN-box (Evans et al. 1983; Murray & Kirschner 1989a). These 
sequences correspond to a two-part degron or degradation signal, which is a disordered 
region where polyubiquitin chains are attached. 
 
APC/C-Cdc20 triggers the onset of anaphase by degrading Securin. This causes the 
release of Separase and cleavage of Kleisin subunit Scc1 in the cohesion ring resulting 
in the separation of sister chromatids (Thornton & Toczyski 2003; J.-M. Peters 2006; 
Acquaviva & Pines 2006). Moreover, APC/C-Cdc20 initiates degradation of mitotic 
Cyclins which results in downregulation of Cdk1 activity (Kramer et al. 2000; J.-M. 
Peters 2006). Due to low Cdk1 activity, the key mitotic substrates are dephosphorylates 
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which leads to decondensation of chromosomes and reformation of the nucleus. 
Moreover, the cytokinesis regulator ECT2 is relieved from its inhibition, allowing the 
cytokinetic ring to constrict (Niiya et al. 2005). 
 
At anaphase, since the Cdk1 activity is low due to Cyclin degradation, Cdh1 is activated 
and can replace Cdc20 on APC/C to maintain high APC/C activity (Castro et al. 2005). 
Unlike Cdc20, Cdh1 (also called FZR1) binds APC/C irrespective of its 
phosphorylation state. However, from late G1 to anaphase, Cdk1 activity is high, and 
the kinase phosphorylates and prevents the binding of Cdh1 to APC/C. APC/C-Cdh1 is 
active in late mitosis and during anaphase and telophase and stays active until late G1. It 
is involved in the degradation of Cyclins, residual Securin, Plk1, Aurora kinases and 
various proteins involved in DNA replication, as well as in the degradation of Cdc20, 
which inactivates APC/C-Cdc20. Eventually, APC/C-Cdh1 degrades its E2 enzyme, 
leading to self-inactivation. This promotes the accumulation of S-phase Cyclins and the 
subsequent entry of the cells into the S phase (J.-M. Peters 2006; Pfleger & Kirschner 
2000). In yeast, following anaphase the phosphatase Cdc14 dephosphorylates Cdh1 and 
promotes the interaction and subsequent activation of Cdh1-APC/C (Hatano et al. 
2016). RNAi and gene deletion studies with Cdh1 show that it is not essential for 
mitotic exit but G1 phase is shortened and S phase is prolonged in its absence. Thus, 
Cdk1 activation switches APC/C-Cdh1 off, while high APC/C-Cdh1 activity prevents 
Cyclin accumulation and leads to establishment of stable G1-phase (Sigl et al. 2009). 
 
Thus, in addition to reversible post-translational modifications such as phosphorylation 
by mitotic kinases, SCF- and APC/C-mediated proteolysis provides an irreversible 
mechanism that ensures a strict unidirectional progression of the cell cycle. 
 
1.3 Greatwall Kinase and the Phosphatase Control System 
 
1.3.1 Phosphatases and Cell Cycle Control 
 
Kinases have been at the centre of attention in cell cycle control research for decades. 
Following the discovery of Cdc2- Cyclin, it was believed that the cell cycle is controlled 
by the activation and downregulation of kinases. However, it was only recently that a 
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prominent role of phosphatases in the regulation of mitotic entry and exit control was 
recognised. Protein phosphatases have counteracting functions to mitotic kinases. These 
enzymes were thought to be ubiquitously present and the dephosphorylation of 
substrates was assumed to be a result of broad-acting phosphatase activity (Trinkle-
Mulcahy & Lamond 2006). However, this view of phosphatases as silent kinase 
partners in regulation is changing. Recent mounting evidence shows that mitotic protein 
dephosphorylation requires involvement of specific phosphatases that are tightly 
regulated in time and space. For example, a large scale RNAi screen of human kinases 
and phosphatases, identified 32% of the total phosphatases to promote survival while 
only 11% of the kinases appeared to be essential (MacKeigan et al. 2005). 
 
Phosphatases have been implicated to play crucial roles for the timely 
dephosphorylation of substrates in events such as spindle assembly, SAC activation, 
anaphase onset and mitotic exit (Bollen et al. 2009). Thus, a delicate interplay of 
kinases and phosphatases is essential for controlling mitotic events (Domingo-Sananes 
et al. 2011; De Wulf et al. 2009). Two important classes of phosphatases have been the 
focus of research: the dual specificity phosphatases Cdc25 and Cdc14 and the serine-
threonine phosphatases PP1 and PP2A. Recently, FCP-1 phosphatase that belongs to the 
Asp family of serine-threonine phosphatases has been implicated to have a regulatory 
role in the mitotic exit network(Visconti et al. 2012; Monica et al. 2015; Hégarat, 
Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & Hochegger 2014a). 
 
Cdc25 is responsible for Cdk1-Cyclin B activation by dephosphorylating the inhibitory 
phosphorylations by Wee1/Myt1 kinase at the G2/M transition (Kumagai & Dunphy 
1992; Lindqvist et al. 2005; Domingo-Sananes et al. 2011). Cdc25 functions and 
regulation has been described in detail in the earlier sections (See section 2.5 and 2.6).  
 
1.3.2 Phosphatases and Cell Cycle Control: Cdc14 
 
Cdc14 is one of the mitotic dual-specificity phosphatases that controls mitotic exit in 
budding yeast. Cdc14 is sequestered in the nucleus from the G1 phase until metaphase 
by its inhibitor Cif1 (also known as Net1). In anaphase, it is released into the cytoplasm 
in a Cdk1 phosphorylation-dependent manner (Stegmeier & Amon 2004; Queralt et al. 
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2006). This results in dephosphorylation of the Cdk1 substrates, eventually leading to 
mitotic exit (Visintin et al. 1998). In addition to Cdk1 inactivation, Cdc14 also triggers 
localization of chromosomal passenger proteins to the spindle midzone in anaphase, 
regulates spindle dynamics, inhibits rDNA transcription during anaphase (Clemente-
Blanco et al. 2009), and contributes to rDNA decondensation and segregation (Varela et 
al. 2009) as well as to cytokinesis (Stegmeier & Amon 2004; D'Amours & Amon 2004). 
Cdc14 inactivates Cdk1 via two mechanisms: mitotic Cyclin degradation by APC/C-
Cdh1 and dephosphorylating Sic1 (Clb-Cdk inhibitor) and Swi5 (Sic1 transcription 
factor) (Stegmeier & Amon 2004). However, the orthologues of Cdc14 are dispensable 
for mitotic exit in S. pombe (Cueille et al. 2001; Trautmann et al. 2001) and 
Caenorhabditis elegans (Roy et al. 2011). Likewise gene deletions of vertebrate 
Cdc14A and B do not display mitotic exit defects (Mocciaro & Schiebel 2010). 
 
The human homologs Cdc14A, B and C are suggested to be involved in various mitotic 
and non-mitotic processes, but are not required to dephosphorylate Cdk substrates. 
Centrosomal Cdc14A counteracts Plk1 function and antagonizes Cdc25C (Krasinska et 
al. 2007). It is also suggested to contribute in centrosome separation, spindle assembly 
and chromosome segregation (Kaiser et al. 2002; Mailand et al. 2002). Cdc14B has 
been implicated in the removal of activating phosphorylations on Cdc25 in anaphase, 
thereby negatively regulating Cdk indirectly to promote mitotic progression (Mocciaro 
& Schiebel 2010; Vázquez-Novelle et al. 2010; Tumurbaatar et al. 2011). Human 
Cdc14 B is also sequestered in the nucleolus and is translocated to the cytoplasm in 
response to DNA damage prior to mitotic entry. Here it dephosphorylates and activates 
Cdh1, which in turn leads to APC/C-Cdh1 dependent degradation of Plk1 that blocks 
mitotic entry (Bassermann et al. 2008). Moreover, Cdc14B also stabilizes microtubules 
by mediating dephosphorylation of the tubulin deacetylase SIRT2. However, Cdc14B 
was also observed to stabilize and bundle microtubules independent of its phosphatase 
activity (Dryden et al. 2003; H. P. Cho et al. 2005; Rodier et al. 2008). Overall, a final 
triple knockout of Cdc14A, B and C has not been reported yet, making it difficult to 
exclude the possibility that this phosphatase might plays a role in mitotic exit in 
mammalian cells. 
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1.3.3 Phosphatases and Cell Cycle Control: PP1 and PP2A 	  
 
PP1 and PP2A are serine threonine phosphatases that are implicated in mitotic exit. 
However, their precise mode of action remains to be determined. These phosphatases 
are multimeric complexes to build up holoenzymes comprising of a catalytic subunit (α, 
β/δ or γ), a regulatory subunit and a scaffolding subunit. Substrate specificity and 
localisations are determined by the catalytic subunit in association with over 200 PP1 
interacting proteins (PIPs) (Bollen et al. 2010). The mitotic functions of PP1 and PP2A 
are briefly described in this section. 
 
Nuclear lamin dephosphorylation is essential for nuclear envelope reassembly at mitotic 
exit. PP1 was implicated in lamin dephosphorylation as this phosphatase activity was 
inhibited by the PP1 inhibitor, Inhibitor-1 and high nanomolar concentration of okadaic 
acid. PP1 was observed to promote timely dephosphorylation and reassembly of the 
nuclear envelope in partnership with PP2A at mitotic exit (Thompson et al. 1997). PP1 
also contributes to kinetochore reassembly and cytokinesis, though its substrates and 
mechanisms in these roles still remain elusive (Barr et al. 2011; Bollen et al. 2009). The 
characteristic architecture of chromosome is preserved by activation of RepoMan-PP1 
activity at anaphase following Repo Man dephosphorylation in co-operation with 
condensin (Vagnarelli et al. 2006). Roles of PP1 in counteracting Aurora B kinase at the 
kinetochore in metaphase and spindle assemble checkpoint have been described earlier 
(See Section 2.7 and 2.8). Studies with the nuclear inhibitor of PP1 (NIPP1) in HeLa 
cells suggest the main function of PP1 in SAC signalling can be rescued by 
simultaneous inhibition of its counteracting kinase, Aurora B. However, these 
observations argue against the role of PP1 as the major Cdk-counteracting phosphatase 
(Winkler et al. 2015).  
 
In Xenopus egg extracts PP1 is reported to be the main catalyst to initiate the 
dephosphorylation cascade at mitotic exit. PP1 is suppressed via two mechanisms: Thr 
320 phosphorylation by Cdc2 (Kwon et al. 1997; Dohadwala et al. 1994) and binding of 
its inhibitor, Inhibitor-1. The binding of Inhibitor-1 is mediated by protein kinase A 
(PKA) –dependent phosphorylation site and is analogous to Ensa/Arpp19-PP2A B55 
interaction explained in the later sections. At mitotic exit, once Cdc2 is inactivated by 
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Cyclin degradation, PP2 auto-dephosphorylates at the Cdc2 site (Thr320) and partially 
activates itself. Full activation of PP1 is achieved by dephosphorylating the activating 
site on Inhibitor-1 (Thr32), leading to its dissociation from the phosphatase(Wu et al. 
2009). PP1 is also shown to initiate Greatwall dephosphorylation (described in the later 
section) as well. This places PP1 at the top of cascade in mitotic exit dephosphorylation 
(Heim et al. 2015; Ma et al. 2016; Rogers et al. 2016). Similar cross talk was observed 
among the serine-threonine phosphatases in fission yeast where PP1 activates PP2A-
B55 and PP2A-B56, suggesting PP1 as the initiator of the relay of mitotic exit 
phosphatases. PP1 was found to bind the regulatory subunits B55 and B56 via the PP1 
docking site. At mitotic exit, once PP1 is activated fully following Cdk inactivation, it 
first activates PP2A-B55. PP2A-B55 in turn activate PP2A-B56 by dephosphorylating 
the PP1 docking site on the B56 subunit (Grallert et al. 2015). However, this function of 
PP1 needs to be verified in mammalian cells as the existing experimental evidence with 
siRNA depletion of PP1 catalytic subunits fails to inhibit Greatwall 
dephosphorylation(Rogers et al. 2016). Moreover, inhibition of PP1 using tautomycetin 
also does not affect Greatwall inactivation and Ensa/Arpp19 dephosphorylation in 
somatic cells (Hégarat, Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & 
Hochegger 2014b). 
 
PP2A is another mitotic phosphatase and is ubiquitously present in the cell cycle. PP2A 
is also a holoenzyme comprising of a scaffold subunit (PP2AA), catalytic subunits 
(PP2Ac) and regulatory subunits (PP2AB). PP2Ac exists as two isoforms: Cα and Cβ. 
The scaffold subunit has two isoforms: Aα and Aβ. There are four isoforms of the 
regulatory subunit: B55/B, B56/B’, PR72/B’’ and PR93/B’’’. Of these B55 and B56 
have been identified to play important roles in cell cycle control (Seshacharyulu et al. 
2013). PP2A holoenzymes of the B55 family have been proposed to have Cdk1-
counteracting roles at mitotic entry and exit (Lorca & Castro 2012). These functions of 
PP2A-B55 are described in further detail in the following sections. There are four B55 
paralogues, alpha to delta, of which alpha and delta are the dominant forms in 
proliferating cells. PP2A-B55α is involved in post-mitotic assembly of the nuclear 
envelope, Golgi apparatus and condensed chromosome. It co-operates with the nuclear 
transport factor Importin β1 to execute these functions (Schmitz et al. 2010).  
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1.3.4 Phosphatases and Cell Cycle Control: FCP1 	  
FCP-1 belongs to the Asp-based group of serine-threonine phosphatases. FCP-1 shows 
the presence of the Asp-based signature catalytic sequence DXDXT/V, in the N-
terminus (FCPH). It was initially thought to be a regulatory subunit of the phosphatase, 
as it had no homology to the known serine-threonine phosphatases. FCP-1 consists of a 
BRCT (BRCA1 C-terminus domain) domain in the mid-region. It is the only 
phosphatase in the transcription machinery to show the presence of this domain and was 
initially identified in the tumour suppressor gene BRCA1 in breast cancer cell lines. 
 
FCP-1 was the first phosphatase shown to dephosphorylate the CTD (C-terminal repeat 
domain) of the largest subunit of RNA polymerase II (Pol II). FCP-1 was first purified 
from HeLa extracts and showed two isoforms: the predominant one of 205 kDa and the 
less abundant one of 150 kDa. It requires magnesium ions for its phosphatase activity, a 
characteristic feature of type 2C phosphatases (Chambers & Dahmus 1994). In 1996, 
yeast CTD phosphatase was seen to exhibit identical properties of mammalian FCP-1. 
Although the human and yeast CTD are almost identical, both phosphatases failed to 
dephosphorylate the polymerase molecule from the other species(Chambers & Kane 
1996). 
 
CTD is observed in various phosphorylation states during transcription. It is a 7-amino 
acid (heptapeptide) repeats, with as many as 52 copies in the mammalian genome. In 
human and mouse, it is phosphorylated at Ser2 and Ser5. These phosphorylation states 
contribute to the recruitment of various nuclear factors involved in mRNA maturation. 
Although various stages of phosphorylation of CTD is required for recruitment of the 
processing factors, docking of Pol II and elongation (Y. Zhang et al. 2006; Meinhart et 
al. 2005), CTD need to be dephosphorylated during the termination phase of 
transcription. This dephosphorylation is crucial for the employment of a new-pre-
initiation complex to continue to the second round of transcription. Thus, FCP-1 is 
important for recycling Pol II (Meinhart et al. 2005). Smaller CTD phosphatases such as 
SCP-1 are present in higher eukaryotes. SCP-1 contains the FCPH domain but lacks the 
BRCT domain (Yeo et al. 2003).  
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Mutating the fcp-1 gene in yeast revealed that it dephosphorylates Ser2 on the CTD 
repeat. (E. J. Cho et al. 2001). Partially purified FCP-1 identified general transcription 
factors such as TFIIF and TFIIB to have roles in is regulation. While TFIIF was seen to 
stimulate FCP-1 activity, TFIIB had an inhibitory effect on the function of TFIIF. 
However, TFIIB on its own did not have any effect on the phosphatase activity 
(chambers 1995). Concurrently, yeast FCP-1 activity was inhibited by TFIIF, purified 
from cellular extracts(Chambers & Kane 1996). TFIIF is a general transcription factor 
comprising of two subunits RAP30 and RAP74 and plays important part in both 
initiation and elongation. Later in 1998, FCP-1 cDNA was isolates in two-hybrid screen 
for RAP74 (largest subunit of TFIIF) interacting proteins(J. Archambault et al. 1998). 
FCP-1 docks on phosphorylated CTD via the BRCT domain in its C-terminal domain 
(X. Yu et al. 2003). 
 
Although the phosphatase function of FCP-1 in the transcriptional machinery was well 
known, it was only recently that the mitotic role of FCP-1 was discovered. FCP-1 
contributes to the mitotic network by dephosphorylating Greatwall kinase at mitotic 
exit(Monica et al. 2015; Visconti et al. 2012). These observations are discussed in detail 
in the following sections (Section 1.3.10). 	  
1.3.5 Greatwall Kinase: Mitotic Functions of a Novel AGC Kinase 
 
Greatwall (Greatwall) kinase was discovered during the last decade due to its mitotic 
phenotypes in Drosophila embryos (J. Yu et al. 2004) and has proven to be a major 
mitotic kinase. The discovery of Greatwall changed the way G2/M transition was 
perceived in cell cycle control. In 1996, greatwall (gwl) was initially discovered in 
Drosophila as scant (Scott of the Antartic). Mutants of scant in female syncytial 
embryos were sterile and when homozygous caused mitotic defects (White-Cooper et 
al. 1996). This gene was later mapped to greatwall gene in Drosophila and found to 
express a hyperactive form of the kinase (K97M) (V. Archambault et al. 2007). The first 
recessive allele of greatwall was identified in Drosophila by Yu et al (J. Yu et al. 2004), 
where it was found to encode a nuclear protein belonging to the AGC kinase family. 
This paper was the first to describe mitotic functions of the kinase in larval neuroblasts. 
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They named this gene ‘Greatwall’ as the mutant phenotype indicated an important role 
for this protein in protecting chromosome structure (J. Yu et al. 2004). 
 
Greatwall is conserved across species from insects to vertebrates. Drosophila and 
human greatwall have 59% sequence identity. The homology extends beyond the 
bifurcated kinase domain into the flanking amino acids. It belongs to the family of 
serine-threonine kinases called AGC kinases, which target amino acids flanked by basic 
residues for phosphorylation (Tamaskovic et al. 2003). Greatwall is an unusual kinase 
as its kinase domain is bifurcated by an unrelated stretch of ~ 500 amino acids 
separating the sub-domains VII and VIII (Hanks & Quinn 1991; J. Yu et al. 2004). 
Greatwall is sequestered in the nucleus due to the presence of two nuclear localization 
signals in the uncharacterized loop region in both Drosophila and mammalian Greatwall 
kinase (P. Wang et al. 2013; Alvarez-Fernández et al. 2013). Greatwall re-localizes 
partly to the centrosomes but is present universally in the cytoplasm during mitosis (J. 
Yu et al. 2004; Voets & Wolthuis 2010). 
 
The initial mitotic phenotypes of Greatwall were characterised by the Goldberg lab in 
Drosophila larval neuroblasts. The most striking phenotype of the mutant gwl allele was 
under-condensed chromosomes and delayed mitotic progression from the late G2 phase 
until nuclear envelope breakdown (NEBD), which was accompanied by chromosome 
segregation defects. Despite the presence of aberrant chromosomes, phospho-histone 
H3 and condensin component Barren was recruited, which is indicative of normal 
chromosome condensation apparatus. However, later it was shown with RNAi treatment 
in Drosophila S2 cells that Greatwall contributes to chromosome congression and 
segregation but not to chromosome condensation (J. Yu et al. 2004; Bettencourt-Dias et 
al. 2004). Greatwall appeared to arrest or delay anaphase onset and the mutants that 
progressed into anaphase or telophase displayed lagging chromosomes or chromosome 
bridges. This was not due to defective spindle apparatus as the spindles in all stages of 
mitosis were morphologically normal. Mutations in gwl also lead to activation of 
spindle assembly checkpoint as the sister chromatids never separated and high levels of 
Cyclin were observed. This was not a consequence of DNA replication problems or 
activation of caffeine-sensitive checkpoint (J. Yu et al. 2004).  
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Similar phenotypes were observed on depletion of the mammalian orthologue of 
Greatwall, MASTL (microtubule-associated serine/threonine kinase-like) using siRNA 
in human cells. Cells strongly depleted of Greatwall exhibited a prolonged delay in G2, 
but eventually entered mitosis. Chromosome condensation and mitotic progression is 
delayed with segregation defects at anaphase. This in turn leads to the trapping of 
chromatin in the cleavage furrow and cytokinesis failure as well as aneuploidy (Voets & 
Wolthuis 2010; Burgess et al. 2010). Genetic ablation of Greatwall in mice is lethal in 
the embryonic stage. Although Greatwall-depleted cells enter mitosis with normal 
kinetics, they display condensation defects with prometaphase arrest. This is 
accompanied by reductions in Cdk1-substrate phosphorylation, which is comparable to 
the mitotic collapse phenotype observed upon on co-depletion of Wee1/Myt1 and 
Cdc25, which was characterised by Potapova et al. (Alvarez-Fernández et al. 2013; 
Potapova et al. 2011). Depletion of Greatwall in Xenopus egg extracts prevents mitotic 
entry (Castilho et al. 2009), while the addition of purified Greatwall to immature 
oocytes initiates meiosis even in the absence of progesterone (Zhao et al. 2008). 
 
Yu et al. suggested that Greatwall is required to maintain high Cdk1-Cyclin B activity 
at mitotic entry and this was further supported by Greatwall depletion in Xenopus 
extracts, where Cdk1-Cyclin B activation and mitotic entry was prevented (J. Yu et al. 
2006). Activate Greatwall in egg extracts was also observed to promote meiotic and 
mitotic entry. Additionally, Greatwall-depletion in CSF extracts results in mitotic exit 
and reversion of MPF activity to interphase levels concurrent with loss of 
phosphorylation of mitotic proteins Wee1, Myt1, Cdc25, Plx (Xenopus Plk1) and MAP 
kinase. This drop in MPF activity occurred due to the accumulation of inhibitory 
phosphorylation (Try15) on Cdk1. Moreover, Cdk1AF mutant (constitutively active 
Cdk1 (Pomerening, Ubersax & Ferrell 2008a)) rescue G2-arrested Greatwall phenotype, 
suggesting that Greatwall is a part of the MPF auto-amplification loop (Zhao et al. 
2008; J. Yu et al. 2006). Activated Greatwall induces CDC25C phosphorylation in the 
absence of Cdk1, Plx and MAP kinase or activator of protein kinase A (PKA) that 
usually blocks mitotic entry. G2 arrest induced by Greatwall depletion can be rescued 
by the phosphatase inhibitor, Okadaic acid. Thus, Greatwall might negatively regulate 
an Okadaic acid–sensitive phosphatase to ensure increased concentration of MPF 
activity in order to maintain M phase–specific phosphorylations of mitotic proteins 
Cdc25 and Wee1/Myt1 (Vigneron et al. 2009; Zhao et al. 2008; Lorca et al. 2010). This 
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phosphatase was later identified to be PP2A-B55delta in Xenopus studies (Mochida et 
al. 2009; Castilho et al. 2009). The PP2A-B55 regulation by Greatwall kinase is 
described in detail in the following section. 
 
1.3.6 Regulation of PP2A-B55 by its Antagonising Kinase, Greatwall 
 
The existence of an MPF-counteracting phosphatase has been hypothesised since a long 
time. Studies in Xenopus extracts by Cyert and Kirschner identified an inhibitor of the 
MPF activity and proposed it to be phosphatase called INH. INH was shown to control 
the nuclear Cyclin accumulation thresholds in Xenopus oocytes. Moreover, protein 
phosphatase -1 (PP1) was thought to regulate the activity of INH either directly or 
indirectly(Cyert & Kirschner 1988; Solomon et al. 1990). These findings were later 
demonstrated using microinjection or incubation with specific phosphatase inhibitor of 
types 1 and 2A protein phosphatases in cytoplasm of G2 arrested starfish oocytes and in 
G2 arrested Xenopus that led to MFP activation. Treatment of okadaic acid in 
mammalian cells also initiated mitotic entry even when Cdk1 was inhibited using 
specific inhibitors, implying that phosphatase activity is crucial for G2/M transition 
(Gowdy et al. 1998). INH was postulated to be type 2A protein phosphatase as only 
okadaic acid treatment but not inhibitor-1 triggered germinal vesicle breakdown in 
Xenopus oocytes. Interestingly, the presence of a nuclear component was prerequisite to 
inhibit the phosphatase in the cytoplasm, which was later discovered to be the unusual 
AGC kinase, Greatwall (Goris et al. 1989; Picard et al. 1989; Picard et al. 1991; J. Yu et 
al. 2004; Castilho et al. 2009; Vigneron et al. 2009; Mochida et al. 2009).  
 
PP2A, with the B55 regulatory subunit, dephosphorylates artificial peptides pre-
phosphorylated with Cdk1 in vitro and Cdk1 substrates in vertebrate cell extracts 
(Agostinis et al. 1992; Ferrigno et al. 1993). Meanwhile, a loss-of-function mutation in 
the gene encoding the PRC55 (B55) subunit of PP2A leads to defective chromosome 
condensation and the subsequent anaphase. These phenotypes were due to the strong 
depletion of PP2A-B55 in embryos, which inhibited dephosphorylation of Cdk1 
substrates at mitotic exit (Mayer-Jaekel et al. 1994). Thus, PP2A-B55 was found to be a 
promising candidate as the Cdk1-counteracting phosphatase in cell cycle control. 
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Mochida and Hunt (2007) observed the regulation of anti-Cdk1 activity in a cyclic 
fashion, where it appeared at mitotic entry and disappeared at mitotic exit and was 
targeted at mitotic phospho-proteins. This phosphatase was later identified as PP2A-
B55δ in Xenopus extracts, inhibiting Cdk1 peptide phosphorylations (Mochida et al. 
2009). Two papers in 2009 by Vigneron et al. and Castilho et al. described the 
Greatwall regulation of anti-Cdk1 phosphatase in mitotic entry. Greatwall depletion in 
Xenopus CSF (Cytostatic factor) extracts caused MPF inactivation by Try-15 
phosphorylation and rapid dephosphorylation of Cdk substrates. This was accompanied 
by DNA decondensation. Co-depletion of Greatwall, Wee1 and Myt1 triggered exit 
form mitosis. This was unusual as MPF activity was highly indicated by the lack of 
Tyr15 phosphorylation. These observations suggests that the principal function of 
Greatwall is phosphatase inhibition and not auto-amplification of MPF (Vigneron et al. 
2009). Furthermore, peptides phosphorylated at Cdk1 phospho-sites were 
dephosphorylated by Greatwall-depleted extracts but not the control or untreated 
extracts. This indicated phosphatase activation in the absence of Greatwall is directed 
towards Cdk1 phospho-sites. The activation of this phosphatase was independent of 
MPF activity as supplementing the depleted extracts with Cdk1AF (Constitutively 
active Cdk1) still led to phosphatase activation(Castilho et al. 2009).  
 
Null mutations of gwl caused significant delay or cell cycle arrest at the G2/M transition 
in Drosophila (J. Yu et al. 2004). Similar phenotypes were observed in ‘Cycling’ 
Xenopus extracts, where Greatwall immunodepletion arrested them in G2 
phase(Castilho et al. 2009). However, a dual inhibitor of PP1 and PP2A, microcystin as 
well as 500 nM of okadaic acid (inhibits 70% of PP2A (Félix et al. 1990; Favre et al. 
1997; Vigneron et al. 2009)) reversed the Greatwall phenotype. However, Inhibitor-1, 
the specific PP1 inhibitor did not. Additionally, immunodepletion of the B55δ subunit 
of PP2A also rescued Greatwall phenotypes. The inhibition of PP2A–B55δ in Cycling 
extracts (interphase) using specific inhibitors or immunodepletion leads to premature 
mitotic entry and arrests them in mitosis. Thus, Greatwall antagonises PP2A–B55δ, as 
depletion of the phosphatase rescues Greatwall-induced phenotypes (Mochida et al. 
2009). 
To investigate if Greatwall influences the phosphatase activity of PP2A in-vitro 
phosphatase assays were performed. The dephosphorylation of Cdk phosphosites on 
synthetic peptides was reduced significantly in the presence of greatwall in comparison 
	   38	  
to exogenous PP2A- B55δ (Castilho et al. 2009). Similarly, cMos was phosphorylated 
in vitro using radiolabelled ATP by its known kinase, Cdk1- Cyclin B IP. 
Phosphorylated substrates were then assayed for release of phosphates with 
immunoprecipitated PP2A/C from control and Greatwall-depleted CSF extracts. A 
three-fold increase in the phosphatase activity was observed with PP2A/C from 
Greatwall-depleted extracts, despite adding equal amounts of substrate and phosphatase 
in the assays (Vigneron et al. 2009). These data convincingly show that Greatwall 
inhibits PP2A dephosphorylation of Cdk1- Cyclin B substrates.  
 
In agreement with these observations, Lorca et al. reported that the Greatwall-PP2A 
B55 pathway functions are important along with the MPF amplification pathway for 
Xenopus first embryonic cycle. In metaphase II-arrested oocytes, inhibition of Greatwall 
before the activation of Cdk1- Cyclin B activation induced premature mitotic entry with 
incomplete mitotic substrate phosphorylation by Cdk1-Cyclin A. This eventually led to 
rapid degradation of the Cyclins A and B and abrupt exit from mitosis. Thus, Greatwall 
functions as an inhibitor of the phosphatase targeting mitotic substrates and is involved 
in controlling mitotic entry as well as maintenance of the mitotic state (Lorca et al. 
2010). 
Direct interaction of the kinase and phosphatase was demonstrated by expressing 
exogenous YFP-Greatwall in Hek293 cells. Transiently expressed PP2A/A (scaffold) 
and PP2A/C (catalytic subunits of the phosphatase) immunoprecipitates with the 
exogenous kinase in mammalian cells. This also occurs when these subunits are used as 
bait by over-expressing HA-tagged PP2A/C, as Greatwall is present in the 
immunoprecipitate. However, Greatwall does not seem to interact with the scaffold 
subunit in the absence of exogenous PP2A/C. Thus, the catalytic subunit of PP2A 
appears to be important for the kinase-phosphatase interaction, although Greatwall 
interacts with both PP2A/A and PP2A/C subunits. These pull-downs were performed 
with overexpression of both the kinase and the phosphatase. Therefore, the observation 
that Greatwall shows very little enrichment of PP2A indicates that either the kinase 
interacts with only a few subunits of PP2A complex or the direct interactions of these 
proteins is mediated by unknown interactors. In agreement with these observations, 
Castilho et al. (2009) reported that no indication of Greatwall phosphorylation of any of 
the PP2A-B55 δ subunits was observed in the in vitro kinase assays (Vigneron et al. 
2009). 
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1.3.7 The Endosulphine Family: Endosulphine-alpha (Ensa) and Arpp19 
 
As observed in the previous Xenopus work (Castilho et al. 2009), Greatwall does not 
directly phosphorylate PP2A subunits. Work in Xenopus extracts by the Mochida and 
Castro labs identified two unstructured small proteins, Endosulphine-alpha (ENSA) and 
cyclic adenosine monophosphate–regulated phosphoprotein 19 (Arpp19) as Greatwall 
substrates that mediated its action on the PP2A-B55 (Fig. 1.4) (Mochida et al. 2010; 
Gharbi-Ayachi et al. 2010)(Fig. 1.8). 
 
Arpp19 was first discovered in the mammalian nervous tissue, enriched in dopamine –
receptive neurons coupled to adenylate cyclase (Ivar Walaas et al. 1983). Its distribution 
was varied in all adult vertebrate tissues and malignant cells, while concentrations 
decreased with embryonic development towards pre-natal and post-natal periods 
(Girault et al. 1990). Arpp19 is a phosphoprotein found to be regulated by cyclic-AMP 
signalling pathway with an increase in phosphorylation at Ser104 in response to PKA 
activation (Dulubova et al. 2001). Arpp19 was found to be similar to another protein 
named Endosulphine-alpha involved in the endogenous regulation of sulfonylurea-
sensitive potassium channels. Endosulphines are described as endogenous ligands that 
bind sulphonylurea receptor and inhibit the coupled potassium channels in the presence 
of ATP. This, in turn, increases the secretion of insulin in the β-cells of the pancreas 
thus mimicking sulphonylurea drugs used to manage non-insulin dependent diabetes 
mellitus. They are ubiquitously present in the muscle, nervous and endocrine tissues 
(Virsolvy-Vergine et al. 1992; Peyrollier et al. 1996; Heron et al. 1998). Structural 
studies displayed similarities of this protein to Arpp19 in mammalian tissues (Peyrollier 
et al. 1996). Endosulphine-alpha comprises of four helices when bound to lipid 
mimetics, while is intrinsically unstructured in solution. Mutating the PKA 
phosphorylation site (S109E) disrupts the fourth helix as well as its interaction with its 
binding partner α-synuclein (Parkinson’s disease associated membrane protein) 
(Boettcher et al. 2008).  
	   40	  
  
Figure 1.4 The Greatwall-Ensa/Arpp19-PP2A B55 pathway at G2/M transition 
 
Schematic representation of the Greatwall-Ensa/Arpp19-PP2A B55 pathway at G2/M 
transition. Cdk1 activates Gwl by phosphorylating various Cdk phosphosites. 
Phosphorylated Greatwall activates Ensa/Arpp19 by phosphorylating Ser67 residue. 
Activated Ensa/Arpp19 are potent inhibitors of PP2A-B55 to prevent Cdk substrate 
dephosphorylation. The faded colours show inactivated proteins and the brighter ones show 
active proteins/protein complexes. Adapted from T Lorca and A Castro (Lorca & Castro 
2012). 	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 Cell cycle phenotypes of the Ensa (Endosulphine alpha) homologue, Endos, were 
identified initially in Drosophila oocytes. Mutating the endos gene in oocytes displays 
phenotypes analogous to that conferred by cdc2 and cdc25, such as an extended 
prophase I and inability to progress after metaphase I, which is also reminiscent with the 
Greatwall-depletion phenotypes observed in Xenopus extracts (Vigneron et al. 2009); 
moreover, protein levels of Polo and Twin (PP2A meiotic homologue) are reduced. 
These meiotic maturation phenotypes could rescued by exogenous human-Ensa, which 
showed that these proteins are conserved functionally in higher eukaryotes. A novel 
binding partner of Endos called Early girl (Elgi), which is known to be an E3 ubiquitin 
ligase, has also been identified (Stetina et al. 2008). 
 
Two papers in 2010 identified Ensa and Arpp19 as Greatwall substrates. Mochida et al. 
identified Greatwall substrates using KESTREL (kinase substrate tracking and 
elucidation) method in which the potential substrates containing extracts were 
phosphorylated in vitro by active Greatwall, while endogenous kinase was inhibited. 
The phosphorylated bands were analysed by proteomic screening, and Arpp19 and Ensa 
were found to be the potential Greatwall substrates(Mochida et al. 2010). Interestingly, 
biochemical fractionation of meiotic-arrested CSF extracts and subsequent mass 
spectrometry only identified Arpp19 as Greatwall substrate in the proteomic screen 
(Gharbi-Ayachi et al. 2010).  
 
As mentioned earlier, Greatwall depletion in interphase extracts inhibits mitotic entry 
and triggers premature mitotic exit in mitotic extracts (Castilho et al. 2009; Mochida et 
al. 2009; Vigneron et al. 2009). Immunodepletion of Ensa (Mochida et al. 2010) and 
Arpp19 (Gharbi-Ayachi et al. 2010) in Cycling extracts prevents mitotic entry, similar 
to that observed with Greatwall depletion. Adding back the wild type or recombinant 
S67 thiophosphorylated Ensa and Arpp19, but not the S67 mutant, can rescue these 
phenotypes. The mitotic phosphorylations were minimal in the depleted extracts while 
the inhibitory Tyr 15 phosphorylation remained on Cdk1. This implies that 
Ensa/Arpp19 control mitotic entry by inhibiting the phosphatase activity towards 
mitotic substrates, in a S67 dependent manner(Mochida et al. 2010; Gharbi-Ayachi et 
al. 2010). Subsequently, the depletion of Arpp19 from mitotic extracts triggers 
premature mitotic exit. PP2A appeared to mediate this abrupt exit, as the inhibition of 
the phosphatase with okadaic acid triggered mitotic re-entry(Gharbi-Ayachi et al. 2010). 
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Mutating the various serine and threonine sites in these small proteins identified S67 in 
Ensa and S62 in Arpp19 as the Greatwall phosphorylation sites. Four distinct 
phosphorylation sites were mapped in these proteins. Of these the FDSGDY motif 
contains the Greatwall site, and is conserved among the Endosulphine family (Gharbi-
Ayachi et al. 2010; Mochida et al. 2010; Labandera et al. 2015). Phosphorylation of 
Ensa/Arpp19 by Greatwall generates a potent inhibitor of PP2A-B55δ, inhibiting its 
phosphatase activity against radiolabelled MBP-Fizzy-Ser50 substrate (Mochida et al. 
2010). Similar inhibition was observed when thiophosphorylated Arpp19 was incubated 
with PP2A purified from CSF extracts and radiolabelled c-Mos (Cyclin-Cdk substrate) 
(Gharbi-Ayachi et al. 2010). This reduction in substrate phosphorylations is key in 
mitotic regulation, as addition of thiophosphorylated Ensa/Arpp19 into Greatwall-
depleted interphase extracts triggered mitotic entry rescuing the Greatwall phenotype. 
Interestingly, phosphorylated forms of Ensa /Arpp19 could not rescue Greatwall 
phenotype as they were actively dephosphorylated in the absence of the kinase. This 
shows that the presence of active Greatwall kinase is essential for Ensa/arpp19 to 
counterbalance their dephosphorylation and induce mitotic entry. Conversely, addition 
of thiophosphorylated Ensa/Arpp19 to CSF Xenopus extracts also inhibited mitotic exit, 
implying that PP2A-B55 could be the Cdk-counteracting phosphatase at mitotic exit 
(Mochida et al. 2010; Gharbi-Ayachi et al. 2010) 
 
Similarly, Arpp19 was found to contribute towards meiotic resumption by promoting 
Cdk auto-amplification (Dupré et al. 2013). Immature oocytes are arrested in prophase 1 
by high PKA activity (Frank-Vaillant et al. 1999). Greatwall (K72M) promotes meiotic 
resumption by activating Cdk1, irrespective of the presence of progesterone (Yamamoto 
et al. 2011). In 2013, Dupre et al. reported that this activity of Greatwall is executed via 
Arpp19 and is S67 dependent (Dupré et al. 2013). This was demonstrated when the 
addition of S67 phosphomutant of Arpp19 (S67A) reversed Cdk1 activation, induced by 
hyperactive K72M Greatwall. Thus, Arpp19 is a downstream effector of Greatwall. 
Additionally, Arpp19 (S67A) prevented meiotic resumption in response to progesterone 
as well as transfer of metaphase II arrested cytoplasm. Moreover, Arpp19 inhibits PP2A 
on Greatwall phosphorylation thereby enhancing Cdk activation. Greatwall 
phosphorylation of Arpp19 appears to be controlled by Cdk activity. Addition of 
thiophosphorylated Arpp19 into prophase oocytes accelerated GVBD in the presence of 
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progesterone. However, this mechanism was dependent on protein synthesis of Cyclin 
B and c-Mos.  
 
A direct interaction of PP2A-B55δ with Ensa/arpp19 was first demonstrated in Xenopus 
extracts. PP2A/C, PP2A/A and PP2A/B55δ were immunoprecipitated using 
recombinant Ensa and Arpp19. Structural data showed that the conserved middle region 
of Ensa surrounding the S67 site physically interacts with the catalytic and regulatory 
subunits of the phosphatase. Greatwall phosphorylation of Ensa/Arpp19 is 
indispensable for its interaction with PP2A-B55, while the T28 and S109 on Ensa might 
influence the binding of the middle region in a stepwise manner (Mochida 2014). Weak 
interaction of PP2A-B55 with Ensa was detected in both interphase and mitosis, but was 
enhanced significantly in mitotic extracts (Mochida et al. 2010; Gharbi-Ayachi et al. 
2010), while Arpp19 was observed to pull down PP2A-B55 only from CSF extracts 
(Gharbi-Ayachi et al. 2010). Similarly, in Xenopus oocytes, once Greatwall activates 
Arpp19 it continuously inhibits PP2A to activate the Cyclin-Cdk complex at prophase, 
even in the absence of protein synthesis, presence of Cdk inhibitors or fully active PKA 
(Dupré et al. 2013). The D66A mutation in Ensa was found to inhibit the interactions of 
Ensa-PP2A B55 and prevent mitotic entry despite being phosphorylated at S67 (Gharbi-
Ayachi et al. 2010). Taken together, these data indicated that Greatwall inhibits PP2A 
by promoting Ensa and Arpp19 binding. 
 
Proline-directed phosphosites in Ensa/Arpp19 can be targeted either by Cdk or by 
MAPK kinases. One such motif containing S28 in Arpp19 and Thr28 in Ensa is 
phosphorylated by Cdk 2-Cyclin A in Xenopus CSF extracts, while T99 is 
phosphorylated in vitro. The Thr28 site is highly phosphorylated in Xenopus oocytes 
and cell-free metaphase-II extracts and results in 14-fold more PP2A inhibition than that 
achieved with the non-phosphorylated version of Ensa; in contrast, no additive effect 
has been observed with S67. Furthermore, PKA phosphorylation antagonises the 
inhibitory function of Thr28 but not that of S67. (Mochida et al. 2010; Mochida 2014). 
It was later demonstrated in starfish oocytes that the Cdk phosphorylation of Arpp19 
(Ser69) also potentiated it to be a PP2A-B55 inhibitor, independent of Greatwall 
phosphorylation. This phosphorylation appeared to be critical for starfish oocyte 
maturations but had only moderate inhibitory effects in Xenopus (Okumura et al. 2014). 
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Finally, S109 in Xenopus Ensa (S107 human) was phosphorylated by PKA kinase and 
thought to contribute towards structural integrity of the protein when bound to lipid 
membrane (Boettcher et al. 2008). However, further structural data is required to 
determine the significance of this phosphorylation in cell cycle control. The PKA site is 
conserved in higher eukaryotes but is not found in lower organisms. Taken together the 
phosphorylation of Ensa/Arpp19 by three distinct kinases contributes differently to its 
cellular functions. 
 
In budding yeast, PP2A-Cdc55 (homologue of mitotic PP2A) was found to interact with 
Igo1/2 (homologue of Ensa/Arpp19) (Bontron et al. 2013; Juanes et al. 2013) and 
Zds1/2 (Wicky et al. 2011; Rossio & Yoshida 2011). Zds1/2 is only present in fungi and 
is cytoplasmic while Igo1/2 were nuclear. Rim15-dependent phosphorylation of Igo1/2 
inhibits PP2A-Cdc55 activity and promotes mitotic entry, while Zds1/2 stoichiometric 
binding to the phosphatase sequesters it in the cytoplasm facilitating closed mitosis in 
yeast (Rossio et al. 2014). Binding of Zds1/2 to the phosphatase also targets it to Cdc25 
(Wicky et al. 2011). Surprisingly, the deletion of zds1/2 impairs mitosis more severely 
than that of igo1/2. These observations, along with the different spatial arrangements of 
these interacting proteins, suggest that their action on PP2A-Cdc55 is distinct from each 
other (Rossio et al. 2014). 
 
These observations from Xenopus, Starfish, Drosophila and yeast studies ultimately 
propose a novel phosphatase inhibition pathway (Greatwall-Ensa/Arpp19-PP2A B55) 
that functions at the mitotic and meiotic entry points to facilitate amplification of the 
Cyclin-Cdk complexes as well as mitotic phosphorylations. 
 
1.3.8 Other Function of Greatwall in the Cell Cycle 
 
Greatwall also performs non-mitotic functions in such as DNA checkpoint recovery, 
cellular adaptation in response to nutrient deprivation in yeast and embryonic 
development in Drosophila and Xenopus. 
 
DNA Checkpoint Recovery 
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DNA damage response (DDR) at G2/M transition has been described in section 2.6. 
Once the DNA is repaired, this signalling pathway must be turned off. This process is 
called checkpoint recovery and it involves deactivation of checkpoint elements followed 
by activation of the proteins promoting G2/M transition. Checkpoint effectors are 
inactivated by dephosphorylation and proteolysis. Wip1 (p53-induced phosphatase) has 
been shown to bind and dephosphorylate key DDR factors such as ATM, γ-H2AX, 
Chk1, Chk2, and p53 (Lu et al. 2008). Additionally, the phosphorylation of Claspin 
(required for Chk1 activation) and Wee-1 (inhibitor of Cdk1) by Plk-1 targets them to 
SCF for proteolysis and inactivation of DDR (van Vugt et al. 2004; van Vugt & 
Medema 2004; Mailand et al. 2006; Peschiaroli et al. 2006; Mamely et al. 2006). In 
addition, Plk-1–mediated phosphorylation of 53BP1 (required for Chk1 and Chk2 
activation) may disrupt its function. These data indicating that Plk-1 acts as a key 
regulator in Xenopus egg extracts (A. Peng et al. 2010) suggest a novel role for 
Greatwall in checkpoint recovery.  
 
Immunodepletion of Greatwall in DDR egg extracts amplifies the response to DNA 
damage, while addition of wild-type Greatwall inhibits the DDR speeding recovery (A. 
Peng et al. 2010). A functional relationship between Plx and Greatwall in checkpoint 
recovery was also proposed based on studies in Xenopus extracts (A. Peng et al. 2011). 
Depletion of Greatwall and Plx individually delays checkpoint deactivation significantly 
but not synergistically. Purified Greatwall and Plx interact directly and Greatwall 
phosphorylation by Plx1 at the N-terminal increases during checkpoint recovery. 
However, an indirect regulation was seen when purified Aurora-A kinase restored Plx 
activation in Greatwall-depleted extracts. Thus, activation of Aurora-a might mediate 
Plx activation by Greatwall, representing a specific pathway for cell cycle entry 
following checkpoint recovery(A. Peng et al. 2011). 
 
Similar studies in human cells, using IR-induced DNA damage suggest that hyperactive 
MASTL (K72M) and its substrates Ensa/Arpp19 control the timing of mitotic entry 
following checkpoint recovery. Although MASTL (K72M) was expressed at very low 
levels (consistent with Drosophila and Xenopus data), it strongly stimulated mitotic 
entry after DNA damage. MASTL does not affect DDR initiation or DNA repair, as the 
53BP1 foci formation were similar after IR with overexpressed K72M Greatwall or 
siMASTL. However, the timing of mitotic entry is accelerated by the K72M MASTL in 
	   46	  
HeLa cells and while mitotic entry is delayed on silencing MASTL. Similar phenotypes 
were observed with the Greatwall substrates Ensa and Arpp19 individually, while both 
together were cytotoxic. Both these phenotypes are independent of DNA repair. 
However, acceleration of mitotic entry after DNA damage led to number of mitotic 
defects such as lagging chromosomes and DNA bridges during anaphase. This work 
also suggested that the Greatwall functions in checkpoint recovery by regulating the 
kinetics of Cdk1 inhibition, as Try15 phosphorylation of Cdk1 reduces in the presence 
of MASTL (K72M) (Wong et al. 2016). 
 
Cellular Adaptation in Response to Growth Factors and/or Nutrients 
 
Preliminary work on Rim-15 (Greatwall homologue in Saccharomyces cerevisiae) 
indicated its interaction with three nutrient sensory kinases (TOR, PKA and Sch9). In 
response to nutrient deficiency, budding yeast cells arrest growth in G1 and enter G0 by 
unknown mechanisms or trigger gametogenesis. TORC1 (Target of Rapamycin) 
pathway responds to nitrogen deficiency and the PKA/Ras pathway responds to 
glucose-deficiency signals (Gray et al. 2004; De Virgilio 2012). Both these pathways 
are highly conserved from yeast to mammals. Both TORC1 and PKA (main controllers 
of the cell growth) negatively regulate Rim-15 (downstream effector) and inhibit G0 
entry. Nutrient deficiency leads to dephosphorylation of the PKA sites and Thr 1075 
(TORC1-mediated site) on Rim-15 and its subsequent nuclear accumulation. Ultimately 
this release of inhibition of Rim-15 kinase activity contributes towards G0 entry 
(Pedruzzi et al. 2003; Swinnen et al. 2006). The activated kinase induces expression of 
the genes controlled by transcription factors Msn2, Msn4, Gi1 and Hsf1. Rim-15 
directly phosphorylates, zinc finger transcription factor Msn2/4 and heat-shock 
transcription factor Hsf but not Gis1, indicating different activation mechanisms (P. Lee 
et al. 2013). The Rim-15 substrates Igo1/2 (Endosulphine homologues in yeast) were 
also found to be crucial for mRNA stabilization and have a proposed role in initiating 
entry into G0 and gametogenesis by regulating PP2A-Cdc55 phosphatase activity 
(Talarek et al. 2010; Sarkar et al. 2014). This was demonstrated in fission yeast where 
the nutritional response pathway is linked to mitotic progression by the Ppk18-Igo1 
(PP2A-B55-Ensa) pathway. Nutrient deprivation permitted smaller cells (adaptation for 
survival) to enter mitosis, due to the inhibition of PP2A by active Greatwall kinase via 
Ensa. This leads to prolonged G1 phase that subsequently leads to quiescence or 
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gametogenesis under starvation conditions. Greatwall kinase is phosphorylated by S6 
kinases that are downstream of TORC1 and PKA in rich medium and these 
phosphorylations inhibit Greatwall activity and to allow the cells to grow larger before 
mitosis (Chica et al. 2016; Pérez-Hidalgo & Moreno 2016). However, this mechanism 




As mentioned earlier, the scant allele encodes a hyperactive version of Greatwall kinase 
with a K97M mutation. Expression of this hyperactive kinase causes developmental 
failure in Drosophila larval neuroblasts. However, a recessive allele that functions as a 
revertant of scant specifically disrupts this isoform. Female larvae containing only one 
copy of this allele (hemizygotic) produce embryos with reduced viability. Oocytes from 
these females do not display secondary meiotic arrest in metaphase 1, and progression 
in meiosis is accompanied with little or no segregation of sister chromatids and 
homologous chromosome pairs on the elongated meiotic spindles. Thus, Greatwall is 
implicated in sister-chromatid cohesion during female meiosis I (V. Archambault et al. 
2007). Surprisingly, the kinase activity of related K71M Greatwall (Scant) is sufficient 
to trigger M-phase entry in Xenopus oocytes despite its low expression levels and high 
rate of proteolysis. Greatwall binds and inactivates PP2A/B55 via Endosulphine 
phosphorylation in G2. When these oocytes are treated with progesterone to induce 
maturation, Greatwall dissociates from PP2A in the M phase, independent of kinase 
activity or T748 phosphorylation (Yamamoto et al. 2011). Preliminary analysis of 
Greatwall function using an RNAi-mediated approach in mouse oocytes also indicated a 
vital role of the kinase in chromosome segregation and in the prevention of exit after 
anaphase 1. Greatwall-depleted oocytes show the presence of the second polar body, 
indicating failure to arrest in metaphase II. However, Greatwall is dispensable for 
resuming meiosis, prometaphase 1 progression, condensation of chromosomes and 
cytokinesis (Adhikari et al. 2014; Pfender et al. 2015). Together, these data suggest a 
yet undiscovered role for Greatwall in oocyte maturation. 
 
Work from Archambault, Wang and Rangone indicate coordination between Polo 
(Plk1) kinase and Greatwall kinase in performing developmental functions in 
Drosophila. Spindle aberrations and developmental failure due to the scant mutation of 
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Greatwall increased proportionally with decrease in Polo function (V. Archambault et 
al. 2007). This coordination was later identified due to the interdependent function of 
Polo and PP2A-B (regulatory) subunit. Depletion of Polo and PP2A-Twins together was 
embryonic lethal, while they ensured proper centrosome attachment to the nucleus in 
early prophase and mitotic exit respectively. Greatwall was found to antagonise PP2A-
Twins function in metaphase 1 and early mitotic cycles. (P. Wang et al. 2011). 
Heterozygous Endos (Drosophila homologue of Ensa/Arpp19) mutants were found to 
suppress scant phenotypes with reduced Polo. However, homozygous Endos mutations 
or depletion and scant dominant mutation have similar phenotypes, which were rescued 
by depletion of catalytic or regulatory subunit of PP2A-Twins in cultured cells(Rangone 
et al. 2011). This shows that Greatwall interacts with Endos and activates it. 
Additionally, when PP2A catalytic subunit is mutated it acts with scant Greatwall 
synergistically, when maternal Polo level are reduced. Based on these genetic 
interactions, Rangone proposed that Greatwall supresses PP2A-Twins via Endos and 
allows Cdk activation. This in turn leads to activation of Polo and execution of its 
mitotic functions via phosphorylated partners. When Cdk activity decreases in 
anaphase, Polo executes its function via partners dephosphorylated by PP2A-B55. Thus, 
when hyperactive Greatwall inhibits PP2A with reduced Polo activity, the interphase 
partners are not dephosphorylated and their association with Polo is prevented (Rangone 
et al. 2011). This proposes precise control of meiotic entry and exit by Greatwall, Polo 
and PP2A-Twins, where Greatwall is shown to play multiple roles in meiotic and 
mitotic progression (V. Archambault et al. 2007). 
 
1.3.9 Regulation of Greatwall Kinase  
 
The regulation of Greatwall kinase has only been studied in detail in the recent years. 
Greatwall is an unconventional AGC kinase due to the presence of a 540 amino acid-
long insertion loop between the N-terminal and C-terminal domains, which separates 
the sub-domains VII and VIII (Hanks & Quinn 1991; J. Yu et al. 2004). Findings in 
recent years advocate that the activation-inactivation of Greatwall is controlled by 
phosphorylation by Cdk1 (Fig. 1.5) (Yamamoto et al. 2011; J. Yu et al. 2004; J. Yu et 
al. 2006; Zhao et al. 2008; Vigneron et al. 2011) and Polo kinase (P. Wang et al. 2013). 
However, mitotic functions also require Greatwall to be spatially regulated in a 
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phosphorylation-dependent manner (P. Wang et al. 2013; Alvarez-Fernández et al. 
2013; P. Wang et al. 2016; Pedruzzi et al. 2003). 
 
The structure of Greatwall comprises of the N-terminal and C-terminal domain 
separated by a long insertion of amino acids called the non-conserved middle region 
(NCMR) and a C-terminal-tail/linker region. The length of the NCMR is conserved in 
all orthologues of Greatwall but the amino acid sequence is very poorly conserved 
between species. Moreover, this region is dispensable for the kinase activity of 
Greatwall(Blake-Hodek et al. 2012). A minimal kinase where the NCMR is substituted 
for conventional AGC kinase activation segment, is functional in vitro and readily 
phosphorylates Ensa in radioactive kinase assays (Ocasio et al. 2016). In Xenopus S3 
cells, Greatwall was found to bind chaperones like Hsp90 (Heat shock protein) that 
influences the stability of the kinase and its mitotic entry function. The glycine rich loop 
on the N-terminal was seen to be important for Hsp90 binding along with its co-
chaperone Cdc37 (Yamamoto et al. 2014). 
 
Two models have been proposed for the activation of the Greatwall. In 2011, Vigneron 
et al. proposed that Greatwall is first phosphorylated at Serine 883, a C-terminal linker 
residue. This phosphorylation causes a conformational change and allows the C- 
terminal tail to interact with N-terminal domain via the tail-linker binding site, 
stabilising the partially activated kinase. Further, full activation of Greatwall occurs as a 
result of its interaction with another AGC kinase via the N-terminal hydrophobic motif 
(Vigneron et al. 2011). This is to compensate for the lack of the C-terminal hydrophobic 
motif in Greatwall, that usually contributes to the intramolecular interaction with the N-
terminal hydrophobic patch and subsequent stabilization in conventional AGC kinases 
(Biondi et al. 2000).Conversely, an alternate model suggested that Greatwall is initially 
phosphorylated by Cyclin-Cdk at the presumptive activation segment residues (T193 
and T206 in Xenopus). This activates Greatwall to enable autophosphorylation of 
Ser883 and subsequent interaction between hydrophobic motifs at the N- and C- termini 
to stabilise the active kinase. The second model suggested multimerisation of Greatwall  
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Figure 1.5 Phospho-regulation of Greatwall kinase 
 
Schematic representation of activation (green arrows) and inactivation (red arrows) of 
Greatwall kinase in mitosis. Cdk1 phosphorylates and activates Gwl kinase at the indicated 
residues at mitotic entry. Ser875 is the auto-phosphorylation site in human Greatwall. At 
mitotic exit PP2A targets Thr194 (Hégarat et al. 2014), PP1 is thought to dephosphorylate 
other Cdk sites such as T207 and/or Ser875 (Heim et al. 2015; Ma et al. 2016; Rogers et al. 
2016) while FCP-1 targets Ser90 and Ser454 (Monica et al. 2015). The N-terminus and C-
terminus of the kinase are shown in blue and the long mid-region thought to be the T-loop is 
shown is yellow. 	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molecules to compensate for the lack of C-terminal hydrophobic motif (Blake-Hodek et 
al. 2012).  
 
Although both models contradict each other, the influence of Cdk1 dependent 
phosphorylation on Greatwall activation is generally well supported. Cdk1 
phosphorylates purified Greatwall in-vitro (J. Yu et al. 2006) while Greatwall is 
specifically phosphorylated in mitosis both in cell extracts and oocytes of Xenopus and 
starfish (Zhao et al. 2008; Yamamoto et al. 2011; M. Hara et al. 2012). Similarly, 
Greatwall activity was required to induce mitotic (J. Yu et al. 2006; Zhao et al. 2008) 
and meiotic entry (Yamamoto et al. 2011), as kinase dead Greatwall could not perform 
this function. Greatwall was found to function downstream of Cdk1-Cyclin B in starfish 
oocytes (K. Hara et al. 1980). Finally, Cdk1 inhibition by Roscovitine or p21/Cip1 
reduces Greatwall phosphorylation both in CSF extracts and oocytes (Zhao et al. 2008). 
However, Cdk1 phosphorylation of Greatwall was not equivalent to endogenous 
Greatwall phosphorylations in Xenopus. This indicates the occurrence of additional 
phosphorylations either by the kinase itself or by other kinases that act on greatwall to 
phosphorylate it completely (J. Yu et al. 2006). Greatwall autophosphorylation has been 
observed in Xenopus extracts (J. Yu et al. 2006) and has also been reported in previous 
papers as essential for its complete activation (Blake-Hodek et al. 2012; Vigneron et al. 
2011). 
 
In Drosophila, Polo kinase interacts with Greatwall specifically and this interactions 
does not require phospho-priming the Polo-box domain(P. Wang et al. 2013). Although 
Plx1 (Xenopus Plk1) was observed to phosphorylate Greatwall in vitro, it showed no 
functional significance, as Plx1-treated Greatwall did not phosphorylate myelin basic 
protein in in vitro kinase assay or autophosphorylate itself. Additionally, this kinase was 
unable to induce mitosis in Greatwall-depleted CSF extracts (J. Yu et al. 2006). 
However, if this binding controls the localisation of Greatwall as observed in 
Drosophila (Yamamoto et al. 2014) is not known. 
 
In addition to phosphorylation, the mitotic functions of Greatwall also depend on its 
cellular localization. Two papers demonstrated that the nucleo-cytoplasmic shuttling of 
Greatwall is phosphorylations dependent in Drosophila and mammalian cells (P. Wang 
et al. 2013; Alvarez-Fernández et al. 2013). Both Drosophila and mammalian Greatwall 
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have two nuclear localization sequences and one nuclear export sequence in the NCMR 
region (P. Wang et al. 2013; Alvarez-Fernández et al. 2013; P. Wang et al. 2016). The 
NES motif is not conserved among vertebrates and is required to control the dynamics 
of Greatwall nuclear export along with NLS sequences (P. Wang et al. 2016). However, 
they are regulated differently. In Drosophila, NCMR contains multiple phosphorylation 
sites for the Polo kinase, which when phosphorylated is thought to promote Greatwall 
association with 14-3-3ε to be sequestered into the cytoplasm. In addition to Polo 
kinase, Cdk1 phosphorylations of Greatwall on the consensus sites in NCMR were 
observed to be important for nuclear exclusion. However, Greatwall localisation is 
controlled by Cdk1 in a Polo/14-3-3ε independent manner (P. Wang et al. 2013). In 
Xenopus S3 cells one NLS motif was identified in the N-terminal region of the kinase. 
This NLS was located around KR456/457 and is conserved in human cell line 
(KR444/445 (Alvarez-Fernández et al. 2013)). Nuclear retention of Greatwall during 
interphase is attributed to its association with importin α and importin β via the NLS 
(Yamamoto et al. 2014). In mammalian cells, Greatwall was translocated just before 
nuclear envelope breakdown (NEBD) in a CRM1-exportin–dependent manner. This 
translocation depends on Cdk1 phosphorylation of Greatwall and the proposed sites are 
T194, T107 and the ATP-binding site D156. The role of Plk1 in gwl translocation is not 
preserved in mammalian cells, probably due to the high sequence dissimilarities in the 
NCMR region across species (Alvarez-Fernández et al. 2013). 
 
Subcellular localisation of Greatwall is necessary to execute its mitotic functions. 
Inhibition or delay of nucleo-cytoplasmic shuttling of the kinase causes mitotic defects 
similar to those observed on Greatwall depletion (P. Wang et al. 2013; Alvarez-
Fernández et al. 2013; P. Wang et al. 2016). While Greatwall was discovered to be 
highly nuclear (J. Yu et al. 2004), PP2A is majorly cytoplasmic during the interphase 
(Schmitz et al. 2010; Mayer-Jaekel et al. 1994; P. Wang et al. 2013; Alvarez-Fernández 
et al. 2013). At the G2/M transition, PP2A activity is high in the cytoplasm, inhibiting 
phosphorylation of initial Cdk substrates at the cell cortex such as membrane proteins 
involved in cell rounding (Gavet & Pines 2010). Alvarez-Fernandez (2013) observed 
that Cyclin B is transported into the nucleus prior to the nuclear export of Greatwall. 
This suggests that the active Cyclin B-Cdk1 complex activates Greatwall and induces 
its nuclear export prior to NEBD (P. Wang et al. 2013; P. Wang et al. 2016). This in 
turn inhibits PP2A activity in the cytoplasm, so that the mitotic substrates can be readily 
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phosphorylated to facilitate mitotic progression. Conversely, PP2A-Tws 
dephosphorylates Greatwall at NLS2 and Cdk sites to regulate the return of the kinase 
to its nuclear location at cytokinesis (P. Wang et al. 2016). Although some of the factors 
contributing to nucleo-cytoplasmic shuttling of Greatwall have been uncovered, the 
exact mechanism regulating this process remains elusive. 
 
1.3.10 Inactivation of Greatwall-Ensa/Arpp19 and Reactivation of Phosphatases 
during Mitotic Exit 
 
Similar to kinase activation during mitotic entry, phosphatases that remove Cdk1 site 
phosphorylations have to be reactivated during mitotic exit. This will, in parallel, 
require the inactivation of Greatwall and dephosphorylation of Ensa/Arpp19. Analogous 
to the G2/M switch, this phosphatase reactivation step is likely to constitute a major 
element of the mitotic exit switch. PP2A-B55 has been implicated as one of the major 
Cdk-counteracting phosphatases in the recent years. However, whether it is the only 
phosphatase at mitotic exit remains a matter of debate. A major question in this 
transition is thus the nature of the phosphatases that inactivate Greatwall and 
EnsaArpp19 in anaphase. As Cdk1 phosphorylates Greatwall and PP2A-B55 
dephosphorylates Cdk substrates at mitotic exit, Greatwall might also be 
dephosphorylated by PP2A-B55. 
 
PP2A/A and PP2A/C subunits have been shown to interact with Greatwall in 
immunoprecipitation experiments in both human cells and Xenopus cell extracts. 
Greatwall-induced phenotypes could also be rescued by the removal of PP2A using 
inhibitors like okadaic acid and immunodepletion using monoclonal antibodies. 
Greatwall depletion enhances the phosphatase activity of PP2A against Cyclin B-Cdk 1 
substrates (Vigneron et al. 2009). Our lab showed that PP2A-B55 αδ acts on the Thr194 
site in Greatwall, based on the observation that siRNA depletion of these subunits 
blocked Greatwall dephosphorylation in HeLa cells during mitotic exit (Hégarat, 
Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & Hochegger 2014b). Moreover, 
depletion of Arpp19, which is an established substrate of Greatwall, leads to a rapid 
decrease in Greatwall phosphorylation and causes mitotic exit. This could be due to the 
reactivation of the phosphatase (Gharbi-Ayachi et al. 2010). However, at mitotic exit, 
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PP2A-B55 is bound and inhibited by Ensa/Arpp19, which suggests the presence of 
another phosphatase that initiates Greatwall dephosphorylation, as postulated by a 
recent mathematical study(Vinod & Novák 2015).  
 
  
Figure 1.6 Dephosphorylation cascade at mitotic exit 
 
Cyclin B results in a drop in Cdk1 activity and activates the Cdk-counteracting phosphatases 
in a stepwise manner. Cdk1 (MPF) directly inhibits PP1 by T320 phosphorylation. The drop 
in Cyclin B levels below a critical threshold can lead to PP1 reactivation by auto-
dephosphorylation at T320. PP1 then inactivates Greatwall, which allows PP2A-B55 
activation, but this remains to be confirmed in mammalian cells (Heim et al. 2015; Ma et al. 
2016; Rogers et al. 2016). FCP-1 has also been implicated in this mechanism by directly 
contributing to Greatwall dephosphorylation (Monica et al. 2015). These phosphatases 
would possibly also participate in the exit reaction (Barr et al. 2011; Bollen et al. 2009; 
Schmitz et al. 2010; Cundell et al. 2013). This figure was adapted from Hegarat et al. (2016) 
with permission from the authors(Hégarat et al. 2016). 	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One of these phosphatases was found to be PP1 in Xenopus (Heim et al. 2015) as well 
as human cells (Rogers et al. 2016). Xenopus studies proposed a model where the 
inactivation of Cdk1 leads to PP1 auto-activation and subsequent dephosphorylation of 
Greatwall at its autophosphorylation site Ser883. In Xenopus extracts, two intermediate 
states of phosphorylated Greatwall were observed. In the presence of Roscovitine, thio-
Arpp19 only blocked the dephosphorylation partially, while Inhibitor-2 blocked 
Greatwall dephosphorylation completely. This confirmed that PP1 is the initial 
phosphatase acting on Greatwall when Cdk1 is inactivated. PP1 was also found to be 
required to keep Greatwall inactivated and prevent rephosphorylation of the kinase at 
the autophosphorylation site (Heim et al. 2015). In human cells, SILAC and subsequent 
mass spectrometry showed that PP1 interacted with MASTL (human homologue of 
Greatwall). Moreover, a simulated mitotic exit network showed that PP1 is associated 
with MASTL in the early phases of mitotic exit and could potentially be the molecule 
that initiates Greatwall dephosphorylation at mitotic exit. PP1α and PP1β were found to 
only partially dephosphorylate Greatwall in an in vitro phosphatase assay, where 
MASTL was purified from cells treated with okadaic acid and PP1 siRNA oligos to 
maintain maximal Greatwall phosphorylation. Although the direct effects of PP1 
dephosphorylation could not be observed using PP1 siRNA in vivo, a simulated mitotic 
exit network was used to confirm the association with Greatwall at mitotic exit. 
Interestingly, the autophosphorylated residue of Greatwall remained stable throughout 
mitosis and was proposed not to contribute to the inactivation of the kinase. 
 
Recent studies have also implicated Greatwall dephosphorylation by FCP-1 
phosphatase at mitotic exit. FCP-1 was observed to bind and dephosphorylate serine 
residues at position 90 and 453, which are phosphorylated by Cdk1 (Monica et al. 
2015). Although PP1 is suspected to initiate Greatwall dephosphorylation and activate 
PP2A at mitotic exit, how FCP-1 fits in in the dephosphorylation cascade is yet to be 
determined(Hégarat et al. 2016)(Fig. 1.6).  
 
Two papers in 2014 explored PP2A reactivation by studying Ensa/Arpp19 
dephosphorylation as well at mitotic exit (Williams et al. 2014; Hégarat, Vesely, Vinod, 
Ocasio, Peter, Gannon, Oliver, Novák & Hochegger 2014b). While the Goldberg lab 
claimed that PP2A-B55 itself is the Ensa/Arpp19 phosphatase, our lab found FCP-1 to 
influence Ensa/Arpp19 dephosphorylation indirectly. 
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Williams et al. (2014) proposed a simple model of ‘unfair competition’ for PP2A-B55 
reactivation. Careful measurements of the binding constant (Km) and catalytic activity 
(Kcat) of the phosphatase against pEndos (Drosophila Ensa/Arpp19) suggested that 
phospho-Ensa/Arpp19 is a potent inhibitor of the phosphatase as it binds strongly to the 
active site, but that it is a bad substrate as the dephosphorylation kinetics were very 
slow. The authors proposed that as long as Greatwall is active, Ensa/Arpp19 that is 
dephosphorylated and released from the Ensa/Arpp19-PP2A B55 complex is 
rephosphorylated and captures the phosphatase repeatedly. However, at mitotic exit on 
Cyclin B-Cdk1 inactivation, Greatwall activity drops (Zhao et al. 2008), thus shifting 
the balance towards the dephosphorylation of Ensa/Arpp19 (anti-Endos activity) and 
subsequent disruption of the Ensa/Arpp19-PP2A B55 complex and releasing PP2A-B55 
to execute mitotic dephosphorylations. The authors additionally observed that other 
serine-threonine phosphatases such as PP4 and PP6 do not contribute to anti-Endos 
activity. Although depletion or mutation of PP2A-B55 reduced majority of anti-Endos 
activity, PP1 was also observed to decrease it by ≈ 15%-20% (Williams et al. 2014). 
The ‘unfair competition’ model also proposes that Okadaic acid outcompetes 
Ensa/Arpp19 for the active site on PP2A-B55. In this scenario, Ensa/Arpp19 should 
remain phosphorylated but the complex should fall apart when okadaic acid is present, 
as observed in vitro (Williams et al. 2014). 
 
In the meanwhile, our lab investigated dephosphorylation of Ensa/Arpp19 in human 
cells artificially synchronised at mitotic exit. Cells were synchronised in mitosis using 
the Eg5 inhibitor, STLC and then inhibiting Cdk1 using the potent inhibitor RO336 
triggered mitotic exit. Under these conditions, Ensa/Arpp19 dephosphorylation was 
blocked only in the presence of okadaic acid and tautomycetin together but not 
individually. This suggests the influence of more than one phosphatase on this 
dephosphorylation process. Additionally, the depletion of FCP-1 (RNA Polymerase II 
carboxy terminal domain phosphatase) blocked Ensa/Arpp19 dephosphorylation but 
Greatwall appeared to be dephosphorylated at Thr194 (Hégarat, Vesely, Vinod, Ocasio, 
Peter, Gannon, Oliver, Novák & Hochegger 2014b). This proposed that PP2A-B55 
dephosphorylates Greatwall at Thr194, while FCP-1 contributes to Ensa/Arpp19 
dephosphorylation indirectly as direct interaction was not demonstrated (Williams et al. 
2014; Hégarat, Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & Hochegger 
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2014b). The later findings that both PP1 and FCP1 act on Greatwall dephosphorylation 
could reconcile the findings of these two studies.  
 
The unfair competition model appears counter-intuitive. How can a phosphorylated 
residue be both an inhibitor and a substrate of a phosphatase at the same time? The 
measurements of the binding affinity and the dephosphorylation dynamics of Ensa 
(pEndos) give a compelling answer to this question. Phosphorylated Ensa is a very 
potent binder of the active site, but is dephosphorylated only very slowly (Km = 
0.0009–0.0017 µM, Kcat = 0.021–0.035 s-1). One pitfall of this model is that at the rate 
of dephosphorylation observed in vitro, a small amount of Greatwall activity would 
always push the equilibrium in favour of re-phosphorylation. Thus, Greatwall would 
have to be completely inactivated by another phosphatase before Ensa can start to be 
dephosphorylated. Conversely, Hegarat et al. showed that Ensa could still be 
dephosphorylated even when Greatwall maintains 60% of its activity. However, this 
data may represent an overestimation of Greatwall activity, since it is performed after 
purification of the kinase. It is possible that the kinase can reactivate itself once 
removed from counteracting phosphatases such as PP1. Overall, a model is taking shape 
whereby; PP1 and FCP1 trigger Greatwall inactivation early during mitotic exit 
allowing Ensa dephosphorylation and PP2A-B55 re-activation. Crosstalk of these 
phosphatases and their regulation as well as additional regulation of pEnsa 
dephosphorylation can, however, not be ruled out. 
 
1.3.11 Greatwall and Ensa/Arpp19 in Mammalian Cells  
 
Greatwall has been well characterised in lower organisms as well as higher eukaryotes, 
though its downstream effectors Ensa and Arpp19 need further investigation. Although 
Greatwall appears to contribute to mitosis among all species, some differences are 
observed between the lower organisms and mammalian studies. 
 
Greatwall is indispensable for mitotic and meiotic entry in lower organisms. However, 
the same phenotypes are not recapitulated in mammalian mouse and human cells. 
Greatwall depletion does not inhibit mitotic entry in mouse embryos and only slows 
down G2/M transition in human cells. Similarly, during mitotic exit, the major 
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phenotypes documented are chromosome segregation and cytokinesis defects. In this 
thesis, I have performed biochemical and cytological analysis of Ensa and Arpp19 to 
characterise the mitotic functions of these small proteins in order to reconfirm the 
mitotic regulation of Greatwall kinase. 
 
The phospho-regulation of Ensa and Arpp19 at mitotic exit is yet to be understood 
clearly. While Xenopus data propose an essential role for PP1 in PP2A-B55 activation, 
this is not completely recapitulated in the mammalian system. Additionally, the 
influence of FCP-1 adds to the complexity of Greatwall dephosphorylation and 
subsequent reactivation of PP2A-B55. In this thesis, I have attempted to analyse mitotic 
exit dephosphorylations by testing the ‘unfair competition’ model in intact mammalian 
cells and by examining the effects of dominant active Ensa/Arpp19 in mammalian 
mitotic entry. I also attempted to identify novel phosphatases interacting with 
Ensa/Arpp19 by performing a proteomic screen. 
 
1.4 Molecular Mechanisms Underlying a Phosphorylation Reaction: 
Thiophosphorylation 
 
Protein phosphorylation is the most common post-translational modification in cell 
cycle regulation and signal transduction. The following section provides a detailed 
explanation of the molecular interactions between kinases and phosphatases with their 
substrates. 
 
1.4.1 Phosphorylation reaction 
 
Protein groups called kinases exert their effect by transferring the terminal γ-phosphate 
of the ATP to the phosphoryl group acceptor on the substrate such as a serine, threonine 
or tyrosine residue. This molecular mechanism is a two-substrate reaction: while a 
phosphate moiety is introduced into a polypeptide substrate, ATP is also converted to 
ADP (Fig 1.7). In addition to exogenous substrates, many kinases undergo auto-
phosphorylation reactions. These auto-phosphorylations could be either intermolecular 
or intramolecular (DeLange et al. 1968). 
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The phosphorylated substrates could elicit a cascade of molecular reactions or carry out 
its own bonafide functions. Phosphorylated proteins are known to exhibit specific 
localisation (Obsil & Obsilova 2008), active enzymatic action (Agius 2008) or protein-
protein interactions (Pieroni et al. 2008). On the contrary, phosphatases hydrolyse the 
bond between the acceptor residues and the phosphoryl group and reverse the effect, 
enabling switch-like transitions in cellular regulation.  
 
1.4.2 Structural similarities among protein kinases  
 
Every kinase defined follows the same molecular reaction of phosphate transfer. Every 
kinase has a catalytic domain and regulatory domain. In eukaryotes, the kinase domain 
extends from 250 to 300 amino acids. The kinase domain in turn is divided into 12 sub-
domains that fold into a common catalytic core (Hanks & Hunter 1995). Conserved 
Figure 1.7 Phosphorylation Reaction 
Schematic representation of a phosphorylation reaction 
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residues essential for substrate recognition were also found among these sub-domains: 
consensus motifs in the catalytic loops region in subdomain VIB and the activation loop 
in subdomain VIII (Taylor et al. 1995; L. N. Johnson et al. 1998). Eukaryotic kinases 
have a conserved catalytic kinase domain with an array of glycine-rich residues at the 
N-terminus close to the lysine-residue involved in ATP-binding and hydrophobic 
residues at the C-terminus (Knighton, Zheng, Teneyck, Ashford, et al. 1991; Knighton, 
Zheng, Teneyck, Xuong, et al. 1991). Following the sequencing of the human genome, 
considerable effort has been put towards mapping the superfamily of eukaryotic protein 
kinases (Kostich et al. 2002; Manning et al. 2002).  
 
 
1.4.3 Challenges in studying phosphorylation reactions 
 
Phosphorylation reactions at the cellular level are ubiquitous and hence there are many 
challenges in studying these reactions. The kinase-substrate network is very complex as 
the human kinome itself consists of around 520 genes (Manning et al. 2002). 
Additionally, other post-translational modifications such as methylation, glycosylation 
and ubiquitylation can also influence phosphorylation levels (Garcia et al. 2005). Owing 
to the ubiquitous nature of these reactions, it is difficult to distinguish between the 
phospho-receptor substrates of every kinase. Moreover, the low abundance of these 
kinases and substrates at the cellular level also make it difficult to study 
phosphorylation stoichiometrically.  
 
The reversal of these reactions is brought about by protein phosphatases, by hydrolysing 
phosphorylated residues back to their native state (Jiang & Z.-Y. Zhang 2008). These 
are also important protein modifications that contribute to signalling pathways and cell 
proliferation. Most kinase and phosphatase reactions are transient and cannot be 
purified unless they form tight complexes. Cell cycle regulation comprises of many 
such transient reactions that enable switch-like responses in mitosis (Rudolph 2007). 
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1.4.4 Thiophosphorylation reaction and its advantages 
 
Thiophosphorylation reactions involve ATP with a thiol on the γ-phosphate group. This 
is a non-hydrolysable, or at least very slow to hydrolyse, analogue of ATP. 
Thiophosphorylation results in the transfer of the thio- γ-phosphate group to the 
substrate, which in turn stays constitutively phosphorylated as the rate of 
dephosphorylation is comparatively slower for this moiety(Shimizu et al. 2002). The 
sulphur atom of the thiol group is both larger and less electronegative than the oxygen 
atom that is replaces and results in a decrease in electrophilicity of the central 
phosphorous atom, making it difficult for the phosphatase to hydrolyse it. As the 
phosphorylated form of the substrate binds with higher affinity to the phosphatase, the 
phosphatase-substrate complex would be slow to disassociate (Fig 1.8), essentially 
trapping the substrate-bound phosphatase. This technique has been used in the past to 
purify tyrosine phosphatases (Mei & Huganir 1991). 
Initial studies were done with tyrosine phosphatases purified from post-synaptic 
membrane lysates using unhydrolysable thiophosphorylated substrates in a species of 
Figure 1.8: Thiophosphorylation reaction 
Schematic representation of phosphorylation and dephosphorylation of a protein in the 
presence of ATP-γ-S 
	   62	  
electric ray called Torpedo californica (Mei & Huganir 1991). Conversely, mutations in 
the catalytic site of phosphatases led to substrate-trapping of associated proteins (Flint 
et al. 1997). However, these techniques have not been used to study serine-threonine 
phosphatases. 
 
Another way of studying the effects of protein phosphorylation is generating phospho-
mimetic mutants. The serine residues in the substrate can be replaced with aspartate or 
glutamate to impart the negative charge associated with phosphorylation. In some cases, 
this might generate a constitutively phosphorylated protein. However, these amino acids 
are much smaller and carry a single negative charge as opposed to the double negative 
charge in a phosphate group. Thus, they fail to recapitulate the steric nature of a 
phosphate moiety. On the other hand, thiophosphorylation does not have these 
shortcomings. 
 
Therefore, thiophosphorylation was used to generate constitutively active Ensa and 
Arpp19. In this thesis, I have attempted to transfect the purified active protein to study 
its effects in mitotic entry. I have also attempted to purify interacting phosphatases from 
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AIMS OF THE THESIS 
 
At the beginning of this project, only preliminary data about Ensa and Arpp19 in 
mammalian cells was available. The aim of this project was to generate tools to 
characterise the mitotic function of Ensa and Arpp19 and to compare them to that of 
Greatwall as well as to determine if Ensa and Arpp19 are redundant in mammalian 
mitosis. This involved generating specific antibodies to study subcellular localisation 
and depletion phenotypes of Ensa and Arpp19 in human cells. 
 
Moreover, the phospho-regulation of Ensa and Arpp19 was not explored when this 
project began. To initiate understanding of the biochemical interaction of Ensa/Arpp19, 
I investigated the formation of its complex with PP2A-B55 in the presence and absence 
of phosphatase inhibitors. In the meanwhile, data from our lab and the Goldberg lab 
describing Ensa/Arpp19 phosphorylation led us to test the ‘unfair competition’ model in 
intact mammalian cells and to perform a proteomic screen to identify novel 
phosphatases acting in the Ensa/Arpp19 dephosphorylation network. 
 
Finally, I also generated dominant active Ensa/Arpp19 and attempted various 
approaches of protein transfection to analyse the effect of the constitutively active Ensa 
and Arpp19 in mammalian mitotic entry and exit.  
 
Overall, this dissertation provides insights into the functions and phospho-regulations of 
Ensa and Arpp19 in mammalian mitosis. 
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2.1.1 Chemicals, Biochemicals and Kits 
 
All chemicals were obtained from Fisher Scientific (Leicestershire, UK) or 
Sigma-Aldrich (Missouri, USA) unless otherwise stated. Complete Protease Inhibitor 
Cocktails were from Roche Diagnostics (West Sussex, UK). The Eg5 inhibitor, S-trityl-
L-cysteine (STLC) was purchased from Tocris Bioscience (Bristol, UK). All restriction 




All buffers were prepared in ddH2O, unless indicated otherwise. Buffers were frozen at 
–20°C and thawed soon before use.  
a. Mitotic Lysis Buffer (Table 1.1) 
The mitotic lysis buffer was prepared as previously described in by Cundell et al. (2013) 
 Working Concentration Stock Concentration 
Tris HCl 50 mM 2 M 
DTT 1 mM 1 M 
MgCl2 1 mM 1 M 
MnCl2 0.1 mM 500 mM 
NaCl 50 mM 5 M 
NP-40 1% - 
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b. Immunoprecipitation Buffers (Table 1.2) 
Flag-IP buffer 
 Lysis Buffer Wash Buffer Elution buffer 
Tris pH 7.5 20 mM 20 mM 20 mM 
NaCl 137 mM 250 mM/500 mM 137 mM 
Glycerol 10% 10% 10% 
NP-40 0.5% 0.5% 0.5% 
EDTA 2 mM 2 mM 2 mM 
Flag peptide 
solution 
- - 0.5 µg/µl 
Protease Inhibitor 1 tablet/50 ml - 1 tablet/50 ml 
 
GFP-IP buffer 
 Lysis Buffer Wash Buffer 
Tris pH 7.5 20 mM 20 mM 
NaCl 137 mM 250 mM/500 mM 
Glycerol 10% 10% 
NP-40 0.5% 0.5% 
EDTA 2 mM 2 mM 
Protease Inhibitor 1 tablet/50 ml - 
 
c. Bacterial protein purification buffers (Table 1.3) 
His purification buffers 
 Lysis Buffer Wash Buffer Elution buffer Stock 
Hepes 50 mM 50 mM 50 mM 2 M 
NaCl 250 mM 250 mM 250 mM 5 M 
TCEP 0.2 mM 0.2 mM 0.2 mM 0.5 M 
Imidazole 20 mM 20 mM 250 mM   
Protease 
Inhibitor 
1 tablet/50 ml - 1 tablet/50 ml - 
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GST purification buffers 
 Lysis Buffer Wash Buffer Elution buffer Stock  
Tris pH 7.5 50 mM 50 mM 50 mM 2 M  
NaCl 250 mM 500 mM 500 mM 5 M 
EDTA 0.5 mM 0.5 mM 0.5 mM 0.5 M 
DTT 1 mM 1 mM 1 mM 1 M 
Glutathione - - 40 mM 0.5 M 
Protease 
Inhibitor 
1 tablet/50 ml - 1 tablet/50 ml - 
 
Kinase Assay Buffer 
 Lysis Buffer Wash Buffer Elution buffer Stock  
Tris pH 7.5 50 mM 50 mM 50 mM 2 M  
EGTA 1 mM 1 mM 1 mM 0.5 M 
MgCl2 10 mM 10 mM 10 mM 1 M 
Protease 
Inhibitor 
1 tablet/50 ml - 1 tablet/50 ml - 
 
 




50% MeOH, 12% acetic acid, 100 µl 37% 
paraformaldehyde solution/200 ml 
Wash Solution 50% MeOH 
Pre-treatment 
Solution 
0.02% (w/v) Na2S2O3 
Silver Solution 0.2% (w/v) AgNO3 
Develop Solution 
6% Na2CO3. 4 ml 0.02% Na2S2O3, 100 µl 37% 
paraformaldehyde solution/200 ml 
Stop Solution 50% MeOH, 12% acetic acid 
Drying Solution 30% MeOH, 5% glycerol 
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2.1.3 Cell Culture 
 
Transformed human cervical epithelial cancer cells (HeLa), human osteosarcoma cell 
line U2OS, Human embryonic Epithelial Kidney (HEK) 293T cells were used.  
The HeLa derivatives, HeLa Kyoto cells, a kind gift from Dr. Mark Petronczki and 
HeLa CDK1_as cells, from Dr. W.C. Earnshaw’s lab, University of Edinburgh. 
The HeLa Kyoto cells stably expressing EGFP-alpha-tubulin and H2B-mCherry were a 
gift from the Dr. Eva Hoffmann. Dr. Thomas Stiff generated U2OS cells stably 
expressing Xenopus laevis CDK1_as and Stephy Joseph generated HeLa CDK1_as cells 
stably expressing RFP-H2B in the lab.  
 
Cell culture reagents like DMEM and Foetal Bovine Serum were purchased from 




Primary antibodies used for this study are enlisted in the Table 1.5. 
Secondary antibodies used were HRP-conjugated (Horseradish peroxidase) rabbit, 
mouse or goat polyclonal antibodies from Dakocytomation (Cambridge, UK). For 
Immunoprecipitation blots, Mouse TrueBlot® ULTRA: Anti-Mouse IgG HRP from 
Rockland, USA was also used. 
Alexa-flour® conjugated secondary antibodies for Immunostaining; Alexa488 anti-
rabbit, Alexa488 anti-mouse, Alexa594 anti-rabbit, Alexa594 anti-mouse, Alexa647 














Rabbit 1:200 1:100 ab180513 Abcam Ltd 
Anti Greatwall Rabbit 1:200  HPA027175 
Sigma-Aldrich 
Company UK 
Anti- α tubulin Mouse 1:2000 1:1000 ab7291 Abcam Ltd 
	   68	  
 
  
Anti- Actin Mouse 1:1000  ab40864 Abcam Ltd 
Anti-B55 alpha 
(2G9) 














Anti-Flag M2 Mouse 1:1000 1:500 F3165 
Sigma-Aldrich 
Company UK 
Anti-GFP Rabbit 1:1000 1:500 A6455 Invitrogen 
Anti-His Mouse 1:1000  27-4710-01 
GE Healthcare 
UK  





Rabbit 1:100 1:100 Clone 73 Eurogentec 
Anti-phospho-
Gwl 
Rabbit 1:100 1:100  Hochegger Lab 
Anti-Ensa Rabbit 1:100   Eurogentec 
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2.2.2 Primers 
 
cDNA and genomic DNA sequences were obtained from the National Centre for 
Biotechnology Information website (NCBI; http://www.ncbi.nlm.nih.gov/). Primers 
were designed according to cloning requirements using Lasergene SequBuilder 10.1 
DNASTAR (Madison, USA) and Serial Cloner 2.5, http://serialbasics.free.fr. Primers 
were ordered from Eurofins MWG Operon (Ebersberg, Germany) or GATC Biotech 
(London, UK). The primers used in this study are listed in the Table 1.6. 
Primers Sequence (5’-3’) 
















hENSA EcoRV rev 
For cloning Flag 
Ensa into 






For cloning Flag 
Ensa into 





GFP ensa_fwd gb 
gacgagctgtacaagtccggaGGCGCCTCAGCGGCATCA 
 





Vectors used in this work are listed in the Table 1.7. 
 
Vector Source Features Notes 
pDONR™221 
Invitrogen 
Att sites P1, P2 
For cloning of Ensa and 
Arpp19 full-length cDNA and 
use with the Multisite 
Gateway®system from 
Invitrogen 
pDEST17 T7 promoter 
Bacterial expression vector for 
N-terminal HIS tagging of 
Ensa and Arpp19 
deltaT-FLAG-
DEST 







Mammalian expression vector 
for N-terminal flag-tagged 





Bacterial expression vector for 
N-terminal GST tagging of 
GFPensa_rev gb 
For GFP Linker 







For Ensa Linker 




















Mammalian expression vector 
for N-terminal GFP-tagged 
Ensa and Arpp19. 





Mammalian expression vector 





Mammalian expression vector 
for C-terminal GFP-tagged 
Ensa-Linker construct. 
p2E -3 








Bacterial expression vector for 
N-terminal His tagging of 
Flag-Ensa and Flag-Arpp19  
p3E- 7  
Bacterial expression vector for 
N-terminal GST tagging of 
Flag-Ensa and Flag-Arpp19 
Flag B55 alpha 
Addgene 
 
Flag-B55alpha was cloned into 
the mammalian expression 
vector pMIG using the BglII 





Linker-Ensa gene was cloned 
into pUC57 vector using XbaI 
and BamHI sites 
Ensa-Linker 
Ensa-Linker gene was cloned 
into pUC57 vector using XbaI 
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2.1.6 siRNA sequences 
 
siRNA oligonucleotides were ordered from Qiagen or from Dharmacon, GE Healthcare 





Source siRNA sequence 







ARPP19  J-015338-06   
CAACAUGGCUAAAGCAAA
A 
ARPP19 J-015338-07    
GUUCAGAUUUCUUAAGGA
A 
ARPP19 J-015338-08    
GCACAAGAGUUCCUACAC
A 
ENSA J-011852-05   
GCUAAAGGCCAAAUACCC
A 
ENSA J-011852-06   
AGAGAGCUGAAGAGGCAA
A 
ENSA J-011852-07   
UGAAGAGACUCCAGAAAG
G 
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2.2 Methods 
 
2.2.1 Molecular Biology 
 
a. Bacterial Culture and Plasmid preparation 
 
Individual colonies were picked from LB (Luria Bertani medium; 0.5% yeast extract, 
1% tryptone and 171 mM sodium chloride (NaCl)) agar plate containing appropriate 
selective antibiotics (kanamycin was used at 50 µg/ml and ampicillin was used at 100 
µg/ml). To prepare small amounts of plasmid deoxyribonucleic acid (DNA), 3 ml LB 
cultures containing the appropriate selective antibiotics were incubated overnight at 225 
revolutions per minute (rpm) and at 37°C. Cells were harvested by centrifugation at 
4000 rpm for 5 min. The plasmid DNA was then purified from the cells using the 
alkaline lysis method following the manufacturer’s protocol with the QIAprep Spin 
Miniprep Kit using microcentrifuge from QIAGEN (West Sussex, UK). Plasmid DNA 
was eluted in 50 µl ddH2O and the concentration was analysed by measuring the 
absorbance at 260 nm on a spectrophotometer and confirmed by restriction digestion 
and sequencing. Restriction digests were performed according to manufacturer's 
instructions and as recommended by the New England Biolabs website 
(https://www.neb.com/) and analysed by agarose gel electrophoresis. DNA was sent to 
GATC Biotech for sequencing and then analysed using Lasergene SequBuilder 10.1 
DNASTAR. 
For preparation of larger quantities of plasmid DNA for transfection into human cells, 
5-ml starter cultures were grown for 8 h at 225 rpm/37°C. Then, 100 µl of the starter 
cultures were used to inoculate 100 ml LB containing appropriate selective antibiotics, 
which were incubated at 225 rpm and at 37°C overnight. Cells were harvested by 
centrifugation at 4000 rpm and at 4°C for 20 min. The plasmid DNA was then purified 
from the pelleted cells again using the alkaline lysis method following the 
manufacturer’s protocol with the QIAFilter Plasmid Midi Kit from QIAGEN. The 
concentration of the purified plasmid DNA was then measured and the presence of the 
expected plasmid DNA confirmed by restriction digestion and sequencing. 
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b. Transformation of Recombinant Plasmids in Bacteria 
 
Competent DH5α Escherichia coli were thawed on ice for a few minutes. Fifty-
microliter aliquots were used per transformation; 50–100 ng of plasmid DNA was used 
and the bacteria were added to the DNA and mixed gently, followed by incubation on 
ice for 20 min. The tubes were then heat-shocked at 42°C for 45 s and incubated on ice 
for 2 min to help the cells to recover. Two hundred microliters of warm SOC media was 
added to the cells and mixed gently. The tubes were incubated for further 1 h in at 37°C 
in a water bath. After this, 50–200 µl of the cell culture were plated onto LB agar plates 
with appropriate selection antibiotics and placed at 37°C overnight. For transformation 
of the Gibson, Gateway and traditionally ligated plasmids, the entire suspension was 
spun down and the supernatant was removed to leave a 50 µl concentrated suspension, 
which was then plated onto LB plates.  
 
c. Cloning, PCR and RT-PCR 
 
All DNA extractions were performed using QIAprep Spin Miniprep from QIAGEN and 
all restriction digests were performed using restriction endonucleases and buffers from 
New England Biolabs (NEB). All ribonucleic acid (RNA) extractions were performed 
using the Phusion High-Fidelity PCR Kit from Finnzymes (Waltham, USA). Reverse –
transcriptase PCRs (RT-PCRs) were performed using the SuperScript™III One-Step 
RT-PCR System from Invitrogen. Ensa and Arpp19 cDNA was amplified from HeLa 
messenger RNA (mRNA) using the att Ensa19 F+R and att Arpp19 F+R respectively. 
They were then cloned into the entry vector pDONR™221 using the Gateway cloning 
method. The entry clone was then used to generate tagged Ensa and Arpp19 using 
different destination vectors.  
The Flag-Ensa and Flag-Arpp19 constructs were used as templates to PCR the Flag-
tagged cDNA with different enzymes. The PCR products were then ligated using the 
Quick Ligation™ Kit from NEB into the p3E and p2E vectors used for bacterial 
purification.  
PP2A B55-alpha was amplified from the pMIG-B55alpha plasmid and ligated into 
pEGFP-C1 with EcoRI and BamHI sites using Quick Ligation™ Kit from NEB. The 
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Linker-Ensa and Ensa Linker cDNA were cloned into pEGFP-C1 and pEGFP-N1 
respectively using the Gibson Assembly® Master Mix from NEB.  
 
d. Agarose Gel Electrophoresis and Gel Extraction 
 
DNA was separated using 1% Agarose gels by electrophoresis in TAE (40 mM Tris 
base, 1 mM ethylene diamine tetraacetic acid (EDTA) and 20 mM acetic acid) for bands 
≥ 1000 kB and TBE (45 mM Tris borate and 1 mM ethylene diamine tetraacetic acid 
(EDTA) for bands <1000 kB. The gels were visualized using the gel imaging system 
InGenius LHR from Syngene (Cambridge, UK). The 1 kB/+ DNA ladder from NEB 
was used to confirm the size of the DNA fragments. The manufacturer’s protocol was 
used to purify DNA using the QIAquick Gel Extraction Kit from Qiagen. The DNA 
fragments were eluted in ddH2O. 
 
e. Gateway Cloning 
 
In this work, MultiSite Gateway® technology from Invitrogen was used to manipulate 
the cDNA of Ensa and Arpp19 to generate various tagged versions of the protein. This 
technology takes advantage of the lambda phage recombination system to allow transfer 
of cloned DNA between site-specific att recombination sequences on different vectors. 
Recombination is conservative and does not require any DNA synthesis. Once the 
cDNA has been cloned into the entry vector in this system, it can be transferred to 
several other destination vectors, i.e. expression vectors, for protein purification or 
protein tagging. 
In order to create an entry clone with the Ensa or Arpp19 cDNA, the appropriate att 
recombination sequences were added to the cDNA by RT-PCR using the primers att 
Ensa F+R and att Arpp19 F+R respectively (listed in section). A BP reaction was then 
performed following the manufacturers’ recommended protocol using Gateway® BP 
Clonase II Enzyme Mix to move the cDNA into the pDONR™221 vector (Invitrogen), 
creating the entry clones. This was then subsequently used for further cloning step by 
performing an LR reaction using the Gateway® LR Clonase II Enzyme Mix 
(Invitrogen) with various destination vectors to yield the different constructs detailed 
throughout this work. Details of all reactions can be found in the Gateway® 
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Technology with Clonase II Manual available on the Invitrogen website 
(www.invitrogen.com). 
 
f. Gibson Assembly  
 
For this work, the Gibson Assembly Cloning Technology from NEB was also used to 
generate GFP-tagged versions of Ensa and Arpp19 with a linker separating the tag and 
the cDNA. Dr. Daniel Gibson and his colleagues developed Gibson Assembly, which 
method allows efficient joining of multiple overlapping DNA fragments in a rapid 
single tube isothermal reaction at 50°C. The reaction Master Mix includes three 
different enzymes for three different enzymatic reactions in one buffer. First, the 5’ 
exonuclease chews the 5’ end sequences to create single stranded 3’ end complementary 
sequence to facilitate annealing. Then the DNA polymerase with the 3’ extension 
activity fills the gaps between the complementary annealed fragments. The DNA ligase 
then seals the nicks and covalently links the DNA fragments together. The PCR 
fragments for Linker-Ensa were amplified using the GFP ensa_fwd gb and 
GFPensa_rev gb and for Ensa-Linker using the Ensa_Linker F+R primers (Listed in 
Table 1.6). The Linker-Ensa and Ensa-Linker plasmids created by Addgene were used 
as templates for the PCR reaction. The PCR products and the linearized destination 
vectors (pEGFP-C1 and pEGFP-N1) were mixed in the appropriate ratio and the Gibson 
Assembly reaction was done as per the manufacturers’ protocol Listed in Table.  
 
 
g. Sequence Alignments 
 
All sequence alignments were carried out using CLUSTAL Omega Version 1.2.1 using 
the Multiple Sequence Alignment Tool on the European Bioinformatics Institute 
website (http://www.ebi.ac.uk/). 
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2.2.2 Biochemical methods 
 
a. Western Blotting  
 
Cells were lysed in Mitotic Lysis Buffer (50 mM Tris-HCl [pH 7.35], 150 mM NaCl, 
1% [vol/vol] IGEPAL, 1 mM dithiothreitol, and protease inhibitor cocktail [Sigma-
Aldrich, P8340]) and 1X SDS sample buffer was added to it. The samples were then 
sonicated at high power with 0.5-s intervals using a Bioruptor (Diagenode, Cambridge, 
UK) for about 10–20 s. Samples were then boiled at 95°C for 5 min and run on SDS-
polyacrylamide gels by electrophoresis using Bio-Rad Mini Protean III System from 
Bio-Rad in running buffer along with a ColorPlus Prestained Protein Marker (Broad-
Range, New England Biolabs). The samples were allowed to run through the stacking 
gel to the resolving gel at 200 V for about 35–40 min. The protein was then transferred 
by electro-blotting onto a nitrocellulose PVDF membrane (Amersham Hyperfilm ECL 
18 × 24 cm 100 sheets, Scientific Laboratory supplies Ltd.) using the semi-dry system 
Trans-Blot® TurboTM Blotting System, BioRad. Stacks of filter papers were immersed 
in Anode 1, anode 2 and Cathode solution and the PVDF membrane was activated with 
methanol before making the transfer sandwich with the gel. Protein bands were then 
visualized using Ponceau S solution. The membranes were washed in PBS with 0.1% 
NP40 and blocked with 5% milk (Marvel with PBS-0.1% NP40) for about an hour at 
room temperature. Antibodies were diluted in 5% milk or 3% BSA (BSA; with PBS-
0.1% NP40), and secondary HRP-conjugates rabbit, mouse or goat polyclonal 
secondary antibodies were used at recommended concentrations. Proteins were then 
visualized with the homemade Luminol, Enhancer and Hydrogen peroxide mix as per 
the protocol. For antibodies with reduced or faint signal, Super sensitive ECL 
(SUPERSIGNAL WEST FEMTO MAX, Thermo Scientific, UK) was used by diluting 
in the homemade ECL mix as per requirement. The membrane was exposed to 
Hyperfilm ECL (Amersham) and processed using an automatic X-ray film processor 
(ECOMAX, PROTEC GmbH & Co. KG). 
 
b. Antibody Generation 
 
Ensa and Arpp19 specific antibodies were custom made by Eurogentec for this study. 
The N-terminal bit of the protein has significant dissimilarities, which were exploited to 
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map a peptide with minimal sequence cross-alignment. This peptide sequence was sent 
to Eurogentec. They provided us with the initial and final bleeds and the affinity-
purified antibodies. The purified antibodies were used in this study to analyse their 




Cells were seeded on glass coverslips (18 mm), prior to fixation. For immuno-staining 
of over-expressed proteins, the transfection was done on cells seeded on coverslips. 
Post-transfection or once the cells reached 60%-80% confluency, the media was 
aspirated and cells were washed with warm PBS. The cells were then fixed with 3.7% 
freshly made Paraformaldehyde (F1635 Formaldehyde solution, Sigma) for 10 min at 
room temperature. The fixed cells were next washed with PBS three times for 5 min. 
For some antibodies, the cells were then treated with ice-cold methanol at -20°C for 30 
s to 1 min. the cells were then washed with PBS three times and then permeabilised 
using PBS 0.1% NP40 for 15–20 min. After this, the cells were blocked for 30 min at 
room temperature in 3% BSA-PBS and incubated for 1 h with primary antibodies made 
up in 3% BSA-PBS. The cells were then washed with PBS three to five times and 
incubated in secondary antibodies diluted in 3% BSA-PBS for 1 h at room temperature. 
The cells were washed again with PBS before being mounted onto standard laboratory 
slides faced down with 5-µl Prolong® Gold mounting solution with DAPI with 
(ProLong® Diamond Antifade Mountant, Thermo Fisher, UK) and allowed to set for at 
least 16 h at 4°C. 
 
d. FACS Analysis 
 
Flow cytometry was used to analyse and sort cells stained with fluorescent antibodies or 
expressing fluorescent proteins. Sorting was done to determine the cell cycle profile 
according to DNA content by Propidium iodide (PI staining) and the expression of 
various proteins stained with different antibodies.  
Cells were fixed in 70% methanol for at least 16 h at 4°C. Cells were then centrifuged at 
1500 rpm for 5 min and rinsed in 0.5 ml of 3% BSA-PBS. For staining mitotic cells, the 
cells were incubated with anti-phospho-histone H3 antibody made in 3% BSA-PBS for 
1 h at room temperature. The cells were then washed with 3% BSA-PBS two times and 
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resuspended in secondary FITC-labelled anti-rabbit antibody at 1:2000 for 1 h in the 
dark. The cells were again washed with 3% BSA-PBS two times. After this, they were 
re-centrifuged and resuspended in 3% BSA-PBS with 5 µg/ml Propidium iodide to stain 
the DNA and 1 µg/ml RNAse. These were analysed on a BD Accuri machine from BD 
Biosciences (Oxford, UK). The BD Accuri software (BD Biosciences) was used to plot 
PI -intensity (FL-2) versus cell count and FITC-phospho-histone H3 intensity (FL-1) 
versus PI-intensity (FL-2) to determine mitotic index. 
 
e. Immunoprecipitation 
i) Immunoprecipitation from overexpressed proteins 
 
Cells were harvested by trypsinisation after transfection of Flag tagged constructs in 
Hek293 or HeLa cells. The cells were resuspended in 25 µl of chilled IP lysis buffer and 
incubated on ice for 20 min. The cell lysates were then clarified by spinning them at 
1300 rpm for 30 min at 4°C and the supernatant was transferred to new tubes. Total 
protein was equalised using the Bio-Rad Protein Assay Reagent (Bio-Rad) and 
measuring absorbance at 600 nm. A 50-µl sample of the whole cell equalised lysate was 
kept and SDS-sample buffer was added for evaluation by immuno-blotting. The Anti 
Flag M2 Magnetic beads were prepared by washing two times with IP buffer on a 
chilled magnetic stand. The equalised whole cell lysate was then incubated with 20 µl 
of equilibrated beads, resuspended in IP buffer for 1 h with end over end rotation at 4°C 
to capture the Flag-Ensa/Arpp19 protein. After this, the supernatant was removed from 
the beads using chilled magnetic stand and the beads were then washed two times with 
High Salt IP buffer. Next, the beads were resuspended in 20 µl of the Elution IP buffer 
and incubated at 4°C in a Falcon tube on a roller for 30 min. The elution was done twice 
with 20 µl of Elution Buffer each time. The eluates were then pooled in a new tube and 
either used for immuno-blotting with SDS-sample buffer or for Size-exclusion 
chromatography.  
 
ii) Immunoprecipitation using recombinant proteins and cell lysates 
 
Cells were seeded in 10 cm dish until they were 50% confluent. Cells were then treated 
with 5 µM STLC for 16–18 h to arrest them in mitosis (metaphase). The following day, 
the cells were collected by mitotic shake-off and counted. Half of the cells were 
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resuspended in media containing 5 µM 1NMPP1 and 5 µM STLC to induce mitotic exit 
and were incubated at 37°C for 30 min. The mitotic and mitotic exit samples were used 
for immunoprecipitation at 7 x 106 per condition. The respective cells were centrifuged 
at 1500 rpm for 5 min and lysed with 200 µl of Mitotic lysis buffer for 20 min on ice. 
The protein concentration was measured using Bio-Rad Protein Assay Reagent (Bio-
Rad) and measuring absorbance at 600 nm. The protein concentration was maintained 
between 10 mg/ml to 20 mg/ml using this method. The cell lysates were clarified by 
centrifuging at 13000 rpm for 30 min. Two hundred nanograms of recombinant protein, 
Flag Ensa/Arpp19 (non-phosphorylated or thio-phosphorylated) was added to the whole 
cell lysates and incubated at 37°C for 30 min to allow protein-protein interaction with 
the recombinant protein. During this time, 20 µl of Anti-Flag M2 Magnetic beads were 
equilibrated, by washing once with High Salt Mitotic lysis buffer and once with Mitotic 
lysis buffer for 5 min using a chilled magnetic stand. They were then resuspended in 
300 µl of mitotic lysis buffer. The protein-lysate mixture was added to the equilibrated 
beads and incubated for 1 h at 4°C with end over end rotation to re-capture the Flag 
Ensa/Arpp19 protein. The supernatant was then removed from the beads using chilled 
magnetic stand. The beads were washed with High Salt Mitotic lysis buffer twice for 5 
min. They were then resuspended in 25 µl of Mitotic Elution buffer and incubated at 
4°C in a Falcon tube over a roller.  
  
f. Size Exclusion Chromatography 
 
Analytical size-exclusion chromatography experiments were performed on a calibrated 
Superose 6 3.2/300 (GE Healthcare Cat: 29-0915-98) Column in the presence of the IP 
buffer run at a flow of 0.04 ml/min at 4°C in a cold cabinet. Sample injection volume 
was 50 µl for all runs (samples + controls). Elution of proteins was monitored at A280 nm. 
To detect complex formation, the elutions from immunoprecipitation were injected 
through the column. Fraction collection was 50 µl each and analysed by SDS-PAGE, 
Coomassie staining and western blotting. 
 
Calibration standards were run using the same settings as with the samples. The proteins 
used for calibration were Thyroglobulin (669 kDa), Ferritin (440 kDa), Aldolase (158 
kDa), Conalbumin (75 kDa) and Carbonic Anhydrase (29 kDa), all from Gel Filtration 
Calibration Kit (GE Healthcare). Void volume of the column was determined using 
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dextran blue (GE Healthcare). Calibration curve plot, formula and statistics are shown 
in the figure. 
 
g. Silver Staining  
 
The SDS-PAGE gels were first incubated in the Fix solution for at least 1 h. After 
fixing, gel was washed with 50% methanol (Wash solution) thrice for 8 min. The gel 
was then sensitized with 0.02% sodium thiosulphate for exactly 1 min. Following 
sensitisation, the gel was washed three times with MilliQ water for 20 s each time and 
then stained with silver staining solution for 20 min. Before developing, the gel was 
washed two times with distilled water for 20 s. The bands were developed with 
developing solution. Development was stopped with stop solution once the bands were 
clearly visible and staining was stopped, by treating with Stop solution for 10 min. To 
preserve the gel between sheets of porous plastic, wash the gel with Wash Solution for 2 
x 10 min. Then incubate the gel with Drying Solution for a maximum of 1 h (the 
glycerol will begin to leach out the silver after 1–2 h). 
 
h. In-gel Trypsinisation and Mass Spectrometry 
 
The elutions form IP were run on SDS-PAGE and stained with InstantBlue-Protein 
Stain (Expedeon). The gel band of interest was excised using a surgical razor blade and 
transferred to a 0.6 mL low retention Eppendorf microcentrifuge tube. Staining was 
removed by two consecutive washes with 50% acetonitrile and 25 mM ammonium 
bicarbonate solution for 5 min with shaking. The sample was then dried to completeness 
for 5 min in a speed vac. The gel pieces were rehydrated with 10 mM DTT solution for 
45 min at 50°C. Once the gel pieces return to room temperature, the liquid was replaced 
with 50 mM iodoacetamide in 25 mM NH4HCO3. The gel pieces were dehydrated as 
before with 50% acetonitrile and 25 mM ammonium bicarbonate solution for 5 min 
with shaking. The sample was then dried to completeness for 5 min in a speed vac. 
Then, 20 µl of trypsin reaction buffer (12.5 ng/µl trypsin in 25 mM NH4HCO3 was 
added and incubated on ice for 5 min. The solution was then replaced with 25 mM 
NH4HCO3 and incubated at 37°C overnight (or for 4 h at least). Formic acid was added 
for a final concentration ~5%. The peptides in the solution were removed into a clean 
tube after vortexing. Next, 1X volume of acetonitrile, i.e. equal to the volume of gel 
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pieces, was added and shaken for 5 min. The supernatant was then removed and added 
to the peptides. The process was repeated if gel pieces did not look dehydrated. When 
the entire sample needed to be loaded in one go, the volume of peptide eluates were 
reduced to ~8 µl using speed vac, with low or medium heat setting. This takes at least 
30 min depending on volume and heat setting. Next, 0.1% FA was added to get a 
volume of ~8 µl when necessary. Storage was done at -20 or -80°C. 
 
i. Protein identification and quantification 
 
Peptide samples were analysed by Nano-LC-MS (Thermo Fisher U3000 nanoLC and 
Orbitrap XL mass spectrometer). Data were acquired using the Xcalibar v2.1 software. 
The raw data files were processed and quantified using MaxQuant version 1.5.5.1 and 
searched against the SwissProt human proteome database. The proteingroups.txt file 
from MaxQuant was loaded to Perseus version 1.5.5.3. The protein list was filtered on 
categorical and text annotations to remove reverse hits, proteins only identified by site, 
and contaminants. Log2 transformation of LFQ Intensity values was performed before 
comparison between the mentioned data sets by two-sample t-test using permutation-
based FDR (P < 0.05) and fold-difference (S0 > 2). 
 
2.2.3 Cell Culture 
 
a. Thawing Cells 
 
Cells frozen at -80°C or -170°C (Liquid nitrogen stocks) were allowed to thaw at 37°C 
in a water bath. These cells were then added to 10 ml of warm media in falcon tubes and 
centrifuged for 5 min at 1500 rpm. The media was aspirated and cell pellet was 
resuspended in 10 ml of fresh warm media. The cells were then plated onto a T75 flask 
and incubated at 37°C  and under 5% CO2 for 1 or 2 days before passaging them. 
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b. Cultivating Cells 
 
Cells were cultured in DMEM supplemented with 2 mM L-glutamine, 10% Foetal Calf 
Serum (FCS) and 1% Penicillin G (sodium-salt)-Streptomycin in saline solution. The 
cells were plated in their respective culture vessels and incubated in 37°C and 5% CO2 
incubators. Trypsin-EDTA (Gibco™) was used to trypsinise and passage cells. 
 
c. Counting Cells 
 
Cells were trypsinised using 0.5 mg/ml of trypsin, to detach them from the cell culture 
vessels for 5 min at 37°C. They were then resuspended in appropriate volume of warm 
media to stop the enzymatic action of trypsin and mixed by pipetting. Eight microliters 
of the cell culture was placed on Neubauer’s chamber and cells were counted under a 
bright-field/phase-contrast microscope. The ‘Neubauer’ chamber is a glass slide with an 
etched grid, defining a specific volume. Four large squares (of 1 mm2 each) further 
divided into 16 smaller squares of equal dimension can be observed when seen under a 
light microscope. The chamber is cleaned, dried and placed on a flat surface and 
covered with a coverslip. Next, 8–10 µl of the cell suspension is carefully introduced by 
placing the tip closer to the edge of coverslip at the centre of the chamber. Care should 
be taken to avoid air bubbles. Cells in the four large squares were counted and cell 
counts per ml were calculated using the formula below 
Total cells per ml = (Total cells counted/4) X dilution factor X 104 
 
d. Freezing Cells 
 
Cell stocks were prepared by centrifuging trypsinised cell cultures at 1500 rpm for 5 
min. The cell pellets were then resuspended in 0.5 ml of freezing media (FCS, 10% 
DMSO) and added in cryo-vial. To achieve -1°C/min cooling rate, the cryo vials were 
placed in “Nalgene TM 1°C cryo freezing container” filled with isopropanol at -80°C 
overnight. The cells were then transferred to the -80°C stock or liquid nitrogen shelves 
for long-term storage. 
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e. Inhibitor Treatment 
 
Cells were treated with different inhibitor to arrest them in different cell cycle phases. 
Cells were treated with 100 ng/ml of Nocodazole or 5 µM of STLC (S-trityl-l-cysteine) 
for 16–18 h for a mitotic arrest. Cells were treated with varying concentrations of 
phosphatase inhibitors like Okadaic Acid. Cells stably expressing the CDK1_as gene 
were arrested in G2 using 1NMPP1 inhibitor in varying concentrations for 18–20 h. For 
these treatments, the media was aspirated and replaced with the drug containing media 
and mixed thoroughly by pipetting. 
 
f. Plasmid Transfection  
i) CaCl2 transfection in Hek293 cells 
 
Cells were seeded into 10 cm3 culture dishes at 0.75 x 106 in 10 ml media. Cells were 
transfected the next day using calcium phosphate precipitation method. For this, 5 µg of 
plasmid DNA was added to 61 µl of 2 M calcium chloride (CaCl2) and sterile water was 
added up to 500 µl. This solution was added drop wise to 500 µl of 2X HEPES-
Buffered Saline Solution (HBSS) (12 mM dextrose, 50 mM HEPES, 10 mM KCl, 280 
mM NaCl, 1.5 mM disodium hydrogen phosphate dihydrate (Na2HPO4. 2H2O)) while 
bubbling gently using a glass Pasteur pipette and electronic pipette to mix. The 1-ml 
solution was then immediately added drop wise to the cells and swirled to mix. The next 
day the precipitate-containing medium was removed, the cells washed with PBS and 
fresh medium added back. Samples were collected 48 h following the transfection. 
 
ii) Jet-Pie transfection in HeLa_CDK1_as cells 
 
Cells were seeded into 10 cm3 culture dishes at 1.5 x 106 in 10 ml media. Cells were 
then transfected the following day using the Jet-Pie (Polyethylenimine, Linear, MW 
2,500 (PEI 2500)) method. For this, 15 µl of Pie reagent was added to 250 µl of 150 
mM sterile NaCl in a tube. Similarly, 5 µg of DNA plasmid was added to 250 µl of 150 
mM sterile NaCl in another tube. The contents in both the tubes were mixed well by 
vortexing and the DNA mix was then added to the transfectant tube and mixed. The 
DNA-PIE mixture was then incubated at room temperature for 15–20 min. During this 
time media was aspirated from the cells and 5 ml of fresh media was added. After 
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incubation, the DNA-PIE mixture was added drop-wise to the cells and incubated at 
37°C for 4–6 h. The media was then aspirated, and fresh 10 ml warm media was added, 
followed by incubation of the cells for 24 h. The transfection was performed again after 
24 h of incubation and the cell lysates were collected after 48 h of the second 
transfection. 
 
iii)  Lipofectamine™ 2000 transfection 
 
Cells were trypsinised and diluted to a concentration of 3.5 x 105 cells /ml. Two 
millilitres of the cell suspension was plated into a well of 6-well plate. The DNA-





Plasmid DNA Serum Free-
Media 
Tube 1 2.5 µl  200 µl 
Tube 2  2 µg 200 µl 
 
Tube 1 was added to tube 2 and mixed well by pipetting. The DNA-Lipofectamine 
complex was incubated for 15–20 min at room temperature. The complex was then 
added drop-wise on the cells. The cells were incubated for 24–48 h and then used for 
further analysis. 
 
g. siRNA Transfection 
 
siRNA transfection was done by a technique called Reverse transfection. For this 
technique, trypsinised cells at the concentration of 1 x 105 cells /ml were used. The 
siRNA mixture with Lipofectamine™ RNAiMAX was prepared as follows: 
 




40–50 nM (total) 5 µl Up to 500 µl 
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This mixture was incubated at room temperature for 20 min and then mixed with 2 ml 
of the cell culture. The cells-siRNA mix was then plated into 6-well dish. Cells were 
then grown at 37°C for 48 to 72 h before the lysates were collected for immunoblotting. 
(Table 1.8) enlists the sequences of siRNA oligos used in this study. 
 
2.2.4 Microscopy 
a. Time Lapse Imaging 
 
Time-lapse imaging was done using the IX71_Olympus or the IX73_Olympus 
microscope. The microscopes were equipped for differential interference contrast 
imaging and with different filter units for epifluorescence microscopy. For live imaging, 
the microscope was further equipped with a CO2 incubator and a heating plate 
(temperature control 37°C). Micromanager software enabled full-control of the 
microscope, allowing acquisition of time-lapse movies, Z-series, as well as image 
manipulation, 3D reconstructions or quantitative analysis. 
 
b. Quantification of Mitotic cells and Phenotypes 
 
Mitotic index was calculated by counting cells on ImageJ. Time in mitosis was 
quantified from nuclear envelope breakdown (NEBD) until telophase. Online tool at 
http://boxplot.tyerslab.com was used to generate boxplots to depict mitotic time. Images 
were cropped an adjusted for brightness and contrast using Omero WebClient and 
appropriate scale bars were added. 
 
2.2.5 Protein Expression, Purification and Transfection 
 
a. Protein Purification from Bacteria 
 
His-Ensa/Arpp19 and GST-Ensa/Arpp19 were cloned using the Gateway technology. 
GST-Flag Ensa and GST-Flag Arpp19 were traditionally cloned into the p3E vector. 
These vectors were transformed in E.coli Rosette strains. Transformed colonies were 
used to inoculate 20 ml culture of LB medium supplemented with appropriate 
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antibiotics overnight. This culture was used to inoculate a 1-L flask of LB broth 
supplemented with appropriate antibiotics. Cultures were grown in an orbital shaking 
incubator until the optical density at 600 nm reached ~0.8, and then induced with 1 mM 
isopropyl-thio-β-galactoside (IPTG) at 18°C overnight. Fifty-microliter aliquots were 
kept and SDS-sample buffer was added to them to analyse the over-expression of the 
protein before and after induction. They were then harvested with 25 ml Bacterial lysis 
buffer per litre of culture and sonicated at 30% amplitude for 1 min with a 5-s on-off 
cycle. The lysates were then clarified at 20,000 rpm for 1 h by centrifugation. Aliquots 
of the lysates were kept and SDS-sample buffer was added to them to analyse the effect 
of sonication on the over-expressed proteins. His-tagged proteins were purified using 
Nickel-NTA Agarose beads (Qiagen) and were eluted using 1 M Imidazole. The GST-
Tagged proteins were purified using the Glutathione Sepharose Beads (GE Healthcare) 
and eluted using 10 mM Glutathione. One-millilitre beads per litre of culture was 
equilibrated, by washing them twice with 20 volumes bacterial lysis and centrifuging 
them at 400g for 5 min. The clarified lysates were added to the equilibrated beads and 
incubated for 1–2 h on a roller at 4°C. After the binding, the unbound fraction was 
separated from the beads and they were washed with 20 volumes of Bacterial wash 
buffer with high salt. The bound protein was eluted by adding 1 ml at a time of the 
respective elution buffers and incubated at room temperature for 10 min. The beads 
were then centrifuged at 400g for 5 min and the elutions were collected. Aliquots were 
kept from each elution and SDS-page sample buffer was added to identify the elution 
containing the protein of interest. Elutes containing the protein of interest in high 
amounts were pooled and dialyzed into the Kinase buffer for in vitro 
thiophosphorylation. 
 
b. In vitro Thiophosphorylation of Recombinant Ensa and Arpp19 
 
The ratio between substrate and kinase is of key importance in an in-vitro 
phosphorylation reaction. At a given time, 0.5 mg of purified Ensa/Arpp19 was 
successfully thio-phosphorylated using 2 µg Gwl-E2. Maximum phosphorylation was 
obtained in 5 h. Reaction was carried out in kinase buffer in the presence of 50 µM 
gamma-S-ATP at 37°C. The condition were adapted from (Allen et al. 2007) and used 
to thio-phosphorylate recombinant Ensa/Arpp19 in vitro.	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c. Protein Transfection with Xfect™ Protein Transfection Reagent 
 
Xfect kit from Clontech, USA was used for the protein transfection initially. Five 
micrograms of protein was transfected using manufacturer’s recommended protocol and 
the cells were harvested 2 h post-transfection. For mitotic entry studies, transfection was 
done on PP2A-B55-alpha and delta depleted cells that were arrested in G2 with 
INMPP1 overnight. In these experiments, the cells were washed with warm PBS 3–5 
times and media-containing 25 µM of MG132 was added. This was done to prevent 
cells from going out of mitosis, which makes it easier to count cells entering mitosis 
from G2 after 1NMPP1 is washed off. 
 
d. Neon Transfection of Proteins 
 
Purified proteins were transfected into 5 x 105 U2OS_CDK1_as cells using Neon® 
Transfection System 10 µl Kit (Invitrogen UK). Two micrograms of protein was 
incubated in resuspension buffer for 10 min at RT before mixing it with cell pellet. 
Meanwhile, 0.5 × 106 cells were transferred to a sterile test tube and centrifuged at 500g 
for 5 min. Supernatant was aspirated and the cell pellet was resuspended in 1 ml of PBS 
without Ca2+ and Mg2+. Upon centrifugation, the supernatant was carefully aspirated so 
that almost all the PBS buffer was removed with no or minimum loss of cells. The 
Resuspension Buffer R containing the purified Ensa/Arpp19 was then used to resuspend 
the cell pellets. A 10-µl cell suspension was electroporated at a given time using 1400 
V/15 ms/4 pulses. Cells were plated in warm media and incubated for varying time-
points.  
 
e. Electroporation of Proteins 
 
Cells were detached from the culture flasks using trypsin/EDTA (0.05%/0.02%), 
centrifuged at 130 × g for 5 min at 25°C, washed once in PBS and counted on a 
haemocytometer. Recombinant Ensa or Arpp19 was added to freshly prepared and 
sterile filtered electroporation buffer (EPB: 100 mM sodium phosphate, 5 mM KCl, 15 
mM MgCl2, 15 mM HEPES, 2 mM ATP (Thermo Fisher), 2 mM reduced glutathione 
(Sigma) at pH 7.2) to final concentrations of 20 µM or 40 µM. Next, the cells were 
pelleted again and mixed with protein solution in EPB. One hundred-microliter aliquots 
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(4 x 106 cells) were then transferred into 2 mm cuvettes and electroporated on an 
Amaxa Nucleofector I (Lonza). Pulse programs were #B28 or #A28 for HeLa cells. 
Cells were pulsed twice with gentle mixing in between the pulses. For control 
experiments, cells were mock electroporated with EPB alone. Directly after 
electroporation, 0.3 mL of pre-warmed (37 °C) CO2-adjusted and cell line-matched 
growth medium was added to each cuvette and samples were transferred to cell culture 
dishes. For small-scale experiments (i.e. immunofluorescence microscopy, western 
blotting, flow cytometry) aliquots of 4 x 106 cells were added to separate wells of a 6-
well plate (3.5 cm diameter), filled with 2 mL/well of pre-warmed cell line-specific 
growth medium. Cells were returned to the incubator and allowed to recover for 5 h. 
During this period, cell viability and morphology was monitored by bright-field 
microscopy. Once cells regained their adherent morphologies, dishes were washed three 
times with pre-warmed PBS and cells were harvested by trypsinisation. Cells were 
washed twice with pre-warmed PBS before further analyses.  
 
f. Pro-DeliverIN™ Transfection 
 
Transfection using Pro-DeliverIN™ Transfection Reagent was optimised using the 
manufacturer’s recommended protocol (http://www.ozbiosciences.com/transfection-
protein/35-pro-deliverin-transfection-reagent-protein-delivery.html), in a 24-well plate. 
The positive control (R-Phycoerythrin) provided was also used as per the 
manufacturer’s protocol.  
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CHAPTER3 PRELIMINARY CHARACTERISATION 
OF ENSA AND ARPP19 
 
Greatwall kinase has been implicated to play a major role in the mitotic entry network 
in higher eukaryotes. Greatwall performs its functions by phosphorylating two small 
phospho-proteins, Endosulphine-alpha (Ensa) and Arpp19. The phosphorylated 
substrates then bind to PP2A-B55, to inhibit the dephosphorylation of Cdk substrates 
and hence maintain the mitotic state. 
 
Ensa and Arpp19 have not been extensively studied in human cells and their precise 
contributions to mitotic entry as well as their mode of action and regulation remain to be 
investigated. Although these proteins are highly similar, we do not know if they share 
individual or overlapping functions. We lack information on their subcellular 
localisation throughout the cell cycle. We also know little about their precise structural 
interaction with the B55/PP2A phosphatase and do not have a good understanding of 
interaction with other proteins. To embark on a study on the cellular function of these 
two proteins we decided to generate the necessary tools for cell-biological and 
biochemical analysis of these two closely related proteins. This includes specific 
antibodies, potent and validated siRNAs and tagged expression constructs that have 
been functionally characterised. In this chapter, we describe the generation of these 
tools and a basic characterisation of Ensa and Arpp19 localisation in interphase and 
mitotic cells. 
 
3.1 Generating Antibodies and Analysing Their Specificity 
 
Ensa and Arpp19 are two small regulatory proteins that are Greatwall kinase substrates. 
They are ~70% identical in their amino acid sequences making it difficult to study them 
individually. This thesis focuses on exploring the proteins Ensa and Arpp19 in the 
mitotic entry network. When I started this study, the functions of these proteins were 
roughly mapped using antibodies raised against full-length cDNA or the dissimilar  
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Figure 3.1 Specificity analyses of antibodies generated against Ensa and Arpp19 for this 
study 
A) Multiple sequence alignment of Ensa and Arpp19 peptides with Clustal Omega used for 
rabbit polyclonal antibody generation. The sequences marked in red show the similarity of the 
peptides to the chicken and human protein sequences. B) Purified antibody was used to test 
specificity using recombinant proteins purified from E.coli Defined amounts of GST-Ensa and 
Flag-Arpp19 were probed to test antibody affinity. C) Purified antibodies were used to probe 
for endogenous Ensa and Arpp19 in total cell lysates from HeLa and chicken DT40 cells. D) 
Defined number of cells was used to test antibody affinity. Total cells lysates were prepared 
from HeLa cells. Purified antibodies were used for immunoblotting.  	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Figure 3.1 Specificity analyses of antibodies generated against Ensa and 
Arpp19 for this study 
E) Hek293 were transfected with expression constructs encoding full length human 
Ensa and Arpp19. After 48 h of incubation, total cell lysates were prepared and 
immuno-blotted with purified antibodies. F) siRNA knockdowns were performed 
using Dharmacon siRNA smart pools at 50 nM concentration for 72 h. Total lysates 
were probed with newly purified and commercial antibodies. G) Western blots of 
siRNA depletion were quantified using ImageJ software and relative intensities were 
plotted. Data expressed as mean (±S.D) and a representative western (F). 
Immunofluorescence staining of endogenous Ensa and Arpp19 using purified 
antibodies after siRNA treatment for 72 hrs. The cells were fixed and co-stained 
with antibodies against α-tubulin (green) and EnsaArpp19 (red). The nuclei was 
visualised with DAPI (blue). Images were taken on the Olympus IX70 microscope 
with a 60X, oil –immersion lens, N.A 1.42. Scale bar: 10 µM 
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C-terminal residues in Xenopus (Mochida et al. 2010; Gharbi-Ayachi et al. 2010). For 
studies in other vertebrates like starfish and mammalians; the full-length cDNA was 
used to raise polyclonal antibodies (Cundell et al. 2013; Okumura et al. 2014; Dulubova 
et al. 2001; Mochida et al. 2010; Gharbi-Ayachi et al. 2010). However, these antisera 
were not tested for cross-reactivity in cellular extracts. Therefore, it was difficult to 
differentiate between specific roles and distributions of Arpp19 and Ensa and to 
determine their relative importance as B55/PP2A inhibitors.  
 
To initiate this study I attempted to generate specific antibodies for Ensa and Arpp19 in 
vertebrate cell lines cells. I started this project before the onset of CrispR technology 
with the plan to perform genetic studies in chicken DT40 lymphocytes. Thus, I raised 
the peptides used for specific antibody generation matching the divergent N-termini of 
Gallus Arpp19 and Ensa. The chicken and human proteins share a significant homology 
and polyclonal antibodies are likely to be cross-reactive between chicken and 
mammalian species. With the help of Eurogentec, we generated peptides mapping 14 
residues at the Arpp19 and Ensa N-terminal (Fig. 3.1A) that showed considerable 
sequence differences between the paralogues. Rabbits were injected with these peptides 
coupled to KLH carrier and we obtained purified antibodies following a standard 
immunisation and purification protocol provided by Eurogentec. To test these 
antibodies I performed immuno-blotting using recombinant human Arpp19 and Ensa 
that were expressed and purified from E.coli. Ensa was tagged with GST (46 kDa) and 
purified with glutathione sepharose beads, while Arpp19 was his-tagged and purified 
with Nickel-agarose-affinity columns (Materials and Methods 2.2.5). Using this 
method, I confirmed that these antibodies could specifically detect recombinant human 
Ensa and Arpp19 and that they showed no sign of cross-reactivity (Fig. 3.1B). I then 
used DT40 and HeLa extracts to probe endogenous expression of Arpp19 and Ensa. The 
antibodies showed a weak signal at the expected size (17 kDa), but also showed a 
number of non-specific bands (Fig. 3.1C). Given this non-specific background, it is 
unlikely that these antisera can be used for immuno-fluorescence studies to assess the 
localisation of Ensa and Arpp19. 
 
The weak signal for the supposedly specific bands in the cell extract blots may be due to 
the limited sensitivity of the antibodies, or due to low abundance of Ensa and Arpp19. 
To improve the signal in the immuno-blots, I prepared highly concentrated cell lysates 
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of HeLa cells and probed them with the newly made antibodies. The signal for the 
expected size band increased proportionally with the increasing cell number, and so did 
the non-specific signal (Fig. 3.1D). However, a band at the expected molecular weight 
was clearly visible, so that these antibodies could be useful to detect the endogenous 
expression of Ensa and Arpp19. 
 
To further confirm that our antisera can specifically detect Ensa and Arpp19 in cell 
extracts, I decided to express Ensa and Arpp19 exogenously in mammalian cells. To 
differentiate between the endogenous and exogenous proteins, I tagged them with a 
Flag-tag. Flag-tag (1 kDa) being negatively charged migrates slower than the 
endogenous protein, even though the molecular weight is approximately the same. The 
constructs were expressed transiently in Hek293 cells, known for their high transfection 
efficiency, using the Calcium chloride method (Materials and Methods 2.2.3). Forty-
eight hours post-transfection, I collected the cells and prepared concentrated lysates. 
Although, the antibodies recognised the exogenous proteins (~22 kDa) specifically (Fig. 
3.1E), they also showed a lot of background along with the endogenous protein (17 
kDa). 
 
The commercial Abcam antibody recognised both the Flag-tagged proteins as well as 
the endogenous ones very strongly. The 17-kDa band also corresponds to the 
endogenous band observed with the homemade antibodies. To assess if these bands 
were the endogenous proteins or background signal, I performed siRNA depletion 
studies in HeLa cells. The depletion of the individual proteins did show a mild 
reduction in their corresponding antibody signal with the commercial antibody, and this 
signal was significantly decreased in the double knockdown cells (Fig. 3.1 F-G). Our 
homemade antisera did not show a significant decrease in the signal at the expected 
molecular weight, suggesting that this was non-specific background staining. From 
these observations (Fig. 3.1 F-H), I concluded that these antibodies could not be used 
for further studies due to their non-specific nature. Further, in this study, only the 
Abcam antibody that recognises both Ensa and Arpp19 is used for analysis. 
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3.2 Localisation of Ensa and Arpp19 in Mammalian Somatic Cells 
 
Localisation of proteins in the cell cycle usually relates to their cellular function. For 
example, the nuclear import of Cyclin B is indicative of mitotic entry. Similarly, 
Greatwall’s nuclear export preceding nuclear envelope breakdown, is important for its 
mitotic function (Alvarez-Fernández et al. 2013). Likewise, identifying the localisation 
of Arpp19 and Ensa in mammalian cells might lead to better understanding of their 
roles in the cell cycle.  
 
Initially when Arpp19 was discovered, Girault observed it in all vertebrate species at 
various levels in all tissues. The highest concentration of Arpp19 was seen in malignant 
tissues and early embryos (Girault et al. 1990). Similarly, Ensa was identified as 
sulfonylurea receptor ligand in brain tissues. It is implicated in dopamine regulation, as 
endogenous regulators of potassium channels. Ensa was classified as an intrinsic 
unstructured protein due to lack of tertiary structure. It formed distinct secondary 
structures only when bound to lipid membrane. Hence, it was speculated to be present 
near the cytosolic phase of the cell membrane (Virsolvy-Vergine et al. 1992). It was 
also thought that the presence of these proteins in tissues with no or less dividing tissues 
(brain, pancreas) may attribute to its role in cell proliferation (Girault et al. 1990). Thus, 
it is important to study the localisation of these small proteins to understand their 
mitotic role.  
 
It might also be useful to compare the subcellular localisation of Ensa and Arpp19 with 
Greatwall and PP2A-B55 to better understand the interaction between these proteins. 
Although, Greatwall was identified as a nuclear protein in Drosophila larvae, in human 
cells it also localises at the centrosomes in the gap phases (G1 and G2) and S-phase 
(Burgess et al. 2010; Voets & Wolthuis 2010). Additionally, Greatwall is concentrated 
at the centrosomes during mitosis in mammalians cells. At mitotic exit it is observed in 
the cytoplasmic cleavage furrow on the midzone microtubules (Burgess et al. 2010; 
Voets & Wolthuis 2010; J. Yu et al. 2004; H. J. Johnson et al. 2009). On the contrary, 
the phosphatase PP2A-Tws or PP2A-B55 is largely localised in the cytoplasm in 
Drosophila (Mayer-Jaekel et al. 1994) and humans (Santos et al. 2012). B55-alpha, the  
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Figure3.2 Localisation of endogenous Ensa and Arpp19 
A) Probing localisation of endogenous Ensa and Arpp19 in interphase (top panels) 
and mitotic phase (bottom panel) using a commercial antibody and 
immunofluorescence. To control for unspecific signal of the antiserum, we 
compared Ensa/ARPP siRNA transfected and control siRNA transfected cells. After 
48 h post-transfection, the cells were fixed and co-stained with antibodies against α-
tubulin (green) and EnsaArpp19 (red). The nuclei was visualised with DAPI (blue). 
Images were taken on the Olympus IX70 microscope with a 60X, oil –immersion 
lens, N.A 1.42. Scale bar: 10 µM. B) Quantification of the number of cells the show 
localisation in A). 	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regulatory subunit of the phosphatase that interacts with Ensa/Arpp19 in mammalian 
cells, is also majorly cytoplasmic (Alvarez-Fernández et al. 2013).  
 
According to Alvarez-Fernández (2013), Greatwall (Gwl) shuttles from the nucleus to 
the cytoplasm just before mitotic entry. This nucleo-cytoplasmic shuttling of Greatwall 
is followed by Cyclin B import and nuclear envelope breakdown. Alvarez proposes that 
this shuttling occurs to inhibit the premature dephosphorylation of Cdk substrates by 
B55-alpha during mitotic entry. If this is true, Ensa and Arpp19 could either localize in 
the nucleus and be exported similar to Greatwall or be present in the cytoplasm and be 
activated following the nuclear export of Greatwall to inhibit B55-alpha. 
 
Thus, the study of localization of these proteins might shed light on the mechanisms of 
the mitotic entry network. 
 
3.3 Localization of Endogenous Ensa and Arpp19 in Mammalian 
Cells 
 
I began the localisation studies by observing endogenous Ensa and Arpp19 in HeLa 
cells. To control for non-specific signal from the polyclonal antibody we compared cell 
before and after siRNA depletion of Ensa and Arpp19 for 72 h (Fig. 3.2). We used the 
same dharmacon smartpools siRNA against Ensa and Arpp19 that showed a good 
depletion of both the proteins in the western blots shown in Fig. 3-1. The Abcam 
antibody showed a significant decrease in the immuno-fluorescence signal in the 
siRNA-treated interphase cells, confirming that is specific to the phosphoproteins in 
interphase cells. However, in the mitotic cells although the signal reduced some 
background was observed. This suggests that either the knockdown was not complete or 
the antibody shows non-specific signal of mitotically enriched proteins. 
 
The immunofluorescence images shown in Fig. 3.2 A indicate that Ensa and Arpp19 are 
enriched in the nucleus, but are also present in the cytoplasm in interphase cells. The 
cytoplasmic staining does not show a significant overlap with tubulin, but shows a 
distinct granular staining, which could be pointing to a more specific sub-cellular 
localisation, but could also be an artefact due to fixation. Further, 90% of the interphase 
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cells showed a considerable (<5%) reduction in the Ensa/Arpp19 signal (Fig 3.2B). The 
antibody showed an even staining throughout mitotic cells but a clear exclusion from 
mitotic chromosomes. However, this signal was only slightly reduced (25-30%) in 
siRNA treated cells (Fig 3.2B), suggesting that this staining could at least partially be 
non-specific. These initial observations need to be confirmed further by using 
alternative methods to study the subcellular localisation of these proteins. 
3.4 Localisation of Overexpressed Ensa and Arpp19 in Mammalian 
Cells using Live-cell Imaging 
 
Another way to study localisation was expressing Ensa and Arpp19 as tagged fusion 
proteins and following them in live cells using fluorescent proteins, or in fixed cells 
using tag-specific antibodies. I generated Flag and GFP-Ensa expression constructs to 
allow over-expression of the tagged protein in mammalian cells. Before the localisation 
study, I analysed the impact of the tag on the function of the protein by 
immunoprecipitation. Flag-Ensa and GFP-Ensa were transiently expressed in Hek293 
cells and the interaction with B55-alpha was investigated using immune-precipitation. 
Both fusion proteins were well expressed in the whole cell lysates and enriched by 
immunoprecipitation. However, GFP-Ensa did not appear to co-immunoprecipitate with 
B55-alpha, suggesting that the tag renders Ensa inactive, while the shorter Flag-tag still 
appeared to be functional and co-precipitated with B55 (Fig. 3.3A). It is also 
noteworthy that the GFP fusion protein showed a smear of apparent degradation 
products in the Ensa immune-blot, suggesting that this protein may be unstable and has 
problem to achieve a stable confirmation.  
 
This discrepancy could be due to the large size of the GFP tag that makes Ensa 
inaccessible to the phosphatase. This hinders their physical interaction and hence the 
pull-down. Therefore, to allow some flexibility and accessibility to Ensa in the presence 
of GFP tag, I integrated a glycine-alanine-serine linker between the GFP tag and the 
protein. These fusion proteins were also overexpressed in Hek293 cells and enriched 
using GFP-Trap beads (Chapter 2.2.2e). However, as observed in Fig. 3.3 B-C, tagging 
Ensa with the linker-GFP on N- or C-terminal did not pull down B55. This implies that 
the presence of large tags really affects the Ensa-B55 interaction and is therefore its 
primary known function. This was further confirmed when GST-Ensa/Arpp19 fusion 
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proteins also failed to interact with B55-alpha (Discussed in Chapter 6.2 and (Williams 
et al. 2014)). 
 
Having made the effort to generate the GFP fusion proteins we decided to nevertheless 
analyse their localisation in live cells and compare it to an available GFP-B55alpha 
expression construct. We expressed the fusion proteins in HeLa-cdk1as cells (see 
Chapter 2.2.3c and f) stably expressing RFP-H2B. The transfected cells were imaged 
over time, to observe the localisation of these fusion proteins during mitosis and the 
impact of the over expression on mitosis (Fig. 3.3D).  
 
We first imaged GFP-B55-alpha in this experiment. As expected, GFP-B55 was 
enriched in the cytoplasm (Fig. 3.3D top panel). GFP-B55 was distributed evenly 
throughout the mitotic cell upon NEBD and did not appear to be excluded from the 
chromosomes during mitosis. It was exported from the nucleus during its reformation in 
telophase. No striking mitotic phenotypes were observed and GFP-B55 positive cells 
went through mitosis in an average of 60–100 min (Fig. 3.3E). 
 
In case of both N and C-terminal GFP-tagged Ensa, the protein did not significantly 
change its localisation during the G2/M transition, but was excluded from metaphase 
mitotic chromosomes, similar to the endogenous proteins. In addition, these proteins 
were enriched in the midzone region during mitotic exit, similar to Greatwall 
localisation (Burgess et al. 2010; Voets & Wolthuis 2010). 
 
Surprisingly, GFP-linker versions of Ensa delayed the exit from mitosis significantly. 
The cells displayed prolonged metaphase and hence, a delayed mitosis (Fig. 3.3D 
bottom panel and 3.3E). In addition, the N-terminal tagging of Ensa seems to have 
stronger mitotic phenotype in comparison to the C-terminal fusion protein, suggesting 
that this protein could exert a specific dominant negative function. However, neither C, 
nor N-terminal fused Ensa can interact with B55. This makes it unlikely that the 
dominant negative effect is exerted via the known function of Ensa as a PP2A-B55 
inhibitor. A possible explanation for the mitotic delay might be a novel uncharacterised 
function of the protein. These functions may require the N-terminal of the protein and 
be  
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Figure 3.3 GFP-Tagging for Ensa and Arpp19 for localisation studies 
 
Hek293 cells were transfected with the indicated vectors A) Flag Ensa (positive control), 
GFP (negative control), GFP Ensa, B) Flag GFP, Flag Ensa (positive control), GFP-Linker-
Ensa and C) Flag GFP (negative control), Flag Ensa (positive control) and Ensa-Linker-
GFP. Forty-eight hours post-transfection, the cells were lysed and subjected to co-IP using 
either anti-Flag M2 resin or GFP-Trap®_M beads. The elutions after the IP were analysed 
by western blotting for interaction with PP2A-B55-alpha. 	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Figure 3.3 GFP-Tagging for Ensa and Arpp19 for localisation studies 
 
D) Time lapse imaging of the GFP-fusion proteins using confocal microscopy to study 
localization. HeLa cells expressing H2B-mCherry (red) were transfected with GFP-fusion 
proteins were imaged overnight using the 3i-Confocal microscope with a 40X lens, N.A 
0.60. Time from the onset to exit of mitosis was recorded and plotted using 
http://boxplot.tyerslab.com. Centre lines show the medians; box limits indicate the 25th 
and 75th percentiles as determined by R software; whiskers extend 1.5 times the 
interquartile range from the 25th and 75th percentiles, outliers are represented by dots. 
Scale bar: 10 µM 	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independent of their interaction with B55-alpha. These phenotypes will need to be 
investigated in detail to understand the mitotic roles of Ensa and Arpp19. 
 
3.5 Localisation of Overexpressed Ensa and Arpp19 in Fixed Cells  
 
Although the GFP-fusion proteins localise similar to the endogenous proteins, their 
inability to interact with B55 make these observations doubtful. Therefore, I examined 
the localisation of Ensa and Arpp19 in fixed cells using smaller Flag-tags to detect them 
with well-characterised and specific antisera raised against the tags. As discussed above 
(Fig. 3.3A-C), Flag tagged Ensa and Arpp19 interact with B55-alpha successfully and 
should therefore be functional as PP2A-B55 inhibitors. 
 
Thus, Flag-Ensa and Flag-Arpp19 were overexpressed transiently in HeLa Kyoto cells. 
A truncated version of Greatwall protein (E2), generated in the lab for other studies 
(Ocasio et al. 2016) was used as a positive control and a non-transfected negative 
controlled was used to exclude background due to Flag tag localisation and non-specific 
staining. Flag E2 like full-length Greatwall localised strongly in the nucleus. Flag Ensa 
and Arpp19 were distributed evenly in the interphase cells (Fig. 3.4 A-B), similar to the 
endogenous staining and GFP-Ensa. I next co-expressed GFP-B55 and Flag-
Ensa/Arpp19 exogenously to visualise the co-localisation of the phosphatase and the 
inhibitor. The transfected cells were fixed and stained 48-h post-transfection. Again, 
Flag Ensa and Arpp19 appeared to be localised both in the cytoplasmic and in the 
nucleus, while B55 appeared to be more concentrated in the cytoplasm and excluded 
from the nucleus (Fig. 3.5 top panel and 3.5 B). On co-expressing both the proteins, we 
observed an overlap in the cytoplasm in interphase cells. In mitotic cells, Flag Ensa and 
Arpp19 appeared to be excluded from the chromosomes co-localising with GFP-B55 
alpha (Fig. 3.5 bottom panel and 3.5 B). An interesting difference became apparent in 
this experiment, because Flag-Arpp19 appeared to be specifically enriched in the outer 
cell periphery, revealing an area that does not co-localise with B55 (compare the yellow 
and red staining in the merged bottom panel in Fig. 3.5A and 3.5 B.  
 
In conclusion, Ensa and Arpp19 are localised both in the cytoplasm and in nucleus 
during interphase and are evenly distributed throughout mitotic cells, but remain 
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excluded from chromosomes during mitosis. The enrichment of Arpp19 at the cell 
periphery could be interesting, especially in the light of the phenotypes described later 
in this thesis. However, we only observed this distinct localisation pattern after 
overexpression, so these data could be artefactual and need to be further confirmed by 
following the endogenous protein  
 
Lastly, the preliminary characterisation in this chapter confirmed that the antibodies 
generated could not be used to study the individual functions of Ensa and Arpp19, as 
they were non-specific on the cellular level. Thus, further in this study both the protein 
have been characterised together, using the commercial antibody recognising both the 
homologues. Alternative approaches with smaller tags have to be used to study the 
localisation of the protein in-vivo, as the fluorescent tags seem to deter some key 
functions of the proteins. From my observations so far, Ensa and Arpp19 appear to be 
present ubiquitously in cells but seem to be excluded from the chromosomes during 
mitosis. The peripheral localisation of Arpp19 needs to be investigated more carefully 
to draw detailed conclusions. 
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Figure 3.4 Overexpression of Flag-Ensa, Flag-Arpp19 and GFP-B55 
 
A) HeLa Kyoto cells were transiently transfected with Flag-Ensa, Flag-Arpp19 and Flag-E2 
(truncated Gwl protein). Cells were fixed and immuno-stained 48 h post-transfection. DNA 
was stained with DAPI (blue). Flag tagged proteins were visualised with anti-Flag antibody 
and a TRITC-labelled secondary antibody. Endogenous tubulin was visualised using an anti-
Tubulin antibody and FITC-labelled secondary antibody. B) HeLa-cdk1as cells stably 
expressing RFP-H2B were transiently transfected with GFP-B55alpha plasmid. Twenty-four 
hours post-transfection images were taken on the Olympus IX73 microscope with a 60X, oil 
-immersion lens, N.A 1.42. Scale bar: 10 µM. 	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Figure 3.4 Overexpression of Flag-Ensa, Flag-Arpp19 and GFP-B55 
 
B) Quantification of number of cells showing nuclear and cytoplasmic localisation in A).  	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Figure 3.5 Co-Expression of B55 and Ensa/Arpp19 to study co-localisation 
 
A) Flag-tagged Ensa and Arpp19 and GFP-B55 were co-expressed exogenously in HeLa 
cells and immuno-stained 48 h post-transfection. GFP-B55 appears to be cytoplasmic and 
was visualised using anti-GFP antibody and FITC-conjugated anti-rabbit secondary 
antibody (green). Both Ensa and Arpp19 were observed mostly in the cytoplasm. Ensa and 
Arpp19 were visualised using anti-Flag antibody and TRITC-conjugated anti-mouse 
antibody (red). Nucleus was stained with DAPI (blue). Images were taken on the Olympus 
IX73 microscope with a 60X, oil-immersion lens, N.A 1.42. Scale bar: 10 µM 	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Figure 3.5 Co-Expression of B55 and Ensa/Arpp19 to study co-localisation 
 
B) Quantification of cells showing different subcellular localisation post-transfection as 
done in A).  	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CHAPTER4 CHARACTERISATION OF MITOTIC 
PHENOTYPES OF ENSA/ARPP19 IN MAMMALIAN 
MITOSIS 
 
In order to understand the mitotic role of Ensa and Arpp19, I decided to observe the 
effect on mitosis when these proteins are depleted. During the initial studies about the 
role of Ensa and Arpp19, they were described as substrates of Greatwall that act as 
phosphorylation dependent inhibitors of PP2A-B55 δ in Xenopus laevis egg extracts 
(Gharbi-Ayachi et al. 2010; Mochida et al. 2010). They were also implicated in mitotic 
progression in Drosophila (Glover 2012; Lorca & Castro 2013). Given that Greatwall 
phosphorylation is thought to be essential for Ensa and Arpp19 activity, it is not 
surprising that the reported phenotypes are very similar to the ones observed after 
Greatwall depletion in these organisms. While Greatwall depletion prevents mitotic 
entry in X. laevis extracts (J. Yu et al. 2006; Zhao et al. 2008) and human cells (Burgess 
et al. 2010; Voets & Wolthuis 2010), Greatwall is also implicated in promoting entry in 
Drosophila (Bettencourt-Dias et al. 2004; J. Yu et al. 2004). Likewise, Gharbi-Ayachi 
showed that RNAi-mediated Arpp19 depletion affects the mitotic index in HeLa cells. 
However, the cytological phenotypes of Ensa and Arpp19 in mammalian mitosis are not 
characterised in detail.  
 
Similarly, the mitotic exit phenotypes of Greatwall are well characterized in Drosophila 
and human cells. In Drosophila, Greatwall depletion leads to delay in progression to 
anaphase. Also, the characteristic phenotype observed is elongated sister chromatids 
scattered on the mitotic spindle in neuroblasts (J. Yu et al. 2004; Bettencourt-Dias et al. 
2004). Chromosome segregation failure was observed in Greatwall/Scant mutants in 
Drosophila (J. Yu et al. 2004; V. Archambault et al. 2007) and on Greatwall depletion 
in human cells. In human cells cytokinesis failure was also a prominent phenotype 
(Burgess et al. 2010; Voets & Wolthuis 2010; Cundell et al. 2013). Still, the Ensa and 
Arpp19 depletion phenotypes have not been identified or studied in mammalian cells. 
 
Several important questions remain to be answered about the function of these two 
proteins. Firstly, characterising Ensa/Arpp19 depletion phenotypes should provide proof 
of principle that these proteins act in the same pathway as Greatwall kinase. Secondly, 
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the relative importance of each paralogue needs to be firmly established. Do these 
highly related proteins have specific functions, or are they entirely redundant? Finally, 
one cannot rule out that these two small proteins have additional Greatwall independent 
functions that remain to be explored. The impact of Ensa and Arpp19 on different 
phases of mitosis can be investigated in detail using time-lapse imaging. This enables 
meticulous classification of the cytological effect Ensa/Arpp19 depletion on mitotic 
entry and exit.  
 
Thus, in this chapter I have characterised the mitotic phenotypes of Ensa/Arpp19 in 
comparison with Greatwall depletion and further explored the mitotic entry role of 
Greatwall and Ensa/Arpp19. 
 
4.1 Depletion Phenotypes of Greatwall and Ensa/Arpp19 in 
Mammalian Cells 
 
Greatwall localisation and mitotic phenotypes have been extensively studied and 
documented. In 2010, Burgess published a detailed characterisation of the Greatwall 
mitotic phenotypes in HeLa cells. Cells were synchronised using thymidine and the 
entry into mitosis and phenotypes in mitosis were documented. Complete Greatwall 
depletion showed an increase in 4n population in FACS and multinucleate cells in 
immunofluorescence. This could be due to improper cytokinesis in these cells (Burgess 
et al. 2010). Similarly, Voets and Wolthuis observed a slower increase in mitotic index 
in 2010, following Greatwall depletion, when thymidine blocked cells were released 
into Nocodazole. Studies in mouse mammalian cells revealed that Greatwall does not 
prevent mitotic entry(Alvarez-Fernández et al. 2013). Taken together these results 
suggest that Greatwall delays mitotic entry in mammalian cells but do not prevent it. 
 
The major phenotypes documented in (Burgess et al. 2010) were non-congressed 
metaphase plate, scattered chromosomes along the spindle, prolonged metaphase or 
metaphase arrest, segregation defects and lagging chromosomes in cells that proceed to 
anaphase. A subpopulation of cells showed DNA bridges and mitotic death in 
metaphase-arrested cells. The metaphase delayed/arrested cells also showed a longer 
transit time in mitosis. Similarly, Voets and Wolthuis observed majority of the cells 
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showing DNA bridges indicative of cytokinesis failure and chromosome segregation 
defects. (Burgess et al. 2010; Voets & Wolthuis 2010). Moreover, prolonged 
prometaphase/metaphase arrest and segregation problems were the major defects 
reported in mouse mammalian cells (Alvarez-Fernández et al. 2013). All these defects 
indicate a prominent role of Greatwall in mitotic progression and exit.  
 
According to the current models, Greatwall functions in mitosis via Ensa/Arpp19 by 
inhibiting PP2A/B55 phosphatase to allow elevated levels of Cdk1 substrate 
phosphorylation in mitosis. In 2010, Burgess et al quantified cells entering mitosis on 
Greatwall-depletion by measuring the percent of Cdk substrate phosphorylation by 2D-
FACS. He observed 22% signal of Cdk substrates following complete depletion of 
Greatwall and a delayed mitotic entry (using time-lapse imaging after release from 
thymidine block). This data shows mammalian cells exhibit delayed mitotic entry with 
~22% Cdk phosphorylated substrates. Following that Arpp19 depletion showed a 50% 
reduction in the mitotic index, in cells released from a thymidine block into nocodazole 
(Gharbi-Ayachi et al. 2010). However, most of these experiments were done using a 
single time point measurement that cannot distinguish between delay in entry or 
problems with maintaining mitotic arrest.  
 
In this work, I wanted to explore the mitotic functions of Ensa/Arpp19 together and to 
compare them to the Greatwall phenotypes. For this, I began by studying the Greatwall 
phenotypes in the HeLa cells stably expressing RFP-H2B and GFP-Tubulin to confirm 
the published phenotypes and have set of data using our cell lines and experimental 
procedures for accurate comparison. This cell line was used as chromosome and tubulin 
dynamics are ideal visual markers of mitosis in mammalian cells. In these experiments, 
I used asynchronous cells to study the mitotic effects of Greatwall and to set an internal 
reference to analyse Ensa/Arpp19 phenotypes. 
 
Greatwall knockdown was induced using Qiagen siRNA oligos for 48 h. The 
knockdown was analysed using western blot. The levels of Greatwall decrease 
significantly to as low as ~10% after 48 h treatment with 40 nM dose of the siRNA 
(Fig. 4.1A-B). I used the 4-well and 8-well microscopic plates for these experiments; 
hence, these plates were also used for quantifying the extent of depletion. After 
transfection, I performed time-lapse imaging on these cells for 16 h on a spinning disc 
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confocal microscope to observe mitotic cells in physiological conditions. As seen in 
Fig. 4.1C, the reduction in the mitotic population is ~10%.  
 
When analysing the time-lapse movies, I observed only a slight decrease in mitotic 
entry in the Greatwall depleted cells, but found a number of mitotic defects reminiscent 
of the published phenotypes mentioned above. Firstly, about 50% of the cells showed 
delayed progression through prometaphase and metaphase and often fail to form a 
compact metaphase plate arrangement of the chromosomes (Fig. 4D-F). Nevertheless, 
most of these cells initiate anaphase within 100 min from NEBD albeit often with 
lagging chromosomes (Fig. 4E). About 15% of cells going through mitosis displayed a 
clear cytokinesis defect resulting in a single binucleate daughter cell, a hallmark 
Greatwall phenotype that was previously characterized (Cundell et al. 2013). In 
addition, around 10% of the cells with cytokinesis defect, showed chromosome 
segregation defects, where the cell divided into 3 daughters of which 2 fused to form a 
single binucleate cell (not quantified separately). A representation of the imaged cells is 
shown in Fig. 4.1F. The top panel for Greatwall knockdown shows a cell with 
prolonged metaphase arrest and the bottom panel shows a cell with cytokinesis defect.  
 
The phenotypes I observed are in support of the previous studies where the 
prometaphase/metaphase delay and cytokinesis defects were documented. It is currently 
unclear why Greatwall depletion in mammalian cells does not cause a more significant 
delay in G2, as would be expected from the X. laevis results. One possibility could be 
that this kinase is highly processive, so that only a complete depletion results in a 
significant loss of Ensa/Arpp19 phosphorylation. The phenotypes we observe could 
thus be simple hypomorphic due to partial activity of PP2A/B55 in mitosis. 
 
Now that the Greatwall phenotypes were reconfirmed, I went ahead and transfected 
HeLa cells with 50 nM (25 nM Ensa and 25 nM Arpp19) Ensa/Arpp19 siRNA 
smartpools. Smartpools are a mixture of four siRNA oligos that have been carefully 
selected and pre-optimized to minimize off-target effects. Ensa/Arpp19 were depleted 
significantly in 72 h and the protein level decreased to ~10–15% (Fig. 4.2A-B). I also 
depleted individual proteins using the smartpools, but the precise extent of knockdown 
could not be measured, as specific antibodies are unavailable (Fig. 4.2C and Chapter 
3.1). However, since the double knockdown has a significant effect on total  
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Figure 4.1 siRNA mediated depletion of Greatwall 
 
A) Western blot analyses of Control (si_ctrl) and Greatwall (si_Gwl) siRNA transfected 
HeLa cells. The depletion experiments were done in 4-well and 8-well microscopic dishes. 
Actin is used as the loading control. B) Western blot quantification using ImageJ to show 
depletion of Greatwall protein. C) Mitotic indices were calculated for asynchronous HeLa 
cells transfected with control and Gwl siRNA and stably expressing RFP-H2B and GFP-
tubulin. D) The percentage of HeLa cells exhibiting mitotic defects (prolonged 
metaphase/cytokinesis defects) were scored over total mitotic cells and plotted graphically. 
E) A box-and- whisker-plot showing the duration from NEB to cytokinesis with control and 
Gwl knockdown in HeLa cells stably expressing RFP-H2B and GFP-Tubulin. Centre lines 
show the medians; box limits indicate the 25th and 75th percentiles as determined by R 
software; whiskers extend 1.5 times the interquartile range from the 25th and 75th 
percentiles, outliers are represented by circles. n = 94, 57 sample points. Analysis between 
samples was performed by the Mann-Whitney Rank Sum test, and p-values are presented 
above the box-plots. 	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Figure 4.1 siRNA mediated depletion of Greatwall 
 
F) Confocal time-lapse imaging of a HeLa cells stably expressing RFP-H2B and GFP-
tubulin with control and Gwl knockdown. The Gwl siRNA kymographs represent both the 
defects (prolonged metaphase and cytokinesis defect) in mitotic cells. Time is in minutes; 
maximum intensity projection of seven-z dimension slices. Images were taken using the 
40X lens, N.A 0.60. Scale bars, 10  µM. 	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Ensa/Arpp19 levels one can deduce that the smartpools are effective against the 
individual proteins. After these preliminary experiments, I could now use the 
smartpools to knockdown Ensa and Arpp19, both individually and together to analyse 
the mitotic profile of the cells. Similar to Greatwall knockdown experiments, I imaged 
the cells transfected with Ensa and Arpp19 for 16 h using time-lapse imaging on a 
spinning disc confocal microscope. When these cells were scored for mitotic index, the 
double knockdown showed a ~10% decrease in mitotic population, similar to Greatwall. 
Ensa seems to affect mitotic entry more than Arpp19 (Fig. 4.2C). Similar to Greatwall, 
Ensa/Arpp19 knockdown does not arrest the cells in G2 but the cells entering mitosis 
exhibit a variety of mitotic defects (Fig. 4.2D). Majority of the cells were arrested in 
metaphase for longer periods (mitotic time >100 min) with chromosomes moving 
towards and from the metaphase plat suggestive of alignment/attachment problems. 
Interestingly, we did not observe an increase in cytokinesis defects as compared to the 
Greatwall depleted cells, even in the case of double Ensa/Arpp19 depletion. Thus, the 
major phenotype of Ensa/Arpp19 knockdown is metaphase arrest and sister chromatid 
alignment defect, although the cells do eventually exit mitosis with lagging 
chromosomes. In addition, it is seen that the mitotic defects increase two-fold after 
double knockdown as compared to the individual proteins. Thus, the Ensa and Arpp19 
have an additive effect with significantly more pronounced metaphase delays in the 
double knockdown cells.  
 
There are two interesting points to be made from the comparison of Ensa/Arpp19 and 
Greatwall depletion phenotypes. First, the argument that partial Greatwall depletion is 
not sufficient for a G2 arrest cannot be maintained for Ensa/Arpp19 since they are 
thought to be tightly binding stoichiometric inhibitors of PP2A/B55. This strongly 
suggests that unlike X. laevis eggs and oocytes, mammalian cells can enter mitosis in 
the presence of active PP2A/B55.  
 
The mitotic defects of Greatwall- and Ensa/Arpp19-depleted cells are almost identical 
and are very likely due to decreased Cdk1 substrate phosphorylation because of 
persistent PP2A/B55 activation. However, the hallmark phenotype of Greatwall 
depletion, namely the cytokinesis defect that led Cundell et al. to propose a novel BEG 
pathway during mitotic exit, seems to be specific to the Greatwall siRNA, and does not  
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Figure 4.2 siRNA mediated depletion of Ensa and Arpp19 
 
A) Western blot analyses of Control (si_ctrl), Ensa and Arpp19 (si_EnsaArpp19) siRNA-
transfected HeLa cells. The depletion experiments were performed in 4-well and 8-well 
microscopic dishes. The lower panel shows actin as the loading control. B) Western blot 
quantification using ImageJ to show depletion of Ensa and Arpp19 protein levels. C) Mitotic 
indices were calculated for asynchronous HeLa cells transfected with control and 
EnsaArpp19 siRNA and stably expressing RFP-H2B and GFP-tubulin. D) The percentage of 
HeLa cells exhibiting mitotic defects (prolonged metaphase/cytokinesis defects) were scored 
over total mitotic cells and plotted graphically. E) A box-and-whisker plot showing the 
duration from NEB to cytokinesis with control and EnsaArpp19 knockdown in HeLa cells 
stably expressing RFP-H2B and GFP-Tubulin. Centre lines show the medians; box limits 
indicate the 25th and 75th percentiles as determined by R software; whiskers extend 1.5 
times the interquartile range from the 25th and 75th percentiles, and outliers are represented 
by dots. n = 153, 85, 169, and 125 sample points. Analysis between samples was performed 
using the Mann-Whitney Rank Sum test, and p-values are presented above the box-plots. 	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Figure 4.2 siRNA-mediated depletion of Ensa and Arpp19 
 
F) Confocal time-lapse imaging of HeLa cells stably expressing RFP-H2B and GFP-tubulin 
with control and EnsaArpp19 knockdown. Time is in minutes; maximum intensity projection 
of seven-z dimension slices. Images were taken using the 40X lens, N.A 0.60. Scale bars, 10 
µM. 
 
	   118	  
occur in Ensa/Arpp19-depleted cells. This could suggest a specific function for 
Greatwall or an off target effect of these siRNAs. 
 
4.2 Detailed Analysis of Mitotic Entry Roles of Greatwall and 
Ensa/Arpp19 on Cdk1 Inhibition 
 
 
Historically, Cyclin B-Cdk1 is known to be the master controller of entry into mitosis. It 
was shown mathematically in X. laevis extracts that once the Cdk1-cyclin B complex 
reaches its activation threshold, a cell could enter into mitosis. They further showed that 
the G2/M switch is bistable with low Cdk1 in interphase and high Cdk1 activity in 
mitosis. The bistable switch causes a shift between 2 stable states, interphase and 
mitosis in case of G2/M transition, with no intermediate state. This was later proven 
experimentally in X. laevis egg extracts (Pomerening et al. 2003; Sha et al. 2003). 
Recent work in mammalian cells has shown that this cycle of Cdk1 
activation/inactivation is conserved evolutionarily in the mammalian system (Yuan et 
al. 2002; Lindqvist et al. 2007; Pomerening, Ubersax & Ferrell 2008b). All these studies 
were based on the Cdk1-CyclinB1 activation levels and the resulting entry into mitosis. 
Initially it was thought that the phosphatases remain stable throughout the cell cycle. 
However, in the past few years it has been shown that even the phosphatase activity 
oscillates counterbalancing the Cdk1 activity. (Mochida et al. 2009; Castilho et al. 2009; 
Vigneron et al. 2009).  
 
In this work, I wanted to clarify if Greatwall and Ensa/Arpp19 affect the Cdk1 threshold 
for mitotic entry in a similar manner, which could help elucidate the specific mitotic 
entry functions of Greatwall that may or may not be independent of Ensa/Arpp19. 
 
Greatwall is activated by Cdk1 and initiates the BEG pathway to inhibit PP2A via Ensa 
and Arpp19. Hence, when Greatwall is depleted, it is expected that the cells would 
arrest in G2. Although this is true for X. laevis and Drosophila, only a delay in mitotic 
entry is seen in human cells (J. Yu et al. 2006; Zhao et al. 2008; Burgess et al. 2010; 
Voets & Wolthuis 2015). These phenotypes could be rescued even by Cdk1 depletion, 
hence proving that Greatwall participates in the auto-regulatory loop of Cdk1 (J. Yu et 
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al. 2006; Zhao et al. 2008). Active Greatwall and consequent PP2A inhibition is 
required both to promote the Cdk1-Cyclin B activation loop and to prevent mitotic 
substrates dephosphorylation. Greatwall achieves this by phosphorylating Ensa and 
Arpp19, which are potent inhibitors of PP2A. However, in addition to that Cdk1 also 
directly phosphorylates Arpp19 in starfish oocytes, promoting mitotic entry in the 
absence of Greatwall (Okumura et al. 2014).Hence, Ensa/Arpp19 promotes mitotic 
entry independent of Greatwall, once they’re phosphorylated by Cdk1.  
 
In the initial experiments with asynchronous cells, both Greatwall and Ensa/Arpp19 
depletion did not affect mitotic entry significantly. This could be because the Cdk1 
activation threshold could overcome the activity of partially active phosphatases. As an 
all or none response was observed on inhibiting of Greatwall in lower organisms, it was 
intriguing to analyse the mitotic entry in a bit more detail when Cdk1 was inhibited in 
Greatwall depleted cells. Subsequently, I could study if these effects on mitotic entry 
were similar or different to the ones seen on Ensa/Arpp19 depletion. For this purpose, I 
used HeLa cells stably expressing the X. laevis analogue sensitive Cdk1 mutant and 
RFP-H2B. Hereafter, in this work, these cells are mentioned as HeLa-Cdk1as cells. 
These cells can be synchronized in G2 when treated with ATP analogue, 1NMPP1 for at 
least 16 h. The X. laevis Cdk1as construct has been tested for varying concentrations of 
1NMPP1 in in-vitro kinase assays and DT40 cell lines; 10 µM 1NMPP1 was used in 
DT40 to synchronise them in G2 (Hochegger et al. 2007). However, when a HeLa cell 
line stably expressing X. laevis Cdk1as was generated, 1 µM 1NMPP1 was sufficient to 
synchronise the cells in G2 (data not shown). 
 
One micromole of 1NMPP1 was used to synchronize the cells in G2, following 
Greatwall and Ensa/Arpp19 knockdown respectively. 1NMPP1 is a reversible drug and 
can be removed by washing the cells with warm media a few times. In my assay, I 
washed the arrested cells five times with warm media to maintain consistency. In order 
to maintain different concentrations of Cdk1, I added different concentrations of 
1NMPP1 and imaged the cells using time-lapse imaging. This assay was to study 
mitotic entry only, hence MG132 (APC/C inhibitor) was used to prevent mitotic exit. 
After 4 h of imaging, 70–75% of control cells were in mitosis and the count did not 
increase further. Hence, the Greatwall and Ensa/Arpp19 knockdown cells were also 
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quantified after 4 h of imaging. Cells with intact nuclear envelope were scored as G2 
and cells without it were scored as mitotic cells.  
 
Surprisingly, Greatwall and Ensa/Arpp19 cells were arrested in G2 at different Cdk1 
concentrations (Fig. 4.3-4.4). While Greatwall-depleted cells could be arrested with 
0.25 µM 1NMPP1 (Fig. 4.3A-B), Ensa/Arpp19-depleted cells required 0.5 µM 
1NMPP1 to be arrested in G2 (Fig. 4.3C-D). This means that Greatwall-depleted cells 
remain in G2 even with high Cdk1 activity as compared to Ensa/Arpp19. Thus, this 
indirectly shows Ensa/Arpp19 and Greatwall perform different functions at mitotic 
entry. In addition, somatic cells can enter mitosis with suboptimal Cdk1 activity even 
when PP2A is active. This, has been indirectly shown when mitotic cells were 
quantified using phospho-Ser antibody in Greatwall-depleted cells (Burgess et al. 2010). 
The Cdk1 threshold decreases in the absence of Ensa/Arpp19, despite the fact that 
PP2A would be active (Fig. 4.3C-D). Ensa/Arpp19 are a stoichiometric inhibitor of 
PP2A and are present in almost equal molar concentration as compared to the 
phosphatase (M. Wang et al. 2015). On siRNA depletion, this concentration is reduced, 
decreasing the number of molecules available to interact with and thus inhibit PP2A. 
However, as Greatwall is active, it can phosphorylate and activate the residual 
Ensa/Arpp19 with higher processivity and inhibit PP2A partially. Moreover, similar to 
X. laevis cells presence of PP2A may inactivate Cdk1, owing to Wee1-dependent 
phosphorylation of Cdk1 (Mochida et al. 2009). Thus, active Greatwall may be 
potentially promoting M-phase entry on Ensa/Arpp19 depletion. Additionally, I 
observed peculiar surface blebbing specific to Ensa/Arpp19 depletion, when G2 arrested 
cell were released from the 1NMPP1 block (Fig. 4.3D). This could be owing to the 
presence of Arpp19 as potassium channels on the cell surface. However, how it relates 
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Figure 4.3 Mitotic entry on Greatwall and EnsaArpp19 depletion 
 
A) Quantification of cells that entered mitosis with varying concentrations of 1NMPP1 (0–1 
µM) on Gwl depletion. HeLa-cdk1as cells stably expressing RFP-H2B were released from 
16 h G2 arrest following control and Gwl knockdowns. Cells were treated with MG132 (25 
µM) to prevent mitotic exit and were quantified 4 h post-G2 release. B) Images of mitotic 
cells 4 h post-G2 release into varying concentrations of 1NMPP1, following control and 
Gwl knockdowns. Images were taken on the IX71_Olympus microscope using the 40X lens, 
N.A 0.60. Scale bars, 10 µM. 	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Figure 4.3 Mitotic entry on Greatwall and EnsaArpp19 depletion 
 
C) Quantification of cells that entered mitosis with varying concentrations of 1NMPP1 (0–1 
µM) on EnsaArpp19 depletion. HeLa-cdk1as cells stably expressing RFP-H2B were 
released from 16 h G2 arrest following control and EnsaArpp19 knockdowns. Cells were 
treated with MG132 (25 µM) to prevent mitotic exit and were quantified 4 h post-G2 
release. D) Images of mitotic cells 4 h post-G2 release into varying concentrations of 
1NMPP1, following control and EnsaArpp19 knockdowns. Images were taken on the 
IX71_Olympus microscope using the 40X lens, N.A 0.60. Scale bars, 10 µM. 	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Figure 4.4 Mitotic entry on Greatwall depletion 
 
A) Quantification of cells that entered mitosis with varying concentrations of 1NMPP1 (0-
0.25 µM) on Greatwall depletion. HeLa-cdk1as cells stably expressing RFP-H2B were 
released from 16 h G2 arrest following control and Greatwall knockdowns. Cells were 
treated with MG132 (25 µM) to prevent mitotic exit and were quantified 4 h post-G2 
release. B) Images of mitotic cells 4 h post-G2 release into varying concentrations of 
1NMPP1, following control and Greatwall knockdowns. Images were taken on the 
IX71_Olympus microscope using the 40X lens, N.A 0.60. Scale bars, 10 µM. 	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It has been shown previously that Greatwall-depleted cells induce mitotic exit even with 
high Cdk1 activity (Vigneron et al. 2009). Here we see that Greatwall arrests cells in G2 
even with Cdk1 activity comparable to 0.25 µM 1NMPP1 (Fig. 4.3A-B). This leads us 
to make a few hypotheses. Firstly, in the absence of Greatwall, the BEG pathway is not 
activated and hence PP2A is highly active. Thus, PP2A could act either on the Cdk-
Cyclin B auto-regulatory loop or on mitotic substrates. Similar to X. laevis, PP2A could 
inactivate Cdk1 and prevent mitotic entry. Additionally, as Greatwall is absent, the 
higher amount of Cdk1 is required to overcome the substrate dephosphorylation by 
PP2A that was earlier inhibited. As mitotic entry phenotypes are not observed on B55 
depletion, it would be interesting to check if in HeLa-Cdk1as cells B55 knockdown 
rescues the Greatwall and Ensa/Arpp19 entry phenotype.  
 
To investigate the exact amount of 1NMPP1 inhibition that the Greatwall cells can 
tolerate, I analysed their mitotic entry with a smaller range of 1NMPP1 concentrations 
(Fig. 4.4A-B). Although, ~5% cells enter mitosis with 0.25 µM 1NMPP1, its 10 times 
less than the control cells. These cells could be the un-transfected population, which 
was observed across three independent experiments. With lower concentrations of 
1NMPP1, cells entered mitosis. Thus, Cdk1 activity any higher than that seen in Fig. 
4.3A-B is able to overcome the phosphatase activity and induce mitotic entry. 
 
Finally, in this chapter, I characterised the major phenotypes of Ensa/Arpp19 in somatic 
cells using RNAi-mediated knockdown. However, as these cells were only imaged 
using fluorescence and no surface markers were present, the characteristic blebbing 
phenotype could not be identified. Majority of the Ensa/Arpp19 cells arrest in 
metaphase for longer duration but exit mitosis eventually with lagging chromosomes. 
Defects like chromosome accumulation at the poles and lagging chromosome are seen, 
indicative of premature mitotic exit. I also confirmed that Greatwall depletion prevents 
mitotic entry with higher Cdk activity as compared to Ensa/Arpp19. The most probable 
reason for this observation could be a highly processive Greatwall kinase that activates 
even low amounts of Ensa/Arpp19 to partially inactivate PP2A. This is not possible 
when Greatwall is inhibited and leads to higher activation threshold. However, further 
experiments quantifying the cellular processivity of Greatwall are required to confirm 
this observation. 
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 It can also be speculated that an unknown phosphatase downstream of Greatwall and 
independent of Ensa/Arpp19 is opposing the Cdk1 activity at mitotic entry. This could 
lead to higher Cdk1 thresholds in the absence of Greatwall, as both PP2A and the 
unknown phosphatase are highly active against the mitotic substrates. However, this 
possibility needs to be investigated in detail to understand the role of Greatwall and 
Ensa/Arpp19 in mitotic entry better. 
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CHAPTER5 ANALYSIS OF ENSA/ARPP19 
DEPHOSPHORYLATION IN MAMMALIAN CELLS. 
 
Entry into mitosis is preceded by substrate phosphorylation on multiple mitotic proteins 
(Dephoure et al. 2008; McCloy et al. 2014). The active complex Cdk1-Cyclin B carries 
out majority of these phosphorylations. Although there is no strict Cdk consensus 
recognition element, preferred residues are on a proline–directed serine threonine sites, 
which means serine and threonine is followed by a proline (Nick R Brown et al. 1999). 
Mitotic entry also relies on the inactivation of phosphatases, to prevent the premature 
dephosphorylation of these mitotic proteins and futile phosphorylation and 
dephosphorylation cycles. This is reversed in mitotic exit where Cdk1 is inactivated and 
the counteracting phosphatases become active (Barr et al. 2011; Bollen et al. 2009). It is 
experimentally shown in Xenopus, that the activity of phosphatases fluctuates in the cell 
cycle being high in interphase and low in mitosis, contrary to the Cdk-Cyclin 
oscillations (Mochida & Hunt 2007; Virshup & Shenolikar 2009). 
 
It was discovered in Xenopus that Cdk dynamics were controlled by a phosphatase of 
the type 2A that was named INH (Cyert & Kirschner 1988; Solomon et al. 1990). Later 
in 2009, Mochida et al. identified PP2A-B55δ as the major Cdk-counteracting 
phosphatase in Xenopus (Mochida et al. 2009). Similarly in mammalian cells, inhibition 
of an okadaic acid sensitive phosphatase initiated mitotic entry even when Cdk1 is 
inhibited (Gowdy et al. 1998). In recent years an unusual AGC kinase, Greatwall was 
found to control this phosphatase. Greatwall works on PP2A via its substrates Ensa and 
Arpp19, which are small proteins and potent inhibitors of the phosphatase (Zhao et al. 
2008; Castilho et al. 2009; Vigneron et al. 2009; Mochida et al. 2009; Mochida et al. 
2010; Gharbi-Ayachi et al. 2010). Greatwall kinase is phosphorylated and activated by 
Cdk1, which further leads to inactivation of phosphatase PP2A-B55, to prevent 
premature dephosphorylation of mitotic substrates at G2/M transition. Thus, Cdk1 
inhibits its counter-acting phosphatase via the Greatwall-Ensa/Arpp19/B55 pathway 
(Blake-Hodek et al. 2012; Vigneron et al. 2011). Cdk1 also phosphorylates Arpp19 
directly in starfish oocytes, thus inhibiting the phosphatase in a Greatwall independent 
manner. However, this does not have a significant impact on Xenopus Ensa (Okumura 
et al. 2014; Mochida 2014). 
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PP2A is a hetero-trimeric complex. It consists of the catalytic subunit CA or CB, the 
scaffolding subunit A and the regulatory subunit B, which is variable. The different 
regulatory subunits are responsible for substrate specificity of the phosphatase. The 
different regulatory subunits are B55 (B), B56 (B’), B’’, B’’’. PP2A-B55 has been 
suggested to be the major Cdk1 countering phosphatase, based on the observation that 
the B55 δ depleted cycling extracts advance into mitosis faster, whereas the mitotic exit 
is compromised. Conversely, addition of purified PP2A-B55 δ complex delays and 
blocks Cdk1 activation and mitotic entry (Mochida et al. 2009).  
 
Direct interactions of purified Ensa and Arpp19 with B55 and C subunits of PP2A were 
also shown in Xenopus extracts. Mochida et al. showed that Ensa interacts with the 
active site of the phosphatase in Xenopus (Mochida 2014), while Williams et al. showed 
Okadaic acid competes with Ensa for the active site in HeLa extracts (Williams et al. 
2014). Greatwall phosphorylation of Ensa and Arpp19 is important for this interaction 
to occur. Also the binding of the inhibitor reduces the phosphatase activity towards Cdk 
substrates significantly (Gharbi-Ayachi et al. 2010). These interactions lead to the 
somewhat counter-intuitive model that a phosphorylated residue becomes an inhibitor 
of a phosphatase by directly binding its active site. Williams et al. (2014) confirmed this 
model by carefully measuring the binding rates (Km) of pEnsa to PP2A-B55 and the 
catalytic activity of PP2A/B55 to dephosphorylate pEnsa. The results led to the “unfair 
competition model” of action. Ensa is a very strong binder (Km = 0.009–0.0017 µM) 
but a very poor substrate of PP2A-B55 (Kcat = 0.021–0.035 s-1) thereby blocking the 
active site for access to other substrates.  
 
In parallel, our lab reported (Hégarat, Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, 
Novák & Hochegger 2014b) that the phosphatase inhibitor okadaic acid did not inhibit 
pEnsa dephosphorylation, but maintained Greatwall phosphorylation on its Cdk1 site 
Thr194. Ensa phosphorylation was only blocked either when both PP2A and PP1 were 
inhibited using a combination of okadaic acid and tautomycetin or when the 
phosphatase FCP1 was depleted by siRNA. Interestingly, FCP1 had previously been 
implicated in mitotic regulation besides its role as a RNA-polymerase 
phosphatase(Visconti et al. 2012)and also in Greatwall kinase regulation later (Monica 
et al. 2015).This led us to propose that FCP1 and PP2A-B55 were the major 
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contributors of Greatwall Ensa dephosphorylation during mitotic exit, with a potential 
additional role for PP1. 
  
Subsequently, Heim et al. found that PP1 does indeed target the C-terminal 
autophosphorylation sites of Greatwall (Heim et al. 2015). Moreover, FCP1 was also 
shown to regulate Greatwall kinase rather than Ensa. These results could be summarised 
in a model whereby PP1 and FCP1 collaborate during early mitotic exit to deactivate 
Greatwall. This deactivation of Greatwall causes a shift in the balance of pEnsa/Ensa 
ratio and triggers dephosphorylation of Ensa by PP2A/B55. Subsequently, PP2A/B55 
could also further contribute to completely inactive Greatwall kinase.  
 
One particular problem with this model is that the activity of PP2A/B55 towards pEnsa 
is so poor that it would only ever work directly as a phosphatase, if the counteracting 
Greatwall kinase activity were completely removed. This does not to appear to be the 
situation in cells. Thus, our lab found that pEnsa dephosphorylation could still occur 
when Greatwall inactivation is blocked by okadaic acid and that it retains at least 50% 
of its mitotic activity. This could imply that another phosphatase directly contributes to 
pEnsa dephosphorylation in anaphase and captures that protein when it is not bound to 
PP2A/B55. 
 
In this chapter, I set out to test the “unfair competition” model, to analyse the interaction 
between Ensa/Arpp19 and PP2A-B55 in human cells and to identify novel phosphatases 
acting on Ensa/Arpp19 using purified thio-phosphorylated protein as a bait in a 
proteomic screen. 
 
5.1 Testing the “Unfair Competition” Model of Ensa/PP2A-B55 
Interaction 
 
Work form Williams et al. predicted the unfair competition model shown in Fig. 5.1A. 
According to this model, phosphorylated Ensa/Arpp19 act as both inhibitors and 
substrates of PP2A-B55. As long as Greatwall kinase activity remains high, the balance 
will be on the inhibitor side. Once Greatwall kinase is inactivated, the balance will shift 
to the phosphatase and dephosphorylation of Ensa and Arpp19 will occur.   
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Figure 5.1 Model for PP2A-B55-Ensa/Arpp19 interaction in mammalian cells 
 
A) Schematic representation of model proposed for Ensa/Arpp19 dephosphorylation at 
mitotic exit by Williams et al. (2014) B) Phosphorylation of Ensa/Arpp19 in asynchronous 
and nocodazole-treated mitotic cells, after Ensa and Arpp19 siRNA (20 nM each) for 48 h in 
HeLa cells. Cell lysates were probed with the indicated antibodies and alpha-tubulin was 
used as a loading control.  	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Figure 5.1 Model for PP2A-B55-Ensa/Arpp19 interaction in mammalian cells 
 
C) Immunofluorescence of HeLa_as cells released from G2 arrest. Cells were synchronised 
in G2 for 16 h with 1 µM 1NMPP1 and samples were taken 0, 1 and 3 h after wash-off. Cells 
in different phases of mitosis were fixed with PFA and visualised with FITC-Tubulin (green) 
and TRITC-phospho-Ensa/Arpp19 or TRITC-phospho-Gwl (red). DNA was visualised using 
DAPI (blue). Images were taken on the IX73_Olympus microscope using the 40X lens, N.A 
0.60. Scale bars, 10 µm. D) A box-and- whisker-plot showing quantification of 
phosphorylation signal of Greatwall and Ensa/Arpp19 in different phases of mitosis. 
Centre lines show the medians; box limits indicate the 25th and 75th percentiles as 
determined by R software; whiskers extend 1.5 times the interquartile range from the 
25th and 75th percentiles, outliers are represented by dots. Greatwall: n = 51, 37, 3, 4 
sample points. Ensa/Arpp19: n = 48, 26, 14, 10 sample points. E) Mass spectrometry 
data from PaxDB database (http://pax-db.org) showing the abundance of PP2A-B55 
regulatory subunits α and δ, Ensa and Arpp19 in human cells lines. 	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This model makes two testable predictions. First Greatwall needs to be inactivated 
before Ensa is dephosphorylated. The Kcat of PP2A/B55 on Ensa is so low that in the 
presence of residual kinase activity, dephosphorylation would never proceed. Secondly, 
since pEnsa acts as a substrate and binds the phosphatase directly in the active site, 
okadaic acid should be a competitor of this interaction and disrupt the complex. 
 
To test the first prediction we decided to measure the dephosphorylation of 
Ensa/Arpp19 and Greatwall kinase using immunofluorescence with phospho-specific 
antibodies (Hégarat, Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & 
Hochegger 2014b). Nocodazole-treated cells exhibit an increase in phosphorylation of 
Ensa/Arpp19 at S67 (Fig. 5.1B). This signal appears to be specific since there is a 
significant decrease following Ensa/Arpp19 siRNA depletion. To observe the mitotic 
exit and dephosphorylation of Ensa/Arpp19 and Greatwall, HeLa-cdk1as cells were 
arrested in the G2 phase using 5 µM 1NMPP1, and samples were collected 1 and 3 h 
after release from 1NMPP1. Cells were fixed and visualised using phospho antibodies 
against T194 for Greatwall and S67 for Ensa/Arpp19. Cells in distinct phases of mitosis 
were identified to observe the dephosphorylation profile of these proteins during mitosis 
and at mitotic exit. The Greatwall phospho-signal disappears completely at telophase, 
while Ensa/Arpp19 stays phosphorylated until late telophase (Fig. 5.1C-D). This is in 
agreement with the Goldberg model, as Greatwall needs to be inactivated first, to 
prevent futile phosphorylation and dephosphorylation cycle of Ensa/Arpp19. This 
observation is also in agreement with the findings that PP1 initiates Greatwall 
dephosphorylation, while PP2A-B55 is still inactivated by phosphorylated Ensa/Arpp19 
in Xenopus (Heim et al. 2015) and challenges the notion that T194 is dephosphorylated 
by PP2A/B55 (Hégarat, Vesely, Vinod, Ocasio, Peter, Gannon, Oliver, Novák & 
Hochegger 2014b). However, measuring the dynamics of phosphorylation of both 
residues directly side by side is necessary to firmly conclude that one site is 
dephosphorylated before the other. This is currently not possible because both antisera 
were raised in rabbit and cannot be used in a single immune-fluorescence experiment. 
 
The Goldberg model also demonstrates that PP2A dephosphorylates Ensa/Arpp19 with 
very slow kinetics while being bound to the protein. However, the molar concentration 
of Ensa and Arpp19 is more than twice the amount of PP2A-B55δ and more than a few 
parts per millions for PP2A-B55-alpha in most mammalian cell lines (Fig. 5.1E). This 
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calls for a highly processive PP2A to dephosphorylate the molar excess of Ensa and 
Arpp19 in the short frame of time at mitotic exit. The switch-like transition of mitotic-
exit does not seem possible if Ensa/Arpp19 remain phosphorylated and keep inhibiting 
PP2A until telophase. Thus, it is not unreasonable to speculate that a separate 
phosphatase assists PP2A-B55 in inactivating Ensa/Arpp19 in telophase. 
 
5.2 Immunoprecipitation using Transient Ensa/Arpp19 Expression 
in Hek293 Cells 
 
To test the second prediction of the “unfair competition” model, i.e. that okadaic acid 
competes with Ensa/Arpp19 for binding the phosphatase, I transiently over-expressed 
Flag-tagged Ensa and Arpp19 and analysed the co-immuno-precipitation of PP2A-B55. 
It was previously shown in Xenopus using interphase and CSF extracts, that 
Ensa/Arpp19 interacts with the catalytic subunit of PP2A-B55 specifically in mitotic 
extracts (Gharbi-Ayachi et al. 2010). Surprisingly, when this experiment was done in 
asynchronous (~10% mitotic cells) Hek293 cells, I observed a strong interaction Flag 
Ensa and Flag Arpp19 with the B55-alpha subunit, despite the minor fraction of mitotic 
cells. This interaction was indicated both by the B55-alpha and by PAN antibodies for 
all the subunits of PP2A-B55. The increasing salt concentration does not affect the 
complex; hence proving Ensa/Arpp19 binds strongly to the phosphatase in 
asynchronous extracts. To analyse if this interaction is independent of the mitotic 
phosphorylation of Ensa/Arpp19, it was essential to check if the exogenous Flag Ensa 
and Arpp19 are phosphorylated in-vivo at Serine 67, specifically in mitosis. The IP 
eluates also show exogenous Ensa/Arpp19 to be phosphorylated in asynchronous 
extracts in both high and low salt conditions (Fig. 5.2A). This could reflect specifically 
the mitotic population in the cells, or point to cell cycle independent phosphorylation of 
the two PP2A-B55 inhibitors.  
 
According to the Goldberg model, okadaic acid will compete with Ensa/Arpp19 for 
binding to PP2A-B55 (Williams et al. 2014). To observe the effect of okadaic acid on 
Ensa/Arpp19-B55 interaction, the pull downs were also performed in the presence of 
Okadaic acid. As seen in Fig. 5.2 B, the binding affinity is significantly reduced in the 
presence of 100 nM Okadaic acid, but it does not disappear completely. This 
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observation is compatible with the predicted model. Interestingly, we could not detect 
phospho- 
 
Figure 5.2 Co-immunoprecipitation with exogenously expressed Flag-Ensa/Arpp19 in 
Hek293 cells 
 
A) Immunoprecipitation assays with transiently expressed Flag-Ensa and Arpp19 in Hek293 
cells in the presence of high (500 mM) and low (137 mM) salt buffers. Aliquots of whole 
cell extracts (WCE) and IP elutions (IP Eluates) were analysed with the indicated antibodies. 
Flag-GFP was used as a negative control. Arrow indicates endogenous Ensa/Arpp19 
observed in the eluted fractions. B) Immunoprecipitation assays with transiently expressed 
Flag-Ensa and Arpp19 in Hek293 cells. Lysis buffer with and without 100 nM Okadaic acid 
was used to prepare Whole cell lysate (WCE). Aliquots of WCE and IP elutions (IP Eluates) 
were analysed with the indicated antibodies. Arrow shows endogenous Ensa/Arpp19 
observed in the eluted fractions. C) Flag GFP, Flag Ensa and Flag Arpp19 were transiently 
overexpressed using CaCl2 transfection in Hek293 cells for 48 h. Cells were either untreated 
or nocodazole-treated for 16 h and cells lysates were probed with the indicated antibodies. 
Arrows indicate the Flag-tagged  
Ensa and Arpp19. 	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Ensa/Arpp19 in the immune-precipitates. This could suggest that complex does fall 
apart after it has been captured on the beads and Ensa/Arpp19 become 
dephosphorylated. 
 
We also observed that exogenous Ensa and Arpp19 were seen to interact with a smaller 
protein that is identified by the Ensa/Arpp19 antibody but not the Flag-antibody 
(indicated by arrows in Fig. 5.2A-B). This co-purifying protein was also reduced after 
okadaic acid treatment. It is tempting to speculate that this band could represent 
endogenous Ensa/Arpp19 that forms a dimer with the exogenous protein to bind with 
PP2A-B55. However, before we proceeded to study the Ensa/Arpp19-B55 interaction in 
Hek293 cells line, I decided to check if the exogenous protein behaved similarly to the 
endogenous one and if it was highly phosphorylated specifically in mitosis. The strong 
interaction between B55 and Ensa in asynchronous cells that we observed was 
somewhat surprising, as this should only be specific for the small pool of mitotic cells. 
Accordingly, both the Flag-tagged Ensa and Arpp19 are highly phosphorylated in 
asynchronous population (Fig. 5.2C). This constitutive phosphorylation of exogenous 
protein could mean that high overexpression of Ensa/Arpp19 in the Hek293 triggers a 
feedback resulting in B55 inhibition and Greatwall activation. This makes this cell 
system unsuitable to study the dynamics of Ensa/Arpp19 interaction with PP2A/B55. 
Thus, further studies were done in HeLa cells after the necessary preliminary 
investigations.  
 
5.3 Immunoprecipitation and Size-Exclusion Chromatography using 
Transient Ensa/Arpp19 Expression in Hela-Cdk1as Cells 
 
Preliminary examination of the phosphorylation profile of exogenous Flag-Ensa and 
Arpp19 show that over-expressed Flag-Ensa and Arpp19 are highly phosphorylated 
only in STLC arrested mitotic cells (Fig. 5.3A-B). To examine if B55 interaction with 
Ensa/Arpp19 is enriched in mitosis, I performed Flag-pull-downs from asynchronous 
and STLC-treated mitotic cells. Surprisingly, B55 subunits co-precipitated equally well 
from interphase and mitotic extracts (Fig. 5.3C). It is possible that during the extraction 
process mixing of mitotic and interphase cells cause phosphorylation of the exogenous 
proteins. To observe an all-or-none binding of B55 to exogenous Ensa/Arpp19, I  
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Figure 5.3 Co-immunoprecipitation with exogenously expressed Flag-Ensa/Arpp19 in 
HeLa-cdk1as cells 
 
A) Flag GFP, Flag Ensa and Flag Arpp19 were transiently overexpressed using Jet-Pie 
reagent in HeLa-cdk1as cells for 48 h. Cells were either untreated or treated with STLC for 
16 h and cells lysates were probed with the indicated antibodies. Arrows indicate the Flag-
tagged Ensa and Arpp19. B) Immunoprecipitation assays with transiently expressed Flag-
Ensa and Arpp19 in HeLa-cdk1as cells for 48 h. Transfected cells were either untreated or 
arrested in mitosis with 5 µM STLC for 16 h. Aliquots of Whole cell extracts (WCE) and IP 
elutions (IP Eluates) were analysed with the indicated antibodies. Flag-GFP was used as a 
negative control. Arrow indicates endogenous Ensa/Arpp19 observed in the eluted fractions.  	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Figure 5.3 Co-immunoprecipitation with exogenously expressed Flag-Ensa/Arpp19 in 
HeLa-cdk1as cells 
 
C) Flag GFP, Flag Ensa and Flag Arpp19 were transiently overexpressed using Jet-Pie 
reagent in HeLa-cdk1as cells for 48 h. Cells were treated with either 5 µM 1NMPP1 or 5 
µM STLC for 16 h and cells lysates were probed with the indicated antibodies. Arrows 
indicate the Flag-tagged Ensa and Arpp19. D) Immunoprecipitation assays with transiently 
expressed Flag-Ensa and Arpp19 in HeLa-cdk1as cells for 48 h. Transfected cells were 
either treated with 5 µM 1NMPP1 or 5 µM STLC for 16 h. Aliquots of whole cell extracts 
(WCE) and IP elutions (IP Eluates) were analysed with the indicated antibodies. Flag-GFP 
was used as a negative control. Arrow indicates endogenous Ensa/Arpp19 observed in the 
eluted fractions. 	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performed co-immunoprecipitation assays in HeLa-cdk1as cells. These cells were 
synchronised either in G2 with 5 µM 1NMPP1 or in mitosis with the Eg5 inhibitor, 5 
µM STLC, for 16 h. Surprisingly, even in these pull downs, equal binding of B55 was 
observed in the G2 and M phases. In addition, exogenous Ensa and Arpp19 showed 
similar phosphorylation level in the G2 and M phase IP fractions (Fig. 5.3D), unlike the 
marked increase in mitotic phosphorylation that was observed directly in the total cell 
extracts (Fig. 5.1B). It is possible that Ensa/Arpp19 are phosphorylated during 
immunoprecipitation, either during lysis or during the binding procedure.  
Interestingly, even in the HeLa-cdk1as IPs, a specific small protein around the size of 
endogenous Ensa/Arpp19 was observed in the IP fractions with Flag Ensa and Flag 
Arpp19 (indicated by arrows in Fig. 5.3B and D). This protein was not identified by the 
Flag-antibody, suggesting that they could be N-terminal truncations of the exogenous 
proteins. However, if this is the case the truncated proteins should also be seen in the 
negative control pull-downs or be washed away by high-salt buffer. Moreover, this 
second Ensa/Arpp19 band disappears from the IP fraction after okadaic acid treatment 
(Fig. 5.5B), suggesting that it is involved in PP2A-B55 complex formation. This could 
mean that more than one Ensa/Arpp19 proteins bind PP2A-B55, either as a complex or 
at separate sites, or that the entire phosphatase/inhibitor complex forms a large 
heterodimer. 
 
To test these possibilities, we fractionated the elution from the co-immunoprecipitation 
experiments using a size-exclusion chromatography column (Superose 6 3.2/300). Flag-
GFP elution was used as a negative control to identify any background proteins binding 
to the beads. As expected, PP2A-B55 co-purified with Flag-Ensa and Flag-Arpp19 
confirming that they form a complex. As seen in the profile the complex elutes 
approximately around 140 kDa (141.2 kDa for Flag Ensa-PP2A B55 and 138.4 kDa for 
Flag Arpp19-PP2A B55), determined by the standards and calibration curve-plot (Fig. 
5.4A). The approximate calculations are based on the elution volumes and depend on 
the shape of the interacting proteins. This is the expected molecular weight when a 
single PP2A-B55 heterotrimer, comprising of the catalytic subunit (36 kDa), the 
scaffolding subunit (65 kDa) and the regulatory subunit B55-alpha (46 kDa) binds to 
the exogenous Ensa/Arpp19 (22 kDa), and rules out the possibility of a phosphatase 
heterodimer that separately binds two Ensa/Arpp19 inhibitors. However, the complex 
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co-purifies with a 17-kDa protein co-eluting with the complex (Fig. 5.4B) that is 
recognized by the Pan-ENSA/Arpp19 antiserum. This protein does not cross react with 
  
  
Figure 5.4 Analytical size exclusion chromatography of the Co-immunoprecipitated 
complex. 
 
A) Elution profiles from Superose 6 3.2/300 column for calibration standards Thyroglobulin 
(669 kDa), Ferritin (440 kDa), Aldolase (158 kDa), Conalbumin (75 kDa) and Carbonic 
Anhydrase (29 kDa, Dextran blue (void volume) as absorption at 280 nm (mAU) versus 
elution volume (ml). The elution profile of Flag-Ensa co-immunoprecipitation is labelled as 
1 and Flag Arpp19 co-immunoprecipitation is labelled as 2. Flag GFP (negative control) IP 
elution profile is labelled as CTRL. The calibrations curve was plotted the gel-phase 
distribution co-efficient (Kav) versus log of the molecular weighs. Kav = (Ve - Vo) / (Vc - 
Vo) where Ve = elution volume, Vo = column void volume, Vc = geometric column volume. 
Straight line is the calibration curve calculated from the data for the molecular weight 
standards (inset). The molecular weight of the complexes was determined to be 
approximately 141.2 for Flag Ensa complex (2.172 ml elution volume) and 138.4 kDa for 
Flag Arpp19 complex (2.28 ml elution volume). 	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Figure 5.4 Analytical size exclusion chromatography of the Co-immunoprecipitated 
complex. 
 
B) Flag-GFP Co-IP eluted fractions from the Superose 6 3.2/300 column were run on a 
SDS-PAGE and analyzed on a western blot using the indicated antibodies. C) Flag-Ensa Co-
IP eluted fractions from the Superose 6 3.2/300 column were run on a SDS-PAGE and 
analyzed on a western blot using the indicated antibodies. D) Flag-Arpp19 Co-IP eluted 
fractions from the Superose 6 3.2/300 column were run on a SDS-PAGE and analyzed on a 
western blot using the indicated antibodies. 
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Figure 5.4 Analytical size exclusion chromatography of the Co-immunoprecipitated 
complex. 
 
E) and F) Multiple sequence alignment of Ensa and Arpp19 isoforms respectively with 
Clustal Omega. The FASTA sequences were obtained from Uniprot database. The peptide 
sequences marked in red indicated the motif interacting with the Ensa and Arpp19 antibody 
respectively. 	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Flag antibody or the specific Ensa and Arpp19 antibodies generated in the lab (see 
Chapter 3.1). This could be because the specific Ensa-Arpp19 antibodies identify 
peptides around the N-terminal of the protein, whereas the Abcam Ensa/Arpp19 
antibody spans 50 aa to the C-terminus. One possibility is that the complex co-purifies 
an N-terminal degradation product of the exogenous Flag-Ensa/Arpp19 proteins.  
 
Alternatively, this protein could constitute a specific isoform of Ensa/Arpp19 that has a 
separate N-terminus. Upon searching the relevant databases, we discovered that Ensa 
has nine isoforms, of which three have distinguished N-terminal sequences. As shown 
in Fig. 5.4C and D, these isoforms do not cross-react with our ENSA specific antiserum 
due to high sequence dissimilarities. Likewise, the only splice variant reported for 
Arpp19 differs in the N-terminal sequence to the over-expressed cDNA and cannot 
cross-react with our N-terminal antiserum.  
 
In summary, we found that the Flag-Ensa and Flag-Arpp19 PP2A-B55 complex co-
purifies with a protein that is recognized by the Pan Ensa/Arpp19 but not the Flag, or 
the N-terminal ENSA and Arpp19 antisera. The binding of this protein to PP2A-B55 is 
inhibited by okadaic acid, suggesting that it is associated with the active site and does 
not bind independently at another site of the phosphatase complex. It could either 
constitute an N-terminal degradation product of the exogenously expressed protein that 
co-purifies for artefactual reasons. Alternatively, this could be biological meaningful 
data and the co-purifying protein could constitute an endogenous isoform of 
Ensa/Arpp19 that contains a distinct N-terminus.  
 
5.4 Proteomic Screening for Ensa/Arpp19 Phosphatases at the 
Metaphase-Anaphase Transition 
 
Due to the constitutive phosphorylation of exogenously expressed Ensa and Arpp19 in 
Hek293 cells and the phosphorylation of G2 Ensa/Arpp19 in HeLa cell extracts, these 
cells lines and methodologies were not suitable to further study Ensa/Arpp19 
dephosphorylation. Thus, we resorted to recombinant proteins to identify phosphatases 
interacting with Ensa/Arpp19 in mitosis. Phosphatase and substrate interactions are 
transient; hence, it is challenging to identify phosphatases by co- 
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Figure 5.5 Co-immunoprecipitation with recombinant Flag-Ensa/Arpp19 from 
metaphase and anaphase HeLa-cdk1as extracts. 
 
A) Flag Ensa and Flag Arpp19 were purified from E. coli were quantified by SDS-PAGE 
against bovine serum albumin (BSA) standards.  	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Figure 5.5 Co-immunoprecipitation with 
recombinant Flag-Ensa/Arpp19 from 
metaphase and anaphase HeLa-cdk1as 
extracts. 
 
B) Immunoprecipitation assays using 
purified 100 ng Flag Ensa and Flag-thio-
Ensa from STLC-treated mitotic cell lysate. 
Aliquots of whole cell extract (WCE), 
unbound fraction (FT) and eluted fractions 
(IP Eluates) were analysed with the 
indicated antibodies. Arrows show the Flag-
tagged proteins. C) Elutions from (B) were 
run on SDS-PAGE and subjected to silver 
staining. Beads only were used as a 
negative control for the IP. Arrow indicates 
the bait; Flag tagged Ensa and thio-Ensa in 
the elutions. D) Immunoprecipitation assays 
using purified 100 ng Flag Ensa and Flag-
thio-Ensa from STLC-treated mitotic cell 
lysate (metaphase extracts) and STLC + 
1NMPP1 treated (anaphase extracts) mitotic 
exit extracts. Aliquots of whole cell extract 
(WCE) and IP eluted fractions (IP Eluates) 
were analysed with the indicated antibodies. 
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immunoprecipitation with phosphorylated recombinant proteins. The phospho-group 
placed on the substrates by kinases is easily hydrolysable by endogenous phosphatases 
and it is difficult to trap these interactions. In the recent years, in-vitro thio-
phosphorylation has been used to overcome these problems. The thio-phospho group is 
non-hydrolysable due to the electronegativity and spatial arrangement of the thio-
phospho group and thus traps any interacting phosphatase when incubated with the cell 
lysates. Thus, in this study we used recombinant thio-phosphorylated Ensa to pull-down 
interacting phosphatases in mitosis and at mitotic exit. 
 
Flag-Ensa and Flag-Arpp19 were overexpressed from a GST vector and purified from 
E.coli using standard GST purification protocols (See Materials and Methods 2.2.5). 
The purified GST proteins were thio-phosphorylated by hyperactive truncated Greatwall 
(E2), in vitro at 37°C for 5 h as described in more detail below in chapter 6.2. E2 and 
residual thio-ATP were removed by re-purification of the GST proteins. The GST-tag 
was cleaved using prescission protease (Fig. 6.4), and the concentration of purified Flag 
Ensa and Flag Arpp19 was quantified using a BSA standard (Fig. 5.5A). HeLa-cdk1as 
cells were synchronised in metaphase using the Eg5 inhibitor, 5 µM STLC. Mitotic 
lysate was prepared using optimised conditions for phosphatase assays (Cundell et al. 
2013). The cell lysate was then incubated with 100 ng of the thio-phosphorylated 
protein at 37°C for 30 min to allow binding of the phosphatases to the recombinant bait. 
As the thio-phospho group is non-hydrolysable, the phosphatases or any other proteins 
interacting with it could be co-immunoprecipitated and identified by proteomic 
screening. As expected, PP2A-B55 is enriched specifically with thio-Ensa (Fig. 5.5B). 
Interestingly, in this immuno-precipitation of the recombinant protein we could not 
observe the usual co-purifying 17-kDa protein. This could mean that the recombinant 
protein already formed a dimer or multimer and did not co-purify endogenous protein, 
or that post-translational modification in the recombinant protein that are necessary for 
complex formation were lacking.  
 
The silver staining of the IP elution showed a number of non-specific proteins binding 
with the negative control. Stringent washes with 1 M NaCl and 1% detergent were 
unable to reduce these background proteins. However, as the bait is seen specifically in 
the Ensa and thio-Ensa fraction we hoped to identify some specific targets binding to 
thio-Ensa specifically even if they were unidentifiable on a silver stain (Fig. 5.5C). 
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Following the preliminary optimisation of the IPs, to gain further insight into the 
dephosphorylation dynamics at mitotic exit, I synchronised the cells in mitosis and 
triggered mitotic exit by inhibiting Cdk1. As in the previous experiment, I synchronised 
the cells in mitosis with STLC and triggered exit by using 5 µM 1NMPP1 to inhibit 
Cdk1 for 30 min at 37°C. The mitotic extracts are referred as metaphase extracts and the 
STLC+NMPP1 extracts are referred as anaphase extracts in this work. Due to the non-
hydrolysable nature of thio-Ensa, PP2A-B55 interaction was observed in IP elution 
from both metaphase and anaphase extracts. These elutions were subjected to SDS-
PAGE and Coomassie staining before in-gel trypsinisation.  
 
5.5 Mass Spectrometry and Identification of Peptides Interacting 
with Thiophosphorylated Ensa 
 
In-gel digestion of the protein bands stained with Coomassie was carried out (See 
Materials and Methods 2.2.2). Quantitative label-free LC/MS was used which allows 
peptides present in a complex protein mixture to be identified and the abundance of 
proteins quantified across different samples. The peak areas of the peptide ions from 
different peptides were measured and compared to their respective signals in other 
samples, thus generating relative, quantitative data (Bantscheff et al. 2007).  
 
MaxQuant was used to process the raw mass spectrometric data with subsequent data 
analysis using Perseus. The data were analysed in sets of two to identify proteins 
interacting specifically with Ensa and the thio-phospho group in metaphase and 
anaphase. The groups used for comparison are shown on either sides of the curve. 
 
As seen in Fig. 5.5A, Lamin B1, DKC1 and Matrin 3 were enriched with Ensa pull-
downs from metaphase extracts, versus anaphase extracts. Lamin B1 belongs to the 
family of proteins (Lamins) that provide a framework for the nuclear envelope and may 
also interact with chromatin. DKC1 is a part of the ribonucleoprotein complex subunit 4 
and has been proven to have roles in cell to cell or substratum adhesion and increase 
cell proliferation when overexpressed in HeLa cells (Angrisani et al. 2011). Matrin 3 is 
a nucleoplasmic protein and co-immunoprecipitates with Lamin A (Depreux et al. 
2015). Recent studies have shown its association with microtubule-associated protein 
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RNAs and their regulation in triple-negative breast cancer cell lines (Subbarayalu et al. 
2016). Interestingly, Ensa shows more than 2-fold enrichment but does not pass the 
estimated 5% FDR when compared with the bead sample (Fig 5.6B). No purified 
protein was added in the beads sample and hence significant enrichment is expected 
with the Ensa sample. This could probably be due to non-specific binding of 
endogenous Ensa to the Beads, as the silver staining of the IP eluates did not show a 
clear distinction between the negative and the Ensa/Thio Ensa samples. In addition, no 
proteins were significantly enriched in the Ensa samples compared to the bead-only 
controls. This would be consistent with the three identified nucleoplasmic proteins 
discussed above being bound non-specifically to the beads in the metaphase at higher 
levels than in anaphase. Therefore, although, these proteins might point towards an 
unknown nuclear function of Ensa, optimising the IP to reduce non-specific binding is 
required to identify and analyse them thoroughly.  
 
Surprisingly, Lamin B1 also showed more than 2-fold enrichment with un-
phosphorylated Ensa when compared with Thio-Ensa in metaphase extracts pull-downs 
(Fig. 5.6D). This could be biologically significant and point towards the association of 
Ensa with the nuclear membrane protein that might contribute to the blebbing observed 
in Chapter 4.2 (Fig. 4.4). However, the reduced signal in thio-Ensa can also be due to 
the specific binding and enrichment of the PP2A-B55 subunits to the Thio-Ensa that 
makes it unavailable for any non-specific binding, or simply stochastic variation in non-
specific binding between samples. As seen in Fig. 5.6D-E, the PP2A-B55 subunits are 
enriched more than 2-fold with thio-phosphorylated Ensa. This is in agreement with the 
previous studies where Greatwall phosphorylation of Ensa is necessary for PP2A 
binding (Gharbi-Ayachi et al. 2010; Mochida 2014). The binding of the phosphatase to 
phospho-Ensa is also seen in anaphase due to the unhydrolysable nature of the thio-
group. When pull-downs from anaphase and metaphase extracts with thio-Ensa were 
compared, no new interactors were found. Ensa and PP2A-B55 subunits show a slight 
preference towards metaphase, but this does not approach statistical significance (Fig. 
5.6F). As seen in Fig. 5.6F, VDAC3 was found at the edge of the curve showing 
enrichment in anaphase extracts. Five unique peptides were identified for this protein, 
which accounts for 25% of the sequence coverage. However, it is not clear if this 
protein is significant, as it is not far from the other insignificant hits on the plot.  
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Figure 5.6 Proteomic screening for Ensa/Arpp19 phosphatases at the metaphase-
anaphase transition 
A) - F) ‘Volcano plot’ illustrating statistical significance against fold-change of the 
proteomic data set. The x-axis reflects the difference in protein abundance in the groups 
mentioned on the right side of the curve compared to the sample mentioned on the left side. 
The y-axis shows the -log10 of the p value of the Student’s t-test. The proteins groups of 
PP2A-B55 subunits, Ensa (positive controls) and the significantly enriched protein groups 
are indicated by red dots (FDR = 0.05, S0 = 2, indicated by black line). Each dot represents 
a protein group.  A) The data indicates the distribution of protein groups interacting with 
Ensa in metaphase and anaphase. B)- C) The data indicates the distribution of protein groups 
interacting specifically with Ensa in comparison to the Beads (negative control).	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Figure 5.6 Proteomic screening for Ensa/Arpp19 phosphatases at the metaphase-
anaphase transition 
D)- E) The data indicates the distribution of protein groups interacting specifically with 
Thio-Ensa in comparison with the unphosphorylated Ensa in metaphase and anaphase. F) 
The data indicates the distribution of protein groups interacting with Thio-Ensa in 
metaphase and anaphase extracts.  	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  Figure 5.6 Proteomic screening for Ensa/Arpp19 phosphatases at the metaphase-
anaphase transition 
G) Tabular representation of the number of unique peptides (peptide that occurs in only 
one protein in the proteome of interest), sequence coverage and molecular weight of the 
protein groups marked in the volcano plots. 	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Phosphatase subunits of PPP1, PPP5 and PPP6 were detected but not enriched in Enso 
or thio-Ensa over the beads, which indicated non-specific binding. 
 
As no other phosphatases were identified in anaphase with thio-Ensa in these 
preliminary analyses, it seems that PP2A-B55 is the dominant phosphatase it interacts 
with. These results are in agreement with the observations from Williams et al. that 
Ensa acts both as an inhibitor and as a substrate of PP2A-B55. However, as 
phosphatases like PPP1, PPP5 and PPP6 are expressed in such low amounts in the cells 
cycle, it might be worth analysing the spectral data with a much-relaxed FDR of 5%. 
This could also identify low-level interactors of Ensa and shed light on new function the 
protein might be involved in and out of the cell cycle. However, due to time constraints 
these analyses could not be carried out at the time of writing this work. Overall, the 
large contamination of the beads only sample probably masked meaningful interaction 
data. Thus, the purification and elution method will need to be further optimised to 
allow this method to be successfully applied to thio-phospho interactor analysis. 
 
In conclusion, this chapter probed the interaction of Ensa/Arpp19 with PP2A-B55. We 
have identified a potential dimer of different Ensa/Arpp19 isoforms in the PP2A/B55 
complex but this has to be further investigated using differentially tagged Ensa/Arpp19 
and their isoforms. The preliminary proteomic screen did not identify any novel 
phosphatase interacting with phosphorylated Ensa at mitotic exit, but it is likely that the 
high background in the sample preparation did mask potential novel interactors. 
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CHAPTER6 GENERATING A DOMINANT ACTIVE 
ENSA AND ARPP19 FOR FUNCTIONAL ANALYSIS OF 
THE ENSA/ARPP19-B55 PATHWAY 
 
The precise role of the Gwl/Ensa/B55-PP2A axis in the mammalian G2/M switch 
remains to be determined. Depletion of either Ensa/Arpp19 or Gwl does not appear to 
have a significant impact on the dynamics of mitotic entry when Cdk1 is fully active 
(see Chapter 4.2). This suggests that cells can trigger Cdk1 activation and mitotic 
phosphorylation even in the presence of high phosphatase activity. On the other hand, 
inhibition of phosphatases by okadaic acid (OA) triggers rapid and premature mitotic 
entry even when Cdk1 is inhibited, suggesting that it is indeed a phosphatase that 
constitutes the major obstacle to enter mitosis. A critical question that remains to be 
addressed is whether the major target of OA that prevents premature mitotic entry is 
indeed B55-PP2A. It also remains unclear what the consequences of prolonged B55-
PP2A inhibition on mitotic exit will be. Artificially activating and maintaining 
Ensa/Arpp19 phosphorylation could be used to investigate this question. This can be 
achieved by activating either Greatwall or Ensa/Arpp19 constitutively. However, 
attempts to generate phospho-mimicking mutants of human Greatwall have failed in the 
past (Vesely 2013). Another attractive approach would be to generate dominant active 
Ensa or Arpp19. Unfortunately, phospho-mimicking mutants of Ensa/Arpp19 that 
express negatively charged amino acids such as aspartate or glutamate instead of S67 
are unlikely to be functional. The negative charge on an aspartate or a glutamate might 
not be enough to execute the function of Ensa/Arpp19, as this phospho-site has to 
interact directly with the catalytic domain of the phosphatase to exert its inhibitory 
effect.  
 
Dominant active thio-phosphorylated recombinant Ensa/Arpp19 has been used in the 
past in Xenopus to study its effects on mitotic entry and exit. In Xenopus interphase 
extracts, previously depleted of Gwl, the addition of thio-phosphorylated Ensa or 
Arpp19 rescues Gwl phenotype and induces mitotic entry (Gharbi-Ayachi et al. 2010). 
Thus, cell cycle mechanisms can be easily analysed by adding recombinant effector 
proteins in cell extracts. In addition, recombinant proteins can be injected easily into 
Xenopus oocytes to observe their effects. One such example was microinjection of Cdk 
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inhibitor, p21, into oocytes that prevent Gwl phosphorylation (Zhao et al. 2008). 
Although very few similar experiments have been done with human cells, protein 
delivery techniques in mammalian cells need to be improved to study cell cycle 
functions.  
 
Thio-phosphorylated Ensa/Arpp19 have been generated and either added into cell-free 
extracts or injected in Xenopus. However, this cannot be exploited in the human system, 
as cell-free mammalian extracts do not mimic in-vivo cellular transitions like frog 
extracts. In addition, the few existent protein delivery methods in mammalian cells take 
a long time to display the effect and cannot be used to study the mitotic entry and exit 
switch-like transitions. 
 
Hence, we are engineering a technique to produce constitutively active Ensa and 
Arpp19 that can be directly transfected into mammalian cells in-vivo. This will enable 
us to have a replica of the Xenopus technique in mammals to investigate the effects of 
dominant active Ensa/Arpp19. 
 
6.1 Analysing the Effects of PP2A/B55 Depletion on Mitotic Entry 
 
To begin determining if PP2A-B55 is the okadaic acid (OA)-sensitive Cdk- 
counteracting phosphatase, I decided to first reproduce the okadaic acid experiment 
using the HeLa-cdk1as cells to analyse the effects of a general phosphatase inhibitor in 
these cells. OA is a chemical inhibitor of various protein phosphatases. It inhibits PP2A 
at lower concentrations (0.5–1 µM), while PP1 is only inhibited at 5–10 fold higher 
concentrations (M. Hara et al. 2012). I synchronised the HeLa-cdk1as cells in G2 with 5 
µM 1NMPP1 and added varying concentrations of OA to inhibit the phosphatases. The 
cells were imaged every 30 min for 4 h to see the effect of phosphatase inhibition on 
mitotic entry. Fig. 6.1A shows that OA overrides Cdk1 inhibition and promotes mitotic 
entry even at 125 nM concentration. This agrees with the previous studies that indicate 
that OA triggers mitosis even in Cdk1 inhibited cells (Gowdy et al. 1998). To verify if 
B55-PP2A is the target of OA in this experiment, I used siRNA depletion in the HeLa-
cdk1as cell line. The cells were treated with B55 siRNA (α+δ: 20 nM each and PP2A 
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catalytic subunit siRNA (CA/CB: 25 nM each) for 72 h and synchronised in G2 with 








Figure 6.1 Analysing the effect of Okadaic acid and PP2A-B55 depletion on mitotic 
entry. 
A) HeLa-cdk1as cells were arrested in G2 with 5 µM 1NMPP1 for 20 h and then treated 
with varying amounts of Okadaic acid. Time-lapse imaging was done for 4 h post-
treatment. The cells were quantified and mitotic index was plotted. Images were taken 
using DIC on the IX71_Olympus microscope, using the 40X lens, N.A 0.60. Scale bars, 
10 µm.  	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Figure 6.1 Analysing the effect of Okadaic acid and PP2A-B55 depletion on mitotic 
entry. 
B) HeLa-cdk1as cells were treated with B55α and δ siRNA (20 nM each) for 72 h or PP2A-
CA/CB (25 nm each) for 48 h. These cells were then arrested in G2 with 0.5 µM 1NMPP1 
for 16–18 h. Samples were collected and the mitotic index was determined using phospho-
H3 staining. Representative western blots show efficiency of depletion with the indicated 
antibodies. Histone H3 was used as a loading control. 	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I used recombinant thio-phosphorylated Ensa that I had already generated for the 
proteomic experiments in chapter 5.4. Initially, my aim was to optimise protein 
transfection and apply this method to G2 arrested HeLa-cdk1as or U2OS-cdk1as cells. 
Once the technique was established, I could test if premature inhibition of B55-PP2A by 
thio-Ensa would mimic the effects of OA and trigger mitotic entry.  
 
Fig. 6.2 gives an overview of the reaction to generate constitutively active Ensa/Arpp19. 
Hyperactive truncated Gwl (E2) generated in the lab (Ocasio et al. 2016) was used to 
thio-phosphorylate purified recombinant Ensa and Arpp19 in the presence of ATP-γS. 
The thiol group in the phosphate moiety confers the non-hydrolysable property on these 
purified proteins. The aim of this work is to observe the effect of dominant active 
Ensa/Arpp19 on mitotic entry and exit, by transfecting the purified protein using 
MATERIchemical or physical transfection approaches in mammalian cells. 
 
6.2 Affinity Purification and Transfection of Dominant-Active 
Ensa/Arpp19 
 
From the previous work described in this thesis, a gateway entry clone with human 
Ensa and Arpp19 cDNA was available. These clones were used to generate His-tagged 
Ensa using Gateway cloning. His-Ensa plasmid was expressed and induced with IPTG 
overnight. The protein was purified using Nickel-NTA beads by batch purification as 
shown Fig. 6.3A workflow (Materials and Methods 2.2.5). Aliquots from different steps 
of purification are shown in Fig. 6.3B. Purified His-Ensa was thio-phosphorylated with 
E2 for varying time-points at 37°C to obtain maximum phosphorylation of the substrate. 
The phosphorylation was complete in 5 h of the reaction and these conditions was later 
used in this work to thio-phosphorylate recombinant Ensa and Arpp19. Thio-
phosphorylation was also probed with the thio-ester antibody (Allen et al. 2007) 
following PNBM treatment (Fig 6.3C-D). However, when the protein was transfected 
into HeLa cells using a lipid-based Xfect protein transfectant, it was unsuccessful. This 
could be due to the positive charge of the 6X His that hinders its encapsulation into the 
plasma membrane and thus, the cytoplasm. Hence, GST-tagged Ensa and Arpp19 were 
cloned and purified, as GST-tag is neutral in charge. 
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GST-tagged Ensa and Arpp19 were expressed and purified as per the workflow shown 
in Fig. 6.3A and eluted with glutathione (Fig. 6.4A-B). The purified proteins were then 
thio-phosphorylated according to conditions optimized for His-Ensa in Fig. 6.2C-D 
 
GST-tagged Ensa and Arpp19 were expressed and purified as per the workflow shown 
in Fig. 6.3A and eluted with glutathione (Fig. 6.4A-B). The purified proteins were then 
thio-phosphorylated according to conditions optimized for His-Ensa in Fig. 6.2C-D 
(Fig.6.4C). Auto-phosphorylation of E2 was also observed in the kinase assay. The 
purified proteins were then dialysed and concentrated into a neutral PBS/glycerol  
GST-tagged Ensa and Arpp19 were expressed and purified as per the workflow shown 
in Fig. 6.3A and eluted with glutathione (Fig. 6.4A-B). The purified proteins were then 
thio-phosphorylated according to conditions optimized for His-Ensa in Fig. 6.2C-D 
(Fig.6.4C). Auto-phosphorylation of E2 was also observed in the kinase assay. The 
purified proteins were then dialysed and concentrated into a neutral PBS/glycerol 
solution. E2 was used as a positive control for Xfect transfections. I successfully 
transfected GST-tagged Ensa and thio-Ensa into asynchronous and mitotic HeLa cells. 
Figure 6.2 Schematic diagram for generating constitutively active Ensa/Arpp19 and the 
questions addressed using this system. 
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The transfected proteins also retained their phosphorylation post-transfection. Although 























Figure6.3 Transfection of purified His-Ensa using Xfect transfection reagent 
 
A) Schematic representation of generating dominant active Ensa and Arpp19 using bacterial 
purifications of recombinant proteins from E. coli and in vitro thiophosphorylation. B) 
Affinity purification of His-Ensa from E. coli. His-tagged hEnsa was expressed and induced 
using 1 mM IPTG overnight at 18°C. The over-expressed proteins were purified using Ni-
NTA beads and eluted using imidazole. The eluted proteins were dialysed into kinase buffer 
overnight at 4°C. Aliquots of soluble fraction (S), flow-through (FT),  
Washes (W1 and W2) and elutions (E1-5) were subjected to SDS-PAGE and Coomassie-
staining. Arrow indicates the eluted His-Ensa protein. C) Schematic representation of In-
vitro thio-phosphorylation and PMBM alkylation reaction. D) Purified His-Ensa was thio-
phosphorylated by E2 (truncated Gwl) in the presence of ATP-γS at 37°C for varying 
periods. His-Ensa phosphorylated using cold ATP was used as a positive control and the 
reaction without ATP as the negative control. Samples were probed with the phospho-
Ensa/Arpp19 antibody on a western blot. Samples after overnight incubation was treated 
with PNBM for 30 min at RT and probed with the thio-ester specific antibody. E) 
Thiophosphorylated His-Ensa was transfected using Xfect transfection reagent in  
HeLa cells. Samples were collected 2 h post-transfection and probed with the indicated 
antibodies. 	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Figure 6.4 Transfection of purified GST Ensa using Xfect transfection reagent 
 
A) and  B) Affinity purification of GST-Ensa and GST Arpp19 respectively from E. coli. 
Each protein was expressed and induced with 1 mM IPTG individually for overnight at 
18°C. The over-expressed proteins were purified using GST-Sepharose beads and then 
eluted from the beads using glutathione. Aliquots of Lysate (L), soluble fraction (S), flow-
through (FT), Washes (W1 and W2) and elutions (E1–5) were subjected to SDS-PAGE and 
Coomassie-staining. Arrow indicates the eluted proteins. C) Purified GST-Ensa was thio-
phosphorylated by E2 (truncated Gwl) in the presence of ATP-γS for 5 h at 37°C. 	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Figure 6.4 Transfection of purified GST Ensa using Xfect transfection reagent 
 
D) Five micrograms of thio-phosphorylated and non-phosphorylated GST-Ensa was transfected into 
HeLa cells using the Xfect transfection reagent. Cells were collected after 2 h and analysed using the 
indicated antibodies on a western blot. Only GST-Ensa without the reagent was used as a negative 
control. Endogenous Ensa/Arpp19 is used as a loading control. E) Thio-GST Ensa was transfected 
into nocodazole-arrested HeLa cells using Xfect transfection reagent for 2 h. Transfection was 
carried out in 6-well dish and a universal tube. Cells were lysed and probed with the indicated 
antibodies on western blot. Arrow indicates phosphorylated endogenous Ensa/Arpp19. F) Co-
immunoprecipitation assays performed with Xfect transfected GST-Ensa and GST-Thio-Ensa in 
HeLa cells. GST-sepharose beads were used to pull down the transiently transfected proteins. Arrow 
indicates endogenous Ensa/Arpp19 in the whole cell extracts (W). Aliquots of IP elution (E) and 
beads (B) were analysed using the indicated antibodies on a western blot.	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protein transfected in asynchronous cells appears to exceed the endogenous expression, 
the efficiency of transfection was variable between experiments (Fig. 6.4D-E). To test 
the activity of the transfected protein, I performed GST-pull down assays 2 h post 
transfection and analysed its interaction with PP2A-B55. As seen in Fig. 6.4F, although 
GST-thio-Ensa is successfully transfected, it does not interact with PP2A in-vivo. This 
may be due to the misfolding of the transfected protein due to presence of GST-tag, 
which is larger than Ensa itself. It is also possible that although Ensa protein folding is 
unaffected, the large size of the tag interferes in its interaction with B55. This agrees 
with the previous studies by Williams et al., where the interaction with B55 was 
affected when a bulkier MBP (maltose-binding-protein) tag was used (Williams et al. 
2014).  
 
In previous experiments, I found that Flag-Ensa/Arpp19 successfully interacted with 
PP2A-B55 when expressed in mammalian cells. Thus, I decided to optimize protein 
transfection assays with Flag-tagged Ensa and Arpp19. My Flag-tagged Ensa and 
Arpp19 constructs were derived from Flag gateway destination vectors. These plasmids 
have a mammalian EFIa promoter and cannot be used for large-scale purification of the 
protein. To simplify the purification process, Flag Ensa and Arpp19 were cloned into 
p3E vectors designed and produced in Oliver Lab. The p3E vector is a GST- tagging 
vector with T7 promoter, ideal for expression in bacterial system. In addition, the 
presence of a prescission site enables the cleavage of GST tag following purification to 
obtain Flag-tagged Ensa and Arpp19 (Fig. 6.5A-C). The GST-Flag-tagged proteins 
were expressed and purified from E.coli. Aliquots from each step of the purification are 
shown in Fig. 6.5D-G. Un-phosphorylated and thio-phosphorylated Flag Arpp19 was 
successfully transfected in HeLa cells using the Xfect lipid-based reagent (Fig. 6.6A). 
The amount of protein transfected was approximately twice the amount of endogenous 
Ensa/Arpp19. Pull-down assays with recombinant transfected Flag Arpp19 show that 
the protein interacts with B55, thus showing that the protein is active in-vivo. The 
interaction is specific to thio-phosphorylated Arpp19, similar to that observed in 
previous studies (Gharbi-Ayachi et al. 2010) (Fig. 6.6B). Overall, I developed a new 
method to transfect recombinant thio-phosphorylated Ensa/Arpp19 into cells. 
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Figure 6.5 Bacterial purification of Flag-Ensa and Flag-Arpp19 using the p3E 
recombinant vector. 
 
A) Map of the recombinant p3E GST-expression vector with human Flag-Ensa cDNA 
cloned using Nde1 and BamH1 restriction sites. B) Map of the recombinant p3E GST-
expression vector with human Flag-Arpp19 cloned using the Nde1 and BamH1 restriction 
sites. C) Schematic representation of purifying and thio-phosphorylating Flag-tagged Ensa 
and Arpp19 from p3E GST vector.	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Figure 6.5 Bacterial purification of Flag-Ensa and Flag-Arpp19 using the p3E 
recombinant vector. 
 
D) and E) Over-expression and purifications of GST-tagged Flag-Ensa and Flag-Arpp19 
from E.coli respectively. Over-expression of the plasmid was induced with 1 M IPTG 
overnight at 18°C. Aliquots of cell lysate (L), soluble fraction (S), pellet (P), washes (W1–
2), elutions (E1–5) before and after dialysis into kinase buffer and flow-through (FT) after 
treatment with precision protease were subjected to SDS-PAGE and Coomassie staining. F) 
and G) Purified GST-tagged Flag-Ensa and Flag-Arpp19 were thio-phosphorylated by 
hyperactive truncated Gwl (E2) in the presence of ATP-γS for 5 h at 37°C. Thio-
phosphorylated proteins were treated with PNBM for 30 min at RT and probed with thio-
ester specific antibody on a western blot. 	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Figure 6.6 Transfection of Flag-Arpp19 using Xfect™ reagent and Co-
immunoprecipitation to analyse the activity of the transfected protein 
 
A) Transfection of 5 µg purified Flag-Arpp19 into HeLa-cdk1as cells using the Xfect 
transfection reagent. GST-Arpp19 was used as a positive control for the transfection. Flag-
tagged proteins are indicated by ** and arrow indicates endogenous Ensa/Arpp19 used as a 
loading control. Samples were collected 2 h post-transfection and probed with the indicated 
antibodies. B) Co-immunoprecipitation of transfected Flag-Arpp19 protein with Flag-M2 
magnetic beads. Cells were collected 2 h post-transfection for IP. Aliquots of whole cell 
lysate (WCE) and IP were analysed using the indicated antibodies.  
C) Immunofluorescence of HeLa-cdk1as cells transfected with Flag-thio-Arpp19 using Xfect 
transfection reagent. Cells were fixed using PFA and visualised using Flag-FITC and 
phospho-Ensa/Arpp19-TRITC antibodies. DAPI (blue) was used to visualise the DNA. 
Images were taken on IX73_Olympus microscope using the oil immersion 100X lens N.A 
1.40 oil, maximum intensity projections of variable z dimension slices. Scale bar 10 µm. 	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Figure 6.6 Transfection of Flag-Arpp19 using Xfect™ reagent and Co-
immunoprecipitation to analyse the activity of the transfected protein 
 
D) Transfected Flag-Arpp19 protein was subjected to co-immunoprecipitation on Flag-M2 
magnetic beads using half the cell lysate. The other half of the whole cell extract (WCE) and 
the unbound fraction (FT) were precipitated with TCA. Equivalent volumes of WCE, FT and 
IP elution (IP) were analysed using western blot and indicated antibodies. 	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To study the effects of thio-phosphorylated Arpp19 and Ensa on cells I next performed 
immuno-fluorescence analysis using Flag antibodies. Thio-phosphorylated Arpp19 is 
seen to localize on the spindles and poles in metaphase. It localizes globally in anaphase 
and is seen in the midzone at telophase (Fig. 6.6C). In principle, this demonstrates that 
we have generated cells that maintain high phospho-Arpp19 during mitotic exit.  
 
However, cells transfected with the constitutively active protein did not appear to show 
any evident phenotypes, i.e. premature mitotic entry and delayed mitotic exit. This may 
be due to residual B55 present in the cells even after binding the excess transfected 
protein. To test this hypothesis, whole cell lysates were split into two halves. One half 
was precipitated using trichloroacetic acid (TCA) and the other half was used for 
immunoprecipitation. The flow-through (unbound fraction) obtained after incubating 
the lysates with the Flag-beads was also precipitated with TCA. On comparing the 
TCA-precipitated whole cell extract and unbound fractions, residual B55 was observed 
in the unbound fraction with thio-Arpp19 (Fig. 6.6D). Surprisingly, although a 
significant reduction was not observed between the WCE and unbound fraction, distinct 
enrichment was observed in the B55 binding with thio-Arpp19. This is contradicting the 
observation that we transfect an excess of Arpp19, which should be more than enough 
to inhibit the endogenous B55-PP2A pool. One explanation to explain this apparent 
contradiction could be that a large proportion of the recombinant transfected protein is 
not biologically active in the cell either due to misfolding, or due to exclusion from the 
cytoplasm. Thus, the residual B55 needs to be inhibited either by increasing the amount 
of transfected protein or by reducing expression using the siRNA approach. As the 
amount of transfected protein in the cell is already twice the amount of endogenous, I 
decided to reduce the expression of PP2A-B55 optimally using siRNA to enable 
complete inhibition of the phosphatase. Therefore, RNAi depletion was integrated with 
protein transfection of its inhibitor for complete suppression of PP2A-B55 phosphatase. 
 
HeLa-cdk1as cells treated with B55 siRNA for 72 h were synchronized in G2 with 1 
µM or 0.5 µM 1NMPP1 and transfected with 5 µg Flag-thio-Arpp19. Samples were 
collected 2 h post-transfection, stained with PI staining and phospho-Ser10-Histone H3 
antibodies for FACS analysis. Mitotic and G1 cells were gated and quantified using the 
BD Accuri software, FCS Express Flow. 
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Figure 6.7 Mitotic entry experiment using purified constitutively active Flag-Arpp19 
 
A) FACS analysis of HeLa-cdk1as cells depleted of B55α and δ subunit and transfected with 
5 µg purified Thio-Flag-Arpp19. HeLa-cdk1as cells were synchronised in G2 with 1 µM 
1NMPP1 for 20 h and then transfected using Xfect reagent. Samples were collected 2 h after 
transfection and mitotic index was determined using phospho-H3 staining. 	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Figure 6.7 Mitotic entry experiment using purified constitutively active Flag-Arpp19 
 
B) FACS analysis of HeLa-cdk1as cells depleted of B55α and δ subunit and transfected with 
5 µg purified Thio-Flag-Arpp19. HeLa-cdk1as cells were synchronised in G2 with 0.5 µM 
1NMPP1 for 20 h and then transfected using Xfect reagent. Samples were collected 2 h after 
transfection and mitotic index was determined using phospho-H3 staining. 
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As observed in the FACS profile in Fig. 6.7A, B55 depletion with 1 µM 1NMPP1 did 
not show any evident phenotypes. However, B55 depletion with 0.5 µM NMPP1 drove 
the cells into mitosis (M population increases 2-fold) and triggered exit (G1 increases 4-
fold) (Fig. 6.7B). Surprisingly, transfection of Arpp19 has no expected additive effect of 
these cells despite complete inhibition of the phosphatase (Fig. 6.7A-B). It could not be 
determined if the G1 population difference occurred due to the protein transfection.  
 
In addition, the slight decrease in the mitotic index and G1 population on Arpp19 
transfection might be due to variability in B55 depletion among samples (Fig. 6.7B). 
Thus, preliminary experiments with B55-depletion and Flag-Arpp19 transfection 
showed no significant effect on the cell cycle profile. This was also true for cells treated 
with control siRNA. This could mean that B55-PP2A is not the phosphatase that is the 
major target of okadaic acid whose inhibition triggers mitotic entry. However, it is 
difficult to ultimately prove that we have completely inactivated B55-PP2A in the 
1NMPP1-induced arrested cells. Moreover, the protein transfection itself could have 
had an inhibitory effect on mitotic entry over-riding the phosphatase inhibition.  
 
Xfect is a peptide based transfection reagent. The Xfect peptide interacts with the 
protein of interest and transports it into the cells. The amino-acid composition of the 
Xfect reagent confers cell-penetrating properties to execute this function. Thus, the 
transfectant might interact with the cell membrane and inhibit mitosis. To test this I 
treated G2 cells with Xfect reagent and Xfect + Flag-thio-Arpp19. An untreated sample 
was used a control. When these cells were released from the 1NMPP1 block into STLC, 
only the untreated sample entered mitosis. Both the samples treated with Xfect reagent 
failed to enter mitosis even after 8 h of incubation (Data not shown). This result 
prompted us to further optimize the protein transfection procedure. 
 
As an alternative to chemical transfection, I considered physical transfection methods of 
protein transfection. Bekei used Amaxa Nucleofection to transfect αSyn, a small (14.5 
kDa) neuronal protein, for in-cell NMR studies in mammalian cells (Bekei 2013). In 
Bekei’s thesis, the method was optimized to electroporate 2 x 106 HeLa cells with 
protein concentration of 1 mM. For this purpose, purified Flag-thio-Arpp19 was 
concentrated using Vivaspin centricon tubes and the buffer was exchanged to 20 mM 
Phosphate buffer with 150 mM NaCl. Four hundred micromoles of purified protein was 
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resuspended in electroporation buffer containing 2 mM ATP and 2 mM Glutathione. 
Both ATP and Glutathione were shown to improve cell recovery in HeLa cells (Bekei 
2013). Trypsinised HeLa cells were resuspended in the protein-buffer mixture and 
electroporated with A#28 nucleofection program with 1 or 2 pulses. A 3-s gap between 
each pulse was maintained to reduce cell death by electroporation. Samples were 
allowed to recover in complete warm media for at least 5 h before analysing by western 
blot (Fig. 6.8A). Although, we see a band at the expected size, it was also  observed in 
the un-transfected sample. An extra band around the same size was observed in the 
insoluble (pellet; P) fraction of the samples transfected with protein. Endogenous 
Ensa/Arpp19 is observed to be more concentrated in the cytosolic fraction that the pellet 
(marked by **). Thus, the transfected protein seems to be in the non-cytosolic fraction 
of the cell, if the transfection were successful. To optimize this technique further, I 
performed electroporation with two different programs with less cells (to increase the 
ratio of cells: protein) using A#28 and B#28 Amaxa program. Although the band 
around 22 kDA seems to be enriched in the Ensa cytosolic (S) fraction, it is also 
observed in the Buffer (S) fraction. A specific band around the expected size of 22 kDa 
was only observed in the insoluble (pellet, P) fraction with Ensa transfection (Fig. 
6.8B). Thus, Amaxa Nucleofection proved unsuccessful in transfecting Flag-Arpp19 
into the cytosol of mammalian cells. 
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Figure 6.8 Optimisation of protein transfection using Amaxa Nucleofector Technology 
 
A) Transfection of 5 µg of Flag Ensa and Flag-Thio-Ensa into 2 x 106 HeLa_as cells using 
the #A28 program optimised for HeLa cells on the Amaxa Nucleofector. Cells were 
fractionated following 1 or 2 pulses of electroporation and analysed using western blotting. 
Arrow indicates the expected size of Flag-tagged proteins and ** indicates expected size of 
endogenous Ensa/Arpp19. B) Five micrograms of Flag-Ensa was transfected into 0.5X 106 
HeLa-cdk1as cells. Cells were then fractionated and analysed using shown antibodies on a 
western blot. The arrow indicates the expected size of Flag-Ensa and ** indicates the 
expected size of endogenous Ensa/Arpp19. 	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Another approach along the same lines was using the Neon Transfection Kit form 
Invitrogen to perform protein transfections. This approach was adapted from (Kim et al. 
2014). They transfected the Cas protein into U2OS cells and observed its activity 24 h 
post-transfection. This was done to minimize off target-effects, as the protein cleaved 
DNA immediately after delivery and was itself is degraded within 24 h of transfection. 
Thus, this approach is ideal for our experiment, as the active protein can capture the 
residual B55 immediately after delivery and promote mitotic entry. As the protocol was 
optimized for U2OS cells in this paper, I used U2OS-cdk1as cells for this approach. As 
shown in Fig. 6.9A, preliminary experiments with 5 µg Flag-Arpp19 using the Neon Kit 
resulted in the successful transfection of the protein into the cytosolic fraction (S) (Fig. 
6.9A). The amount of protein transfected is less than twice the amount of endogenous 
Ensa/Arpp19 (shown with an arrow). When 1 µg and 5 µg of Flag-Arpp19 were 
transfected and the cells were allowed to recover for 2 h post-transfection, the amount 
of transfected protein was almost equal to that of the endogenous protein (Fig. 6.9B). In 
addition, 1 µg of Flag Arpp19 seemed insufficient for transfection as no band was 
observed at the expected size. Thus, it seems increasing the amount of protein used and 
recovery time are important parameters to consider in Neon transfection. So I 
transfected 1 µg and 5 µg of Flag-Arpp19 using the Neon kit and allowed the cells to 
recover at 37°C for 24 h. When these cells were fractionated and blotted with 
Ensa/Arpp19 antibody, a band of the expected size appears in the soluble fraction, but 
the amount of transfected protein is almost half the amount of the endogenous (shown 
with an arrow) (Fig. 6.9C).  
 
Thus, in all the transfection attempts, the ratio between endogenous and exogenous 
protein shows that we are not dramatically over-expressing thio-Arpp19.  
 
As seen in Fig. 6.9C, the proteins stayed in the cytosol for at least 24 h post-
transfection, unlike Cas9. To observe the effects of this stable and dominant active 
Arpp19 on U2OS cells, I imaged the transfected cells for 3 h, 1 h after transfection to 
observe effects of dominant active Flag-Arpp19. Although the electroporated cells 
recovered and adhered to the surface of the plate coated with Matrigel, very few mitotic 
divisions were observed in the transfected and control cells (Fig. 6.9D). More cell death 
was observed with protein-transfected samples as compared to the control. Thus, 
varying amounts of transfected protein despite using the same amount of recombinant  




Figure 6.9 Optimisation of Neon Protein Transfection   
 
A) Five micrograms of Flag-thio-Arpp19 were transfected into U2OS-cdk1as cells using the 
Neon Transfection Kit (#MPK1025). Cells were incubated at 37°C for 1 h and cell lysates 
were fractionated. The cellular fraction were analysed by western blotting. The arrow 
indicates endogenous Ensa/Arpp19. B) One and five micrograms of Flag-thio-Arpp19 was 
transfected into U2OS_as cells using the Neon Transfection Kit (#MPK1025). Cells were 
incubated at 37°C for 2 h and cell lysates were fractionated. The cellular fraction were 
analysed by western blotting. The arrow indicates endogenous Ensa/Arpp19. C) One and 
five micrograms of Flag-thio-Arpp19 was transfected into U2OS-cdk1as cells using the 
Neon Transfection Kit (#MPK1025). Cells were incubated at 37°C for 24 h and cell lysates 
were fractionated. The cellular fraction were analysed by western blotting. The arrow 
indicates endogenous Ensa/Arpp19. D) Time-lapse imaging of U2OS-cdk1as cells 
transfected with Flag-Thio-Arpp19 plated on matrigel-coated plates. Images were taken on 
the IX73_Olympus microscope using the 40X lens, N.A 0.60, for 3 h after transfection. 
Scale bar 10 µm. 	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Figure 6.10 Protein Transfection using ProDeliverIN Reagent 
 
A) Transfection of the positive control p-Erythrocein into HeLa-cdk1as cells using 
ProDeliverIN reagent. Images were taken using the 20X lens on the Axio Lab. A1 (Zeiss) 
microscope, 4 h and 16 h after transfection. Scale bar 10 µM B) Transfection of different 
amounts of purified Flag-thio-Arpp19 using the ProDeliverIN reagent. Samples were 
fractionated into soluble and insoluble components before analysing them using western 
blotting. The arrow indicates endogenous Ensa/Arpp19 in the cellular fractions.  
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protein shows inconsistency in the method. Additionally, the recovery of the cells from 
the physical transfection seems to be very slow to observe the switch-like G2/M 
transition. 
 
As seen in Fig. 6.9C, the proteins stayed in the cytosol for at least 24 h post-
transfection, unlike Cas9. To observe the effects of this stable and dominant active 
Arpp19 on U2OS cells, I imaged the transfected cells for 3 h, 1 h after transfection to 
observe effects of dominant active Flag-Arpp19. Although the electroporated cells 
recovered and adhered to the surface of the plate coated with Matrigel, very few mitotic 
divisions were observed in the transfected and control cells (Fig. 6.9D). More cell death 
was observed with protein-transfected samples as compared to the control. Thus, 
varying amounts of transfected protein despite using the same amount of recombinant 
protein shows inconsistency in the method. Additionally, the recovery of the cells from 
the physical transfection seems to be very slow to observe the switch-like G2/M 
transition. 
 
Due to these reasons, another milder chemical transfectant called ProDeliverIN was 
tested to transfect Flag-Arpp19 into mammalian cells. ProDeliverIN is a lipid-based 
formulation that forms covalent bonds with the protein of interest. The cell internalizes 
this complex and the protein of interest is released into the cytosol. This product claims 
to be milder transfection reagent and to transfect biologically active molecules into the 
cell. I performed preliminary experiments with 1 x 105 HeLa cells in a 24-well plate. R-
Phycoerythrin provided in the kit was used as a positive control. The transfection was 
done as per the manufacturer’s recommended protocol. Transfected R-Phycoerythrin 
was observed under the microscope using epi-fluorescence and Flag Arpp19 was 
observed using western blot with Ensa/Arpp19 antibody. As seen in Fig. 6.10A, the 
transfection worked very well with the positive control. However, Flag Arpp19 
transfection was unsuccessful, as no band of the expected size was observed in the 
cytosolic fraction (S). This could be due to a variety of reasons like the size of the 
protein, the buffer or the time of incubation. These parameters could not be tested due to 
the limitation of time.  
 
In conclusion, both the chemical and electroporation methods were successful in 
delivering thio-phosphorylated Arpp19 into mammalian cells. Both methods proved to 
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have limitations with regards to cell viability and indirect effects on cell cycle 
progression. Hence, further optimization will be required to transfect biologically active 
thio-Ensa/Arpp19 into mammalian cells to study their effects on mitosis and investigate 
the Ensa/Arpp19-PP2A-B55 pathway in further detail. For single cell studies, 
microinjection will most likely be the preferential technique because the relatively mild 
treatment exerts less indirect effects that influence the outcome of the experiment.  
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CHAPTER7 DISCUSSION 
 
In this thesis, I have performed an extensive genetic and biochemical analysis of 
mammalian Ensa and Arpp19. I have characterised the localisation and depletion 
phenotypes of these proteins, analysed the dynamics of complex formation with 
PP2A/B55 and have aimed at establishing a method to observe the consequences of 
dominant active Ensa/Arpp19 on mitotic entry and exit. The major findings of this work 
and its implication for our understanding of the G2/M transition are discussed below. 
 
7.1 Ensa/Arpp19 Localisation Studies using Specific Antibodies and 
Fluorescent Markers 
 
Although Greatwall kinase localisation and function has been described in various 
systems including mammalian cells, Ensa and Arpp19 have not been characterised 
equally well. In this thesis, I attempted to investigate the mitotic functions of Ensa and 
Arpp19. The first step towards mapping the functions of these highly similar proteins 
was to generate specific antibodies. I generated rabbit polyclonal antibodies against the 
dissimilar C-termini of Gallus proteins (homologous to humans) (Fig. 3.1A), which 
proved to be specific against recombinant (Fig. 3.1B) and exogenously expressed Ensa 
and Arpp19 respectively (Fig. 3.1D). However, these antibodies were unable to generate 
a distinctive signal to detect endogenous Ensa and Arpp19 by immuno-blotting, even 
though they could detect exogenously expressed protein (Fig. 3.1E-F). Thus, the 
specific antibodies could not be used in further investigation. This limits the scope of 
this thesis with regards to distinguishing the function of the individual paralogues Ensa 
and Arpp19. Hereafter, characterisation of endogenous Ensa and Arpp19 has been 
carried out by co-depletion, as it was easily detectable using commercial antibodies. 
 
Localisation of Greatwall contributes to mitotic progression significantly. Greatwall is 
nuclear and is translocated to the cytoplasm in a phosphorylation-dependent manner just 
before nuclear envelope breakdown (NEBD). This enables PP2A inhibition via the 
Greatwall-Ensa/Arpp19 pathway and facilitates mitotic progression (P. Wang et al. 
2013; Alvarez-Fernández et al. 2013; P. Wang et al. 2016). Whether Ensa and Arpp19 
are spatially regulated in a similar way has not been investigated, although, it is likely 
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that Ensa/Arpp19 can diffuse easily through nuclear pores owing to their small size and 
are not spatially regulated (Alvarez-Fernández & Malumbres 2014). Localisation of 
yeast homologues of Ensa/Arpp19 (Igo1/2) is nuclear but has only moderate 
contribution in closed mitosis (Rossio et al. 2014). Thus, cellular localisation of Ensa 
and Arpp19 were investigated in mammalian cells using Pan Ensa/Arpp19 antibody and 
fluorescent markers. 
 
Ensa/Arpp19 were found to be ubiquitously present in interphase cells with a slight 
enrichment in the nucleus. The cytoplasmic staining is granular but this is likely to be 
an artefact of fixation. Ensa/Arpp19 is evidently excluded from the chromosomes and 
appears to be dispersed evenly in mitosis (Fig. 3.2 A-B). The mitotic distribution of 
Ensa/Arpp19 is similar to Greatwall localisation in human cells, proposing an analogous 
spatial regulation of Ensa/Arpp19 in mammalian mitosis. Exogenously expressed Flag-
tagged Ensa and Arpp19 reiterated these observations, as they localised ubiquitously in 
interphase and displayed mitotic chromosome exclusion (Fig. 3.3D and 3.4 A-B). 
Interestingly, Flag Arpp19 appeared to localise at the cortex, which could point to 
cortical functions of this protein (Fig. 3.4 A-B). This notion is further substantiated by 
the extensive blebbing phenotype observed upon Ensa/Arpp19 depletion. A major 
technical obstacle that was revealed during the course of this study is the disruption of 
Ensa/Arpp19 functions when larger fluorescent tags were used both on the N- and C-
terminus (Fig. 3.3A-C). We dedicated a considerable effort to overcome this problem, 
but could not manage to find a suitable way to add GFP tags without disrupting the 
ability of these small proteins to bind to PP2A/B55. This is an important caveat that will 
influence future analysis of these proteins. Perhaps the use of smaller Halo or Snap-tags 
may be useful to overcome this problem in future.  
However, examining GFP fusions of Ensa and Arpp19 showed mitotic exclusion from 
chromosomes similar to the endogenous proteins. Moreover, overexpression of GFP-
Ensa delayed mitotic progression by delaying the cells in metaphase and causing mitotic 
exit with lagging chromosomes (Fig. 3.3D-E). This suggests that these proteins may 
still be functional as PP2A/B55 inhibitors even though the in vitro complex formation 
appears to be disrupted. Alternatively, a dominant negative effect involving other 
interacting proteins could be involved.  
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7.2 Genetic Analysis of Greatwall and Ensa/Arpp19 in Human Cell 
Lines 
 
Using RNAi-mediated depletion, genetic analysis of Greatwall and Ensa/Arpp19 in 
human cells characterised their functions in mammalian mitosis. Depletion phenotypes 
of Greatwall kinase have been well characterised in mitotic entry and exit. Greatwall 
depletion leads to dramatic responses in Drosophila, Xenopus and starfish oocytes 
causing mitotic entry inhibition. This is indicated by Cdk inactivation and minimal 
mitotic substrate phosphorylation when Greatwall is depleted from interphase extracts 
(J. Yu et al. 2004; Zhao et al. 2008; Bettencourt-Dias et al. 2004; Glover 2012; Lorca & 
Castro 2012). However, these phenotypes were not recapitulated in mammalian cells. 
End-point assays such as immunofluorescences and 2D FACS in human cells showed 
chromosome congression and segregation defects accompanied by cytokinesis failure. 
Although endpoint assays showed a slower mitotic index in human cells, mouse cells 
failed to arrest in G2 on Greatwall depletion (Burgess et al. 2010; Voets & Wolthuis 
2010; Alvarez-Fernández et al. 2013). I observed similar phenotypes (Fig. 4.1D-F) in 
Greatwall-depleted HeLa cells using live-cell imaging to measure the mitotic index 
dynamically in asynchronous population. Very little difference was observed in the 
mitotic index between control and Greatwall depleted cells (Fig. 4.1C), indicating the 
kinase does not affect mammalian mitotic entry as observed in Xenopus egg extracts. 
Using the HeLa-cdk1as cells that can be synchronised in late G2 phase, I found that G2-
cells depleted of Greatwall entered mitosis when Cdk1 was activated, thus illustrating 
that mammalian cells can enter mitosis even in the presence of high phosphatase 
activity. However, minor inhibition of Cdk1 causes a G2 arrest in Greatwall-depleted 
cells, suggesting that these cells rely on high Cdk1 activity to counterbalance persistent 
PP2A/B55. Thus, Greatwall is not essential for mitotic entry but has a dramatic effect 
on the required Cdk1 threshold (Fig. 4.3A-B and 4.4A-B). 
 
Ensa/Arpp19 mitotic phenotypes were characterised in human cells by depleting both 
individually and together. Similar to Greatwall, the single or double depletion of 
Ensa/Arpp19 did not affect mitotic entry dramatically. Although a slight decrease in 
mitotic index was observed with Ensa depletion as compared to Arpp19 and the double 
depletion, rescue experiments with Ensa-cDNA have to be performed to draw clear 
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conclusions (Fig. 4.2C). This is in contrast to the observations made by GharbiAyachi et 
al. (2010) where they observed a 50% reduction in the mitotic index with Arpp19 
depletion but not Ensa. This difference in the function of the paralogues could be due to 
the high sequence homology between Ensa and Arpp19 (≈ 70%) making it difficult to 
differentiate between them. It could also be due to the unknown redundancy between 
these proteins and their varying concentrations in different cells lines. Stably expressing 
degron-tagged Ensa and Arpp19 followed by CrispR depletion of endogenous genes 
might be a viable approach to distinguish between these small proteins in addition to 
reducing off-target effects. This approach is however challenging given the number of 
isoforms reported for human Ensa, and the effect on tags on the function of the protein. 
 
Interestingly, Ensa/Arpp19 depletion had a much less dramatic effect on the mitotic 
entry threshold than observed with Greatwall (Fig. 4.3C-D). This is an unexpected 
result, since Greatwall is a processive enzyme while Ensa/Arpp19 are stoichiometric 
inhibitors. Thus, even an incomplete depletion of Ensa/Arpp19 should result in release 
of active PP2A/B55 complexes, while small amounts of Greatwall may still be able to 
phosphorylate most of its substrates. Conversely, efficient depletion of both Ensa and 
Arpp19 was less effective in lowering the mitotic entry threshold for Cdk1 than 
Greatwall. This discrepancy could point to Ensa/Arpp19 independent functions of 
Greatwall and needs to be further investigated. 
 
Characterisation of mitotic phenotypes of Greatwall and Ensa/Arpp19 also exhibit some 
surprising results. As observed with Greatwall, both these proteins displayed longer 
transit time in mitosis. Ensa and Arpp19 showed an additive effect in prolonging mitotic 
time due to metaphase delays when co-depleted as compared to single depletions (Fig. 
4.2E). This implies redundancy between these proteins in their cell cycle functions. 
Greatwall depletion displayed chromosome segregation, condensation and cytokinesis 
defects congruent with previous studies. These defects point towards a major role of 
Greatwall kinase in mitotic maintenance and proper mitotic exit as previously stated 
(Burgess et al. 2010; Voets & Wolthuis 2010; Alvarez-Fernández et al. 2013). 
Ensa/Arpp19 depletion led to chromosome alignment defects like accumulation at the 
poles as well as lagging chromosomes indicative of premature mitotic exit defects (Fig. 
4.2D-F). Surprisingly, the Greatwall hallmark cytokinesis defect was not observed upon 
depletion of Ensa/Arpp19, potentially indicating an Ensa/Arpp19 independent function 
	   180	  
of Greatwall at mitotic exit. Additionally, mitotic entry in Ensa/Arpp19 depleted cells 
exhibit a significant blebbing phenotype that is absent on Greatwall-depletion (Fig. 
4.3D). This implies a novel function of Ensa/Arpp19 in association with the cytoskeletal 
and cortical proteins, independent of Greatwall kinase. Although a few cytoskeletal 
proteins were identified in the proteomic screen with Ensa in metaphase and anaphase, 
these interactions were not significant as compared to the controls. Thus, further 
investigation is required to understand this function of Ensa/Arpp19 in maintaining the 
cell structure of mammalian cells at the G2/M transition. In summary, our siRNA 
results suggest some surprising differences between Greatwall and Ensa/Arpp19. 
However, off target effects of siRNA need to be taken into account, and more precise 
genetic tools such as chemical genetic inhibition of Greatwall and degron-tagged 
Ensa/Arpp19 will be required to come to firm conclusions.  
 
7.3 Ensa/Arpp19 PP2A-B55 Complex Formation with PP2A-B55 
 
Ensa/Arpp19-PP2A-B55 complex formation has been demonstrated in Xenopus 
extracts. The interaction is enriched in mitosis and is okadaic acid sensitive (Gharbi-
Ayachi et al. 2010; Mochida et al. 2010). Cdk1 activates this pathway, inhibiting its 
counteracting phosphatase at the G2/M transition both via Greatwall activation and 
Ensa/Arpp19 phosphorylation independent of Greatwall (Blake-Hodek et al. 2012; 
Vigneron et al. 2011; Okumura et al. 2014). These interactions appeared to be okadaic 
acid sensitive, reducing the phosphatase activity towards Cdk substrates. 
 
Although Greatwall was identified to be dephosphorylated by PP2A and later known to 
be a substrate of PP1 (Heim et al. 2015), Ensa/Arpp19 dephosphorylation remained 
unexplored. Two papers in 2014 proposed two different phosphatases executing 
Ensa/Arpp19 dephosphorylation. While Williams et al, (2014) proposed the ‘unfair 
competition model’ where PP2A itself dephosphorylates Ensa/Arpp19 while being 
inhibited by it (Williams et al. 2014) (Fig. 5.1A), our lab found FCP-1 to influence 
Ensa/Arpp19 dephosphorylation at mitotic exit (Hégarat, Vesely, Vinod, Ocasio, Peter, 
Gannon, Oliver, Novák & Hochegger 2014b). The ‘unfair competition’ model will only 
work when Greatwall is completely inactivated in response to okadaic acid. However, 
in the presence of Okadaic acid 50% of Ensa/Arpp19 inhibitory activity is retained, 
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suggesting residual Greatwall kinase activity. Thus, I attempted to test the ‘unfair 
competition’ model with a view to identify the unknown phosphatases contributing to 
Ensa/Arpp19 dephosphorylation at the metaphase-anaphase transition. 
 
In agreement with the Goldberg model, Greatwall was dephosphorylated before 
Ensa/Arpp19 (Fig. 5.1C-D). Moreover Ensa/Arpp19-PP2A B55 interaction in the 
presence of okadaic acid causes the complex to fall apart in both Hek293 and HeLa 
cells, as proposed by the Goldberg lab (Fig. 5.2B) (Williams et al. 2014). However, 
overexpression of Flag tagged Ensa and Arpp19 seemed to cause deregulated 
phosphorylation of the Greatwall site of these exogenous proteins. This appeared to 
occur both in intact 293T cells (Fig. 5.2A and C) but also during extract preparation for 
immunoprecipitation in HeLa cells (Fig. 5.3D). Thus, the balance of Greatwall, 
Ensa/Arpp19 and PP2A/B55 appears to be highly interdependent and sensitive to 
disturbance in the stoichiometric balance between these proteins. We finally resorted to 
recombinant thiophosphorylated Ensa and Arpp19 to examine its mitotic specific 
interactions. In this case, PP2A-B55 was significantly enriched in Flag Ensa/Arpp19 
immunoprecipitates only in the presence of Greatwall phosphorylation.  
 
Our analysis of Flag-Ensa and Arpp19 immunoprecipitates revealed the presence of a 
smaller protein around the same size of endogenous Ensa/Arpp19 that co-purifies with 
Flag-tagged proteins (Fig. 5.2A and Fig. 5.3C and D). The interaction of the 17-kDa 
protein was sensitive to okadaic acid, suggesting that it is a part of the inhibitor-
phosphatase complex (Fig. 5.2B). Size exclusion chromatography confirmed that the 
presence of this peptide was not due to dimerization of the phosphatase complex, where 
each phosphatase monomer in the dimer, would interact with either an exogenous or an 
endogenous Ensa/Arpp19 (Fig. 5.4A). It is tempting to believe that Ensa/Arpp19 
dimerises/polymerises with endogenous Ensa/Arpp19 in the complex with PP2A-B55. 
However, this interaction was not observed with recombinant Greatwall-
thiophosphorylated Ensa/Arpp19 when incubated with cell lysates (Fig. 5.5B and D). 
This could be either due to the dimerization/polymerisation of the recombinant protein 
beforehand, thus occupying the sites of interaction with its endogenous counterparts. In 
addition, as the recombinant protein is only phosphorylated at the Greatwall site, this 
polymerisation of Ensa/Arpp19 can be dependent on other post-translational 
modifications (PTMs) such as Cdk1 or PKA phosphorylations. The cell lysates do not 
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appear to phosphorylate unphosphorylated Ensa/Arpp19 when incubated at 
physiological conditions, suggesting that the other post-translational modifications of 
these proteins are unlikely in lysates. Moreover, this small peptide could also be an N-
terminal truncation of the Flag fusion proteins or one of the many isoforms of 
Ensa/Arpp19 that differ at their N-termini (Fig. 5.4E and F). This idea is based on the 
observation that the 17-kDa peptide is not identified by Flag or the antisera raised 
against the differing N-termini between Ensa and Arpp19. Only the commercial Pan 
Ensa/Arpp19 antibody that spans the C-termini identifies it (Fig. 5.4C and D). 
Therefore, careful analysis of interactions between these isoforms using different fusion 
tags such as Myc or HA is required to further address this question. 
 
7.4 Identifying Novel Interactors of Ensa/Arpp19 at Metaphase-
Anaphase Transition 
 
As previously discussed, Hegarat et al. (2014) demonstrated that okadaic or 
tautomycetin phosphatase inhibition individually are not sufficient to supress 
Ensa/Arpp19 dephosphorylation during mitotic exit. A recent paper from the Mayer lab, 
demonstrated that Greatwall inhibition is a two-step process in Xenopus extracts - 
initiated by PP1 and majorly executed by PP2A (Heim et al. 2015). Moreover, FCP1 
was also shown to be a major Greatwall phosphatase (Monica et al. 2015). These 
observations could reconcile the ‘unfair competition’ model with the Hegarat study, as 
complete inactivation of Greatwall can be achieved in a stepwise manner. Once 
Greatwall is dephosphorylated partially by PP1, the slow dephosphorylation of 
Ensa/Arpp19 can lead to its release and subsequent complete dephosphorylation of 
Greatwall by PP2A. However, a major finding in the Hegarat paper was that Ensa 
dephosphorylation could proceed even in the presence of high Greatwall activity. This 
finding directly contradicts the unfair completion model, where the slow 
dephosphorylation activity of PP2A/B55 will act on Ensa/Arp only when Greatwall is 
completely inactivated. This suggests the presence of an additional anaphase 
phosphatase that dephosphorylates Ensa/Arpp19 presumably when it is not bound to 
PP2A/B55. 
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I attempted to purify phosphatases acting on Greatwall thio-phosphorylated 
recombinant Ensa using mitotic and mitotic exit extracts from HeLa-cdk1as to 
specifically inhibit Cdk1 activity using 1NMPP1. PP2A-B55 was enriched with only 
thio-phosphorylated Ensa immunoprecipitates as observed in previous studies (Fig. 
5.5B) (Gharbi-Ayachi et al. 2010; Mochida et al. 2010), while interaction was observed 
in both metaphase and anaphase due to the non-hydrolysable nature of the thio-phospho 
group (Fig. 5.5D).  
 
A proteomic screen using these immunoprecipitates displayed significant enrichment in 
the PP2A subunits specifically in thio-phosphorylated Ensa samples (Fig. 5.6D and E). 
A few membrane and cytoskeletal proteins such as lamin B1 were enriched with 
unphosphorylated Ensa (Fig. 5.6A and D). Moreover, reanalysing the data obtained 
from the LC-MS using a relaxed False Discovery Rate (5%) might lead to the 
enrichment of interactors with low molar concentrations in cellular extracts. However, 
the bait itself was not significantly enriched as compared to the negative controls. The 
beads only control displayed large amount of non-specific bands in the Flag elutions on 
the silver stained gel. It is therefore possible that biologically significant interactions of 
thio-Ensa and Ensa are masked by the unspecific interactions of the negative control. 
Further optimisations of the purification protocol will be required to clarify this and 
detect further Ensa/Arpp19 interactors. 
 
7.5 Protein Transfection of Thiophosphorylated Recombinant 
Proteins to Generate Dominant Active Effects 
 
It has been long known that the Cdk-counteracting phosphatase is okadaic acid-
sensitive. In Xenopus, PP2A-B55 was found to contribute to majority of Cdk substrate 
dephosphorylation at mitotic exit (Mochida et al. 2009; Vigneron et al. 2009; Castilho 
et al. 2009). Although okadaic acid promotes mitotic entry in mammalian cells (Gowdy 
et al. 1998), this phenotype is not reiterated by B55α depletion or the depletion of all 
four paralogues of PP2A-B55 (Schmitz et al. 2010; Cundell et al. 2013). These 
observations were made using the RNAi-mediated approach, which might result in 
incomplete inhibition of the phosphatase and hence their effects on global mitotic exit 
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are not visible. Therefore, whether PP2A-B55 is the okadaic acid sensitive phosphatase 
contributing towards mammalian mitosis is still an open question. 
 
To begin addressing this hypothesis, I analysed the effects of B55 inhibition on mitotic 
entry in the absence of Cdk1 activity. Although okadaic acid triggered mitosis even in 
the absence of Cdk1 activity, B55αδ subunits did not appear to have a significant effect 
(Fig. 6.1A and B). Conversely, depletion of the catalytic subunits A/C caused a minor 
two-fold increase in mitotic cells. Additionally, a fraction of these cells also progressed 
into G1 despite the absence of Cdk1 activity. Thus, phosphatase inhibition promotes 
mitotic progression even in the absence of Cdk1 activity, but it remains unclear if this 
phosphatase constitutes PP2A-B55, the target of the Greatwall/Ensa pathway.  
 
As complete depletion of the regulatory subunits of the phosphatase could not be 
achieved using RNAi-mediated approach similar to previous studies (Fig. 6.1C), I 
attempted to generate and transfect constitutively phosphorylated Ensa and Arpp19 to 
achieve more efficient and rapid inhibition of PP2A-B55 (Fig. 6.2). Recombinant Ensa 
was thio-phosphorylated in-vitro at the Greatwall phosphosites by recombinant 
truncated version of Greatwall (E2) (Ocasio et al. 2016) (Fig. 6.3D and Fig.6.5E and G). 
Bacterial purification of human Ensa using various expression vectors was attempted. 
Highly charged tags such as 6X-His failed to enter the cell (Fig. 6.3E) while bulkier tags 
such as GST interfered with the PP2A-B55 interaction of transfected Ensa (Fig. 6.4F) 
(also reported by Williams et al. (2014)). Finally, based on the successful interaction of 
Flag-tagged Ensa and Arpp19 with PP2A-B55 in the earlier experiments in this thesis, 
Flag-tagged Ensa and Arpp19 were purified using the GST vector after which the GST-
tag was cleaved off using a prescission protease (Fig. 6.5A-G). 
 
Various protein transfection techniques were applied to deliver this dominant active 
Ensa into live cells. Chemical methods of transfection were more successful than the 
physical methods for transfecting the protein in the cytosolic fraction. Physical methods 
such as Amaxa were completely unsuccessful (Fig. 6.8), and the Neon transfection 
displayed inconsistency in the amount of transfected protein in the cytosolic fraction in 
comparison to endogenous Ensa/Arpp19 (Fig. 6.9A-C). Additionally, the physical 
methods also appeared to take longer to recover from the impact of transfection and 
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undergo mitosis, and thus were not suitable to study a switch-like response such as 
mitotic entry (Fig. 6.9D). 
 
Among the chemical methods Xfect, a lipid-based transfection reagent proved to be 
most successful in transfecting dominant active Flag-Ensa and Arpp19 (Fig. 6.6A and 
C). The amount of transfected protein almost twice the amount as endogenous 
Ensa/Arpp19. The transfected protein successfully interacted with PP2A-B55 and was 
significantly enriched in the Flag immunoprecipitates (Fig. 6.6B). Thus, Xfect 
transfection generated pool of dominant active Flag-Arpp19 in-vivo. However, this 
extensive amount of thio-phosphorylated Arpp19 failed to cause an increase in mitotic 
index. Examining the unbound fraction of PP2A-B55 after the Flag 
immunoprecipitation experiment suggested that the recombinant protein was not 
sufficient to inhibit all free phosphatase (Fig. 6.6D). The molar concentrations of the 
phosphatase in these cells are not known. However, it is highly unlikely that the cellular 
phosphatase concentrations are more than the amount of endogenous and transfected 
Ensa/Arpp19 put together. One possibility is that the excess amount of transfected 
protein is misfolded which renders it biologically inactive. Therefore, to enable 
saturation of the active inhibitor molecules in-vivo, PP2A-B55αδ subunits were depleted 
using siRNA oligos. 
 
Combining Xfect transfection with siRNA depletion of B55αδ were analysed for mitotic 
cells using Ser10-phospho- Histone H3 staining in G2-arrested HeLa-cdk1as cells (Fig. 
6.7). Though the mitotic index was increased slightly on B55αδ depletion as observed 
earlier, no additive effect was observed on transfecting dominant active Flag-Arpp19. 
One possibility for this observation is that PP2A-B55 is not the only Cdk-counteracting 
phosphatase functioning in mammalian mitotic entry. However, even control G2-
arrested cells treated with the Xfect reagent did not initiate mitotic entry after washing 
off the Cdk-1 inhibitor as compared to the untransfected sample. This further 
complicated the interpretation of the results from the protein transection since the 
experimental manipulation itself appears to block mitotic entry.  
 
Thus, both physical and chemical methods of protein transfection proved unsuccessful 
due to their indirect effects on cell viability and progression through cell cycle. Further 
optimisation of the protein transfection techniques is required to analyse the dominant 
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active effects of Ensa/Arpp19 in mammalian mitosis. Alternative approaches such as 
microinjection could be applied to transfect biologically active proteins and subsequent 
single cell analysis can be carried out. 
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CHAPTER8 FINAL CONCLUSION	  
 
The model in figure 8.1 summarizes the findings in this thesis and the subsequent 
possibilities these might lead to.  
 
1. In this work, we re-established the complex formation of Ensa/arpp19 with 
PP2A-B55 phosphatase in mammalian mitosis. However, the dynamics of this 
interaction need to be studied in greater detail. Interaction studies in this thesis 
indicated the potential dimerization of the small proteins Ensa/Arpp19 while 
binding the active site of the phosphatase. If such an interaction exists, it would 
be interesting to analyse if they form a homo- or hetero-dimer. This in turn 
could shed light on the individual functions of these proteins. Additionally, it 
might be worth addressing this question with bioinformatics tools to understand 
the structure of the active site of the phosphatase with the help of the available 
structure of B56 subunit (J. Wang et al. 2016). This would help in gauging the 
spatial arrangement of the amino acid residues in the active site of the 
Figure	  8:	  Schematic	  representation	  of	  future	  work	  proposed	  in	  this	  thesis	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phosphatase and the hypothetical binding area available for the Ensa/Arpp19 
dimer. 
 
2. Ensa/Arpp19 might have functions at the cell cortex that are independent of 
Greatwall. As explained in Chapter 4, Ensa/Arpp19 depletion led to a blebbing 
phenotype, which was not observed, with Greatwall depletion. This suggests 
Greatwall -independent functions of these small proteins at the cell cortex. 
Ensa/Arpp19 resembles ECT2 overexpression phenotypes documented in (Niiya 
et al. 2006) where phosphorylation of Ect2 at the CDK1 phosphorylation site led 
to excessive blebbing at the cortex in dividing cells. As Rho is required for 
mitotic cortical retraction and rigidity during cell rounding (Maddox & Burridge 
2003) and Ect2 phosphorylation influences its accumulation (Niiya et al. 2006), 
it is possible that Ensa/Arpp19 might contribute to the cortical actin 
rearrangements during mitotic entry via this pathway. Further interaction studies 
and phenotypic analysis is required to uncover these cortical functions of 
Ensa/Arpp19. 
 
3. Similarly, Greatwall depletion leads to defective cytokinesis in 15% of the total 
cell population (Fig 4.1). This is not the case in Ensa/Arpp19-depleted cells. 
These observations point to an Ensa/Arpp19-independent function of the kinases 
in cytokinesis. This points to the presence of additional substrates of Greatwall 
that might contribute to the cytokinesis pathway. This can be investigated by a 
proteomic analysis using wild type and mutant Greatwall, to identify 
cytoskeletal proteins interacting with the kinase. Another striking observation 
from this thesis is that Greatwall depletion cause a significantly more dramatic 
phenotype in the Cdk1 inhibitor titration experiments when compared to 
Ensa/Arpp19 depletion. This indicates a potential function of Greatwall in the 
Cdk1 activation loop that is independent of Ensa/Arpp19 phosphorylation. 
 
Overall, this work identifies the phenotypes of Ensa/Arpp19 and reinstates the dynamics 
of complex formation with PP2A-B55 phosphatase in mammalian mitosis. Further 
investigation will be required to understand the regulation of mitotic entry by fine-
tuning the kinase-phosphatase equilibrium. 
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